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Abstract
During bone growth, remodeling, and fracture repair, skeletal lineage cell responses require the
coordinated activation of multiple transcriptional programs. As defective genetic regulation of bone
formation leads to both developmental and metabolic skeletal diseases, identifying and characterizing
novel transcriptional regulators of skeletal growth, remodeling and repair is important to the future
development of targeted therapeutics. The functions of the paralogous transcriptional co-activators Yesassociated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) in bone are
controversial, with evidence for each either promoting or inhibiting osteogenesis in vitro. Here, we used in
vivo mouse models of combinatorial YAP/TAZ deletion from skeletal lineage cells to investigate their
physiologic roles in bone growth, remodeling, and fracture repair. First, YAP and TAZ in Osterix-expressing
cells combinatorially promoted bone development and growth by regulating osteoblast function,
paracrine regulation of osteoclastic remodeling, and bone matrix quality. Furthermore, combinatorial YAP
and/or TAZ deletion from Osterix-expressing cells mimicked the clinical skeletal fragility disease,
osteogenesis imperfecta, with spontaneous fractures and dysregulated collagen composition leading to
reduced bone mechanical properties. Second, YAP and TAZ deletion later in the skeletal lineage, from
DMP1-expressing cells, promoted bone matrix accrual, organization, and mechanical properties by
regulating osteocyte-mediated coordination of osteoblast/osteoclast activity and osteocytic perilacunar/
canalicular remodeling. Finally, YAP and TAZ in Osterix-expressing cells combinatorially promoted the
expansion and differentiation of periosteal osteoblast precursors to accelerate bone fracture healing.
Taken together, these data establish the paralogous transcriptional co-activators, YAP and TAZ, as
important regulators of bone formation and function during skeletal growth, remodeling, and fracture
repair. Further elucidation of the signaling pathways that control YAP/TAZ-dependent transcriptional
regulation during bone function could enable future therapies to reverse skeletal fragility and enhance
bone healing.
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ABSTRACT

COMBINATORIAL ROLES OF SKELETAL CELL YAP AND TAZ IN BONE
GROWTH, REMODELING, AND REPAIR
Christopher Daniel Kegelman
Joel D. Boerckel

During bone growth, remodeling, and fracture repair, skeletal lineage cell responses require
the coordinated activation of multiple transcriptional programs. As defective genetic
regulation of bone formation leads to both developmental and metabolic skeletal diseases,
identifying and characterizing novel transcriptional regulators of skeletal growth,
remodeling and repair is important to the future development of targeted therapeutics. The
functions of the paralogous transcriptional co-activators Yes-associated protein (YAP) and
transcriptional co-activator with PDZ-binding motif (TAZ) in bone are controversial, with
evidence for each either promoting or inhibiting osteogenesis in vitro. Here, we used in
vivo mouse models of combinatorial YAP/TAZ deletion from skeletal lineage cells to
investigate their physiologic roles in bone growth, remodeling, and fracture repair. First,
YAP and TAZ in Osterix-expressing cells combinatorially promoted bone development
and growth by regulating osteoblast function, paracrine regulation of osteoclastic
remodeling, and bone matrix quality. Furthermore, combinatorial YAP and/or TAZ
deletion from Osterix-expressing cells mimicked the clinical skeletal fragility disease,
osteogenesis imperfecta, with spontaneous fractures and dysregulated collagen
composition leading to reduced bone mechanical properties. Second, YAP and TAZ

v

deletion later in the skeletal lineage, from DMP1-expressing cells, promoted bone matrix
accrual, organization, and mechanical properties by regulating osteocyte-mediated
coordination of osteoblast/osteoclast activity and osteocytic perilacunar/canalicular
remodeling. Finally, YAP and TAZ in Osterix-expressing cells combinatorially promoted
the expansion and differentiation of periosteal osteoblast precursors to accelerate bone
fracture healing. Taken together, these data establish the paralogous transcriptional coactivators, YAP and TAZ, as important regulators of bone formation and function during
skeletal growth, remodeling, and fracture repair. Further elucidation of the signaling
pathways that control YAP/TAZ-dependent transcriptional regulation during bone function
could enable future therapies to reverse skeletal fragility and enhance bone healing.
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CHAPTER 1: INTRODUCTION
1.1

Background
As a composite structure, bone is critical to bearing biomechanical stresses and

strains to support everyday human activity. The form and function of bone tissue depends
not only on its hierarchical structure, but also the composition and organization of the bone
matrix. During development and post-natal growth, the skeleton forms both through direct
intramembranous bone formation and through endochondral ossification, in which bone
formation occurs through a cartilage intermediary. During bone homeostasis and
remodeling, bone tissue is continuously formed and resorbed via coordinated cellular
function. During bone fracture repair, both bone formation and remodeling occur in a
coordinated fashion, reactivating many of the same cellular and molecular mechanisms
found during skeletal development. Although growth, remodeling, and repair are distinct
bone functions, each require activation of multiple transcriptional programs and signaling
pathways. Aberrant genetic regulation of the cellular responses during bone function can
lead to both developmental and metabolic skeletal fragility diseases, highlighting the
importance of identifying transcriptional regulators as targets for future potential therapies.
This work explores the roles of the paralogous transcriptional co-activators, YAP and TAZ,
in regulating osteogenic-lineage cell function during bone growth, remodeling, and fracture
repair. Overall, this work helps to define the implications of YAP/TAZ-mediated control
of bone function and provides a foundation for the development of new therapeutic
strategies to treat skeletal fragility and improve bone fracture healing.

1

1.1

Bone and skeletal fragility
The human skeleton provides rigidity to aid locomotion, protects internal organs,

and provides a source for calcium and phosphate1–3. Bone tissue is a composite structure,
primarily made of a collagen matrix hardened by mineralization consisting of calcium
phosphate in the form hydroxyapatite2. To maintain structural integrity, bone mineral and
matrix undergo dynamic remodeling, consisting of coordinated bone formation and
resorption, during skeletal development, growth, homeostasis, and fracture repair2,4,5. As
tightly regulated processes, defective regulation of coordinated bone formation can lead to
skeletal frailty diseases, such as osteoporosis, osteogenesis imperfecta, and Paget’s disease
of bone6.
Skeletal fragility diseases result in reduced bone quantity and quality, which
together increase fracture risk and complicate fracture healing treatments7,8. Therapeutic
strategies targeting both the underlying bone pathology and subsequent fractures are
challenging9,10. Fragility fractures often relapse with fixation failure, non-union, or delayed
healing as a result of the existing defective bone combined with an impaired cellular
response to injury11–13. Skeletal fragility pathologies include both developmental bone
diseases, such as osteogenesis imperfecta14–17 and metabolic bone diseases, such as
osteoporosis18,19. Efforts to identify key cellular and genetic regulatory components of bone
function provide critical insights for the development of potential targeted therapeutics for
skeletal fragility diseases20,21. Thus, understanding the cellular and molecular mechanisms
regulating bone formation during skeletal growth, remodeling and fracture healing is both
clinically relevant and therapeutically valuable.

2

1.2
1.2.1

Bone: Cellular responses
Development and growth
During bone development and growth, the majority of skeletal elements ossify

through

intramembranous

bone

formation

and/or

endochondral

ossification22.

Intramembranous bone formation requires mesenchymal condensations, consisting of
mesenchymal stem cells, to directly differentiate into bone forming cells, known as
osteoblasts23,24. Osteoblasts are cuboidal cells located along the bone surface that primarily
secrete new bone matrix23,24. In the process of endochondral ossification, mesenchymal
condensations first differentiate into a cartilage template, consisting of chondrocytes,
which is then replaced with osteoblastic deposition of bone matrix25. While
intramembranous and endochondral ossification are distinct bone formation processes,
both involve skeletal lineage cell commitment and osteogenic differentiation, resulting in
osteoblast-mediated bone formation occurring throughout skeletal development and
subsequent post-natal bone growth.
1.2.2

Remodeling and homeostasis
Terminally differentiated osteoblasts become embedded in the bone matrix and

transition into the most abundant bone cell, known as osteocytes23,24,26,27. Osteocytes reside
within lacunae in the mineralized bone matrix and extend dendritic processes through an
interconnected network of micro-channels called canaliculi that permeate the bone
matrix24,28,29. Through this lacunar/canalicular network, osteocytes and osteocyte-derived
molecules orchestrate bone remodeling in part through controlling osteoblast-mediated
bone formation and osteoclast-mediated bone resorption26,27,30,31. Osteoclasts are
terminally differentiated multinucleated cells, originating from the hematopoietic cell
3

lineage instead of the mesenchymal lineage origination of osteoblasts and osteocytes3,23.
Osteoclasts communicate with both osteoblasts and osteocytes to resorb the bone matrix
through excretion of H+ ion to acidify and dissolve the hydroxyapatite mineral3,23.
Osteoclasts then secrete matrix proteases and enzymes such as tartrate-resistant acid
phosphatase (TRAP), cathepsin K (CTSK) and matrix metalloproteinases to degrade the
remaining bone matrix3,23. However, many of the matrix metalloproteinases and enzymes
employed by osteoclasts are also expressed in osteocytes32–34. As a result, osteocytes
directly resorb and deposit bone matrix in their immediate surroundings via
perilacunar/canalicular remodeling35,36 in addition to controlling osteoblast/osteoclastcoupled bone remodeling26,30,31. Thus, bone homeostasis requires the dynamic and
continuous

regulation

of

osteoblast/osteoclast-mediated

and

osteocyte-mediated

perilacunar/canalicular bone remodeling to maintain skeletal integrity and functionality
after initial bone development and post-natal growth.
1.2.3

Fracture repair and healing
Bone fracture healing recapitulates the cellular functions important to skeletal

development,

growth

and

remodeling37,38.

Fracture

repair

requires

extensive

intramembranous and endochondral bone formation to stabilize the initial injury along with
coordinated osteoclast-mediated bone resorption to remodel the fracture callus back into a
functional bone39–41. The initial stages (within 24 hours) of fracture healing include
hematoma formation followed by an infiltration of inflammatory cells, including
macrophages, which are critical for the subsequent phases of bone healing39–42. Next,
progenitor cells located on the periosteal bone surface rapidly expand and differentiate in
response to fracture39,40,43,44. Periosteal progenitor cells cover the surfaces of bone in a
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highly vascularized membrane bilayer between bone and muscle45,46 and derive from a
common embryonic mesenchymal lineage as bone marrow stromal cells (MSCs)47–49.
However, periosteal progenitor cells contain an enhanced post-natal regenerative capacity
with an osteochondral differentiation potential44,47–49, suggesting contributions of the
periosteum to both cartilaginous callus formation and direct bone formation during the
early stages of fracture healing. Following callus generation, mineralization and
ossification, the coupled action of osteoblasts and osteoclasts progressively remodels the
fracture callus back to mature, functional bone50. Thus, bone fracture healing reactivates
and employs similar populations of bone cells as development, growth, and remodeling,
but does so in a unique post-natal environment39.
1.2.4

Conclusion
Although skeletal growth, remodeling, and fracture repair are distinct bone

functions, all of these processes require skeletal-cell lineage commitment, differentiation
into osteoblasts, and eventual functional formation of bone matrix and mineral51. The
skeletal cell response results from the expression and repression of specific genes to acquire
an osteoblastic phenotype24. The genetic profile of progenitor cells differentiating into
osteoblasts, and subsequently osteocytes, is tightly regulated by a variety of transcription
factors52–55. Transcription factors are proteins that control the rate of transcription of
genetic information from DNA to RNA56, allowing for genetic transitions driving different
cellular phenotypes and functionality.
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1.3
1.3.1

Transcriptional regulation of bone function
Cre-loxP skeletal phenotyping
Conditionally inactivating or activating genes that encode for transcription factors

using genetically engineered mouse models has greatly enhanced our understanding of
transcriptional regulation of bone formation57,58. Multiple transcription factors are known
to regulate bone formation at various skeletal cell lineage stages as a result of using bonespecific Cre-loxP mouse models51,58. The Cre-loxP system uses the Cre recombinase
enzyme (Cre) to excise target DNA sequences from the genome that are flanked with
genetically engineered loxP sites, termed Cre-mediated gene recombination59,60. For tissuespecific targeting, Cre expression is downstream of a specific promoter, resulting in Cremediated gene recombination in the subset of cell populations expressing that
promoter58,59. Further, Cre-mediated gene recombination is irreversible with upstream
promoters causing gene recombination in progenitor cell populations and their
progeny58,59. Thus, many different Cre-expressing mouse models exist to target conditional
gene recombination throughout the different stages of the osteogenic cell lineage57,58.
Targeting different stages of the osteogenic cell lineage using the various skeletallineage Cre-expressing mouse models has elucidated cell type-specific, genetic regulation
of bone function. The Runx2-Cre61, 3.6kb-Col1a1-Cre62, and Osterix-Cre63 mouse models
target early osteoprogenitors and subsequently the entire osteoblast lineage, with
differences in promoter expression based on the stage of progenitor cell commitment to the
osteoblast lineage. The 2.3kb-Col1a1-Cre62,64,65 and Osteocalcin-Cre66 mouse models
primarily target osteoblasts, with differences in promoter expression based on osteoblast
maturity. The 10kb-DMP1-Cre67,68, 8kb-DMP1-Cre69, and SOST-Cre70 mouse models
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primarily target late osteoblast and osteocytes with observed Cre-mediated gene
recombination in each cell type depending on the sensitivity of the floxed alleles69–71.
However, various limitations of skeletal lineage Cre-loxP transgenic models exist,
including potential non-skeletal cell targeting, transient Cre expression during
development, and Cre transgene-dependent phenotypes57,58,72–74, highlighting important
considerations for experimental controls and model-specific data interpretation.
Nonetheless, skeletal lineage Cre-loxP mouse models remain critical to enhancing our
understanding and subsequent identification of key transcription factors and their signaling
pathways important to bone health and disease.
1.3.2

Runx2
Runx2 is the most upstream transcription factor critical to osteoblast lineage

commitment and differentiation75. Global deletion of Runx2 in mice caused maturational
arrest of osteoblasts, resulting in perinatal death characterized by no bone formation or
mineralization76,77. Global, heterozygous deletion of Runx2 in mice caused skeletal
abnormalities similar to cleidocranial dysplasia77 while in humans, heterozygous loss of
function mutations in Runx2 caused clinical cleidocranial dysplasia78. In addition to a
developmental bone phenotype, global heterozygous Runx2 deletion in mice enlarged
cartilaginous callus formation, but delayed later stages of endochondral bone fracture
repair79, demonstrating a dominant role in chondrocyte maturation. Consistent with these
observations, conditional deletion of Runx2 in chondrocytes using Col2a1-Cre
phenocopied global Runx2 gene inactivation with perinatal lethality and no ossification80.
However, the functions of Runx2 in committed osteoblasts are disputed81. Conditional
deletion of exon 4 within the Runx2 gene in committed osteoblasts using 2.3kb-Col1a1-
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Cre caused no overt skeletal phenotype80, yet osteoblast-conditional deletion of exon 8
resulted in a progressive reduction in post-natal bone formation and osteoblast
functionality82,83. Several reports of conditional Runx2 overexpression using the 2.3kbCol1a1 promoter observed osteopenia with a reduction in mature osteoblasts and
osteocytes84–86, suggesting Runx2 differentially regulates osteoblastogenesis depending on
the stage of skeletal cell lineage commitment. Runx2 overexpression in committed
osteoblasts also enhanced osteoclast-mediated bone resorption by inducing expression of
receptor activator of nuclear factor kappa beta (Rankl)86,87, highlighting how post-natal
osteoblastogenesis affects the tightly regulated balance of bone remodeling. Taken
together, the observed skeletal phenotypes from global and skeletal-lineage conditional
genetic manipulations of Runx2 underscore many critical contributions of Runx2 to bone
formation during skeletal development, growth, remodeling, and fracture repair.
1.3.3

WNT/β-catenin
WNT signaling and its primary transcriptional effector molecule, β-catenin, are

similarly critical to osteoblastogenesis with differential functions depending on the stage
of skeletal lineage commitment88. As global β-catenin inactivation in mice caused
embryonic lethality due to gastrulation defects89, conditional Cre-loxP-based approaches
have extensively dissected the function of β-catenin in skeletal lineage cells during bone
function. Conditional deletion of β-catenin in mesenchymal limb bud cells using Prx1-Cre
resulted in ectopic chondrocyte formation instead of osteoblast differentiation, suggesting
β-catenin promotes osteogenic commitment and differentiation of mesenchymal
precursors90,91. However, constitutively active β-catenin in committed osteoblasts using
2.3kb-Col1a1-Cre caused osteopetrosis due to defective osteoclast differentiation while
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conditional deletion of β-catenin using 2.3kb-Col1a1-Cre caused low bone mass due to
increased bone resorption92. Conditional deletion of β-catenin in mature osteoblasts and
early osteocytes using Osteocalcin-Cre and 14kb-DMP1-cre, respectively, caused similar
low bone mass phenotypes with premature death due to skeletal fragility in both
models93,94. Recent work in osteocytes demonstrated a dominant active form of β-catenin
under control of 8kb-DMP1-Cre mediated the anabolic bone formation response71,
corroborating numerous studies demonstrating the importance of β-catenin to osteocyte
viability, function, and mechanotransduction95. Similar to development and remodeling,
the function of β-catenin during fracture repair depends on the stage of healing96. During
early stages of fracture healing, β-catenin regulates mesenchymal progenitor osteogenic
differentiation97, while in later stages, active β-catenin signaling in osteoblasts promotes
coordinated osteoblast-osteoclast mediated callus remodeling98. In summary, the resulting
phenotypes from conditional genetic manipulation of β-catenin throughout the different
stages of the skeletal lineage highlight various critical functions for β-catenin in regulating
bone formation during skeletal development, growth, remodeling, and fracture repair.
1.3.4

TGF-β/Smad
TGF-β signaling and its primary signal transducer molecules, Smads, are also

critical

to

osteoblastogenesis

throughout

skeletal

development,

growth,

and

homeostasis99,100. Activated TGF-β binds a tetrameric receptor complex consisting of two
TGF-β type I (TβRI) and two type II kinase receptors (TβRII), resulting in the subsequent
phosphorylation of receptor activated Smads, Smad2 and 3101. Smad2 and 3 then interact
with Smad4 in order to translocate to the nucleus, where the Smad complex recruits various
co-factors to regulate subsequent gene expression101. Thus, identifying roles for each
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component of TGF-β/Smad signaling during osteoblastogenesis is complex with many
insights coming from skeletal lineage conditional genetic manipulations. Conditional
deletion of both TβRI and TβRII in mesenchymal limb bud cells using Prx1-Cre resulted
in short long bones and defective joint development characterized by decreased
chondrocyte proliferation and increased chondrocyte hypertrophy102–104. In contrast,
conditional TβRII deletion in mature osteoblasts using Osteocalcin-Cre resulted in a high
bone mass phenotype105 while conditional TβRII deletion in early osteocytes using 10kbDMP1-Cre demonstrated increased trabecular bone mass, despite defective osteocyte
perilacunar canalicular remodeling106. Furthermore, global Smad3 inactivation caused
osteopenia with decreased bone formation and increased osteoblast apoptosis107.
Conditional ablation of Smad4 from embryonic development onward in osteoprogenitor
cells using Osterix-Cre impaired collagen matrix synthesis, causing an osteogenesis
imperfecta-like phenotype108, while post-natal ablation of Smad4 in osteoprogenitors
increased osteoblast proliferation, yet impaired osteogenic differentiation109. Similarly,
conditional Smad4 disruption in osteoblasts using Osteocalcin-Cre inhibited bone
formation and osteoblast differentiation during post-natal bone homeostasis110. Together,
these observations suggest TGF-β/Smad signaling likewise plays multiple important roles
during osteoblastogenesis to regulate bone formation during development, growth,
remodeling, and homeostasis.
1.3.5

Conclusion
Although additional transcription factors and their respective signaling pathways

regulate bone function, Runx2, WNT/ β-catenin and TGF-β/Smad signaling are known to
have signaling crosstalk amongst each other111, adding another layer of contextual
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complexity to the regulation of bone formation. Thus, a multilayered interplay between
these various signaling pathways and their essential transcriptional regulators is required
to coordinate skeletal lineage cell responses during bone function.
1.4
1.4.1

YAP and TAZ
Crosstalk
Despite our growing knowledge of transcription factor regulation of skeletal

function, the current understanding is insufficient to fully explain the vast heterogeneity
found in bone disease and fracture healing. The paralogous transcriptional co-activators,
YAP (Yes-associated protein) and TAZ (Transcriptional co-activators with a PDZ-binding
motif) are known to interact with the above-mentioned, signaling pathways and their coeffectors, which are critical to bone function. Both YAP and TAZ were shown to
independently bind to and mediate Runx2-dependent osteogenic transcriptional
activity112,113. In addition, WNT/ β-catenin114–116 and TGF-β-Smad2/3117,118 signaling
pathways converge on YAP/TAZ via interactions with the β-catenin destruction complex
and Smad-dependent nucleocytoplasmic shuttling. Furthermore, YAP and TAZ are known
as potent regulators of organ growth and tissue regeneration in non-skeletal tissues119,120.
These distinct tissue functions require a diverse YAP/TAZ-dependent transcriptional
regulatory capacity within different cellular contexts. YAP and TAZ contain transcription
activation domains, but lack DNA-binding domains121. Thus, YAP/TAZ-dependent
transcriptional regulation is inherently diverse in part through forced interactions with coeffectors containing DNA-binding domains (e.g. Runx2, β-Catenin, Smad2/3, etc.) to
regulate gene expression and subsequent cellular function112–118,122, positioning YAP/TAZ
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as a critical signaling node to potentially regulate bone growth, remodeling, and fracture
repair.
1.4.2

Regulation
YAP and TAZ are primarily known as the main downstream effectors of the Hippo

signaling pathway in vertebrates, yet become activated by numerous upstream signals
including G protein-coupled receptors, adherens junctions, and cytoskeletal tension123–125
(Figure 1-1). The most potent and well-studied downstream co-effector interactions of
YAP and TAZ are with the transcriptional enhancer activator-domain (TEAD) family
proteins126, as TEAD proteins lack transcriptional activation domains that provide
specificity for YAP/TAZ-TEAD signaling (Figure 1-1). Canonical Hippo pathway
signaling is composed of two sets of kinases, named MST and LATS, which control
YAP/TAZ activation127–129. MST activates LATS and LATS in turn phosphorylates YAP
and TAZ at specific serine residues located within each protein, which targets YAP and
TAZ for 14-3-3 protein sequestration in the cytoplasm, inhibiting YAP/TAZ-dependent
gene regulation127–129. If YAP and TAZ are not phosphorylated by LATS kinase, they
translocate to the nucleus and bind with various co-effectors (e.g. TEAD, Runx2, βCatenin, Smad2/3) to regulate gene expression112–118,121. Non-canonical Hippo-signaling
refers to when YAP and TAZ are regulated independently of MST/LATS kinase cascade,
which include a diverse set of upstream signal inputs and post-transcriptional modifications
that further modulate YAP/TAZ activity129–131.
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Figure 1-1: YAP/TAZ activation and co-factor interaction.
YAP and TAZ are activated by a diverse network of signals, including cytoskeletal stretch (ɛ), extracellular
matrix stiffness (E), shear stress (τ), cell-cell junctions, and biochemical cues. Following activation, YAP
and TAZ translocate to the nucleus to interact with transcriptional co-factors, such as TEAD. Figure made
by J. Boerckel. Reproduced with permission.

1.4.3

Structure
As paralogs, the protein configurations of YAP and TAZ contain subtle structural

differences that enable distinct interactions of YAP versus TAZ, resulting in either
equivalent or divergent regulatory capacities132–134 (Figure 1-2). Both YAP and TAZ
contain at least one WW domain135, consisting of two tryptophan residues with 20-23
amino acids in between, that allow interactions with co-factors containing PPxY
motifs131,136. Both YAP and TAZ contain a C-terminal PDZ-binding motif131,137, an
extended C-terminus with a transcriptional activation domain (TAD)112,138,139, a TEADbinding region134,140, and a 14-3-3 binding region141,142 (Figure 1-2). Structural differences
between YAP and TAZ include the N-terminus end of YAP consisting of a proline-rich
region and an SH3-binding motif131,143, both of which are not found in TAZ (Figure 1-2).
Thus, both distinct and overlapping functions of YAP versus TAZ are beginning to
emerge131,133, depending on cell type and context. However, the current evidence for the
contributions of YAP versus TAZ during osteogenesis in vitro and in vivo is complicated.
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Figure 1-2: Regulatory structure of YAP and TAZ.
Illustration of the key regulatory domains found in the protein structure if YAP and TAZ, including the
TEAD binding domain, the WW domain(s), the transcriptional activation domain (TAD), and the PDZbinding motif. Figure made by J. Boerckel. Reproduced with permission.

1.5
1.5.1

YAP and TAZ in osteogenic lineage cells
In vitro evidence
Although identified as critical regulators of mesenchymal progenitor cell

differentiation, the evidence for positive vs. negative roles for YAP and/or TAZ during
osteogenic differentiation in vitro is complicated. Studies have demonstrated both pro- and
anti-osteogenic functions for both YAP and TAZ, depending on the context. Differences
in experimental and cellular context may partially explain the conflicting evidence, but
further study is necessary. Here, the existing evidence for both YAP and/or TAZ in both
promoting and inhibiting in vitro osteogenic differentiation in model and primary skeletal
cells is discussed.
A majority of the evidence for YAP and/or TAZ in inhibiting in vitro osteogenic
differentiation is focused on YAP. YAP was first reported to suppress osteoblastic
differentiation through sequestration and transcriptional repression of RUNX2 in
ROS17/2.8 rat osteosarcoma cells112. Sen and colleagues found that, in mouse bone marrow
stromal cells (BM-MSCS), nuclear YAP inhibited RUNX2-mediated initiation of
osteogenic

differentiation

while

YAP

nuclear

export

enhanced

osteogenic

differentiation144. More recently, activator protein 2a (AP2a) was shown to recruit YAP
and release the inhibition of RUNX2 by forming a YAP-AP2a protein complex, resulting
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in elevated osteogenic differentiation145. Similarly, Basu-Roy and colleagues observed that
SOX2 antagonized YAP expression to reduce osteogenic differentiation and maintain
stemness in mOS-482 mouse osteosarcoma cells while YAP overexpression in primary
mouse osteoblasts inhibited alkaline phosphatase activity and osteogenic differentiation146.
Seo and colleagues identified YAP as a target of SOX2 that antagonized activation of
WNT/b-catenin target genes to inhibit osteogenic differentiation in both a model stem cell
line (C3H10T1/2) and primary bone marrow stromal cells147. With respect to TAZ, Park
and colleagues implicated both YAP and/or TAZ as mediators of alternative WNT
signaling via antagonizing WNT/b-catenin signaling, and found that either YAP or TAZ
overexpression inhibited WNT/b-catenin signaling and osteogenesis148.
In contrast, YAP has also been found to promote osteogenic differentiation in vitro.
YAP overexpression enhanced, while YAP depletion inhibited, osteogenic differentiation
in MC3T3-E1 cells149. In BM-MSCs, over-expressing a constitutively active YAP mutant
(YAP5SA) promoted osteogenic differentiation even under conditions more favorable for
adipogenesis150. Further, enhanced YAP activation by cytoskeletal contractility in
differentiating BM-MSCs promoted osteogenic capacity in both the context of
topographical cues151 and mechanical stimulation152. Both pharmacological treatment and
RNAi-depletion of YAP inhibited topography-induced osteogenic differentiation in BMMSCs153. In addition to topographical cues, reductions in extracellular pH inhibited
osteogenic differentiation by suppressing YAP in BM-MSCs154. Finally, olfactomedin-like
protein (OLFML1) negatively regulated mineralization in primary calvarial osteoblasts by
inhibiting YAP nuclear translocation, consistent with a role for YAP promoting osteogenic
differentiation in vitro155.
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In contrast to YAP, evidence for TAZ is largely consistent and indicates a role for
TAZ in promoting in vitro osteogenic differentiation. TAZ was first identified as a RUNX2
co-activator and inhibitor of adipogenic nuclear receptor, PPARg, in C2C12 cells156,157.
More recent evidence in both C2C12 and C3H10T1/2 cells further found TAZ promoted
osteogenic differentiation through both RUNX2-158,159 and b-catenin-160 dependent
transcription. Similar work by Byun and colleagues observed that TAZ activation
downstream of FGF2 and ERK mediated RUNX2-related osteogenic gene expression161.
Similar to YAP, both topographical cues and mechanical stimulation affected TAZdependent in vitro osteogenic differentiation in BM-MSCs. For example, both nanotopographical surfaces162,163 and extracellular matrix stiffness164 promoted osteogenic
differentiation through nuclear TAZ activation. Furthermore, simulated microgravity
depolymerized F-actin and reduced TAZ nuclear translocation, which hindered osteogenic
differentiation in BM-MSCs165. Conversely, fluid shear stress stimulated TAZ nuclear
localization and increased osteogenic differentiation166. Lastly, pharmacological activation
of TAZ enhanced osteogenic differentiation in adipose-derived stem cells167 while BMMSCS from mice with heterozygous global deletion of TAZ exhibited defective in vitro
osteogenic differentiation168.
In addition to their individual roles, a few studies have modulated both YAP and
TAZ during in vitro osteogenic differentiation. For example, Park and colleagues
demonstrated RNAi-depletion of YAP/TAZ in BM-MSCs reduced alkaline phosphatase
activity and mineral deposition148. Similarly, dual RNAi-depletion of YAP/TAZ in BMMSCs inhibited alkaline phosphatase activity under conditions favorable for
osteogenesis150. Finally, heterozygous deletion of both YAP and TAZ in BM-MSCs
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inhibited osteogenic differentiation with reduced mineral deposition and downstream
osteogenic gene expression169.
Synthesizing these studies suggest TAZ primarily promotes osteogenic
differentiation in vitro, while YAP can either promote and inhibit osteogenic differentiation
in vitro, depending on the cellular and experimental context. Despite the emerging
important roles of YAP and TAZ during osteogenic differentiation in vitro, continued
careful and thorough interpretation of experiments modulating either YAP and/or TAZ is
warranted. For example, the limitations of overexpression approaches that nonphysiologically express otherwise tightly regulated transcriptional co-effectors should be
taken into consideration. Further, dissecting the individual roles of YAP versus TAZ during
osteogenic differentiation is necessary as current evidence suggests the potential for both
divergent and convergent functions of YAP versus TAZ. While important for dissecting
molecular mechanisms, in vitro studies must be supported and validated by in vivo
approaches that enable the study of YAP/TAZ function in a physiologic context.
1.5.2

In vivo evidence
In light of the conflicting in vitro evidence for the roles of YAP and TAZ during

osteogenic differentiation, genetic manipulations using bone-specific Cre-loxP mouse
models have partially elucidated the in vivo roles of YAP and TAZ in osteoblast lineage
cells. Here, the current evidence for the roles of YAP and/or TAZ in vivo throughout the
osteoblast lineage is discussed.
Evidence for the roles of YAP and TAZ in osteoprogenitor cells using Osterix-Cre
is seemingly contradictory. Constitutive, homozygous deletion of both YAP and TAZ
using Osterix-Cre caused perinatal lethality due to asphyxiation secondary to rib cage
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malformation, signifying a critical role for YAP and TAZ together in osteoprogenitors for
overall survival170,171. Mice with a single allele of YAP or a single allele of TAZ in Osterixexpressing cells survived the perinatal lethal phenotype, suggesting mutual, but partial
compensation of YAP and TAZ in this context. Mice expressing only a single allele of
either gene exhibited severe skeletal defects including spontaneous neonatal femoral
fractures, defects in collagen content and organization, and altered osteoblast/osteoclastmediated bone remodeling, implicating both YAP and TAZ promote post-natal bone
function170. However, post-natal deletion of both YAP and TAZ (tetOFF-Osterix-Cremediated deletion at 3 weeks of age, and assayed at 12 weeks of age) increased osteoblast
numbers and mineralizing surface percentage, yet represents a distinct experimental
context from constitutive deletion of YAP and/or TAZ from embryonic skeletal
development onward171. Orthogonally, Li and colleagues demonstrated that genetic
deletion of MST1/2, an upstream regulator of YAP/TAZ, using Osterix-Cre inhibited bone
accrual, formation and remodeling while stabilizing the key glucose transporter, Glut1172.
Although the effect of MST1/2 deletion on glucose metabolism was independent of
YAP/TAZ expression, these data further implicate the importance of understanding how
upstream regulators in the Hippo pathway coordinate bone function in addition to YAP and
TAZ.
In contrast to their roles in osteoprogenitor cells, the evidence for the roles of YAP
and TAZ in osteoblasts is largely convergent. To date, neither the 3.6kb- nor the 2.3kbCola1-Cre173,174 model has been used to conditionally delete YAP and/or TAZ. However,
Col-1(2.3kb)-conditional over-expression of TAZ promoted bone formation, suggesting a
similar role for TAZ in osteoblasts compared to osteoprogenitors175. Although not specific
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to skeletal lineage cells, in vivo lentiviral delivery of TAZ alleviated osteoporotic
symptoms in ovariectomized rats, further implicating that TAZ promotes bone formation
in vivo176. Consistently, YAP deletion from osteoblasts using Osteocalcin-Cre significantly
reduced bone formation, impairing osteoblast proliferation induced by YAP co-activation
of β-catenin signaling177, supporting a role for YAP in promoting osteogenesis in vivo. In
contrast, dual deletion of the upstream YAP/TAZ regulator MST1/2 from Osteocalcinexpressing cells inhibited bone accrual and formation, consistent with a negative role for
YAP in bone formation172. Nonetheless, deletion of both downstream YAP/TAZ-TEAD
target genes, CTGF and CYR61, from osteoblasts using Osteocalcin-Cre resulted in a
reduced bone mass phenotype178,179, consistent with the evidence of osteoblast-specific
genetic manipulations of YAP and TAZ.
Although the roles of YAP and TAZ in osteoclasts using cell-specific loss of
function models has not been directly investigated, their functional roles in regulating
osteoblast/osteoclast signaling in conditional osteoblast-lineage knockout models are
consistent. Dual deletion of MST1/2 using Osteocalcin-Cre inhibited osteoclast formation,
suggesting YAP/TAZ negatively regulate osteoclasts172. Consistent with this role, both
deletion of YAP and/or TAZ using Osterix-Cre and deletion of CYR61 with OsteocalcinCre cells increased osteoclast activity170,178. However, deletion of YAP in osteoblasts using
Osteocalcin-Cre did not significantly impact osteoclastic remodeling, potentially due to the
compensatory effects of TAZ and/or the Cre model used177. As the roles for YAP and TAZ
in regulating both osteoblastogenesis and osteoclastogenesis are beginning to emerge, a
complete mechanistic understanding of their role in osteoblast/osteoclast-mediated bone
remodeling during skeletal development remains incomplete.
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Similar to their role in osteoblasts, the evidence for the roles of YAP and TAZ in
late stage osteoblasts and osteocytes is consistent. Despite the cell population targeting
differences between the 10kb- and 8kb-DMP1-Cre model, consistent evidence exists for
the role of YAP/TAZ in both models. Dual, homozygous YAP/TAZ deletion using both
10kb-DMP1-Cre and 8kb-DMP1-Cre reduced bone formation in vivo with decreased
osteoblast numbers and increased osteoclast activity171,180. Furthermore, dual deletion of
YAP/TAZ using 8kb-DMP1-Cre impaired perilacunar/canalicular remodeling, resulting in
skeletal fragility180. Thus, YAP/TAZ in late stage osteoblasts and osteocytes promote bone
function in vivo.
The evidence for YAP/TAZ-mediated regulation of bone formation at various
stages of the osteoblast lineage in vivo are beginning to emerge. In contrast to the in vitro
evidence, these studies suggest both YAP and TAZ promote bone formation throughout
different stages of the osteoblast lineage. However, evidence exists demonstrating negative
YAP and/or TAZ-dependent regulation earlier in the mesenchymal lineage, using Prx1Cre171 and Col2a1-Cre181, suggesting potential cell lineage stage-specific differences in
how YAP and TAZ regulate bone function. Overall, the existing evidence for the roles of
YAP and TAZ in skeletal lineage cells in vivo demonstrates how critical these paralogous
transcriptional co-activators are to bone function, similar to their previously identified roles
in non-skeletal tissue regeneration and organ growth182,183.
1.6
1.6.1

Significance of Studies
Clinical significance: Skeletal fragility
YAP and TAZ are known to drive aberrant cellular function in many diseases

including atherosclerosis184, cancer185, fibrosis186,187, cardiac hypertrophy188, and muscular
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dystrophy189,190, but the role of YAP and TAZ in bone disease is unknown. Due to the
altered mechanical environment in disease pathogenesis, the mechanotransductive effects
of YAP and TAZ are implicated in driving abnormal cellular function191. Further synthesis
of the upstream signals and the downstream targets of YAP/TAZ signaling in bone is
therapeutically important to understand skeletal fragility disease pathology and potential
therapeutic interventions. Accordingly, the emerging roles of YAP and TAZ in skeletal
lineage cells implicate YAP and TAZ in both developmental and metabolic skeletal
fragility diseases.
1.6.2

Bone development diseases
Dysfunctional YAP and/or TAZ signaling in mice mimicked characteristics of

human cases of developmental bone diseases in humans such as skeletal dysplasia192 and
osteogenesis imperfecta (OI)16,17,170,193. As a heterogeneous group of inheritable diseases,
the severity of OI ranges from mildly increased fracture risk to perinatal lethality16. OI is
characterized by increased bone fragility and deformity as well as collagen matrix
disorganization17. Osterix-Cre-mediated YAP and/or TAZ deletion in mice also mimicked
several established mouse models of OI194–196 with spontaneous fractures, disorganized
collagen, and altered osteoblast/osteoclast-mediated remodeling. More recently, a novel
transgenic mouse model of OI type I with mutations in the COL1A1 gene demonstrated
downregulation of YAP expression in bone, potentially implicating a feedback loop
between upstream matrix activation and downstream transcriptional regulation197.
Although the emerging evidence of YAP/TAZ in skeletal lineage cells resembles OI
pathogenesis, loss of function mutations directly in either YAP or TAZ are unlikely to play
a casual role in human OI. Nonetheless, a variety of signaling axes such as TGFb117,118 and

21

WNT-b-catenin115,116 are already implicated in developmental bone diseases and converge
on YAP/TAZ signaling, potentially placing YAP/TAZ upstream of development skeletal
diseases.
1.6.3

Bone metabolic diseases
In addition to developmental bone diseases, the emerging role of skeletal cell YAP

and/or TAZ in regulating bone remodeling implicate a potential link to metabolic skeletal
diseases, specifically related to the coordination of osteoblast/osteoclast and osteocyteintrinsic remodeling. Metabolic skeletal disorders and diseases primarily result from
abnormal bone remodeling, which include Paget’s disease and osteoporosis198. In the
context of both diseases, aberrant cellular function in osteoblasts, osteoclasts, and
osteocytes causes altered bone remodeling, resulting in low bone mass, structural
deterioration and/or deformities198. DMP1-Cre-mediated YAP/TAZ deletion in mice
resulted in low bone mass with increased osteoclastic remodeling, similar to these
diseases171,180. While targeting osteoblast/osteoclast-mediated bone remodeling is under
clinical investigation, therapies targeting bone quality to treat metabolic bone remodeling
disease are currently emerging. Treating bone quality to improve bone strength relates
improving the integrity of the osteocyte lacunar/canalicular network. Both increased age199
and reduced TGFb signaling106 caused defects in osteocyte lacunar/canalicular network
associated with skeletal fragility. Correspondingly, YAP/TAZ deletion from osteocytes
using 8kb-DMP1-Cre reduced both bone quantity and quality via defects in
perilacunar/canalicular remodeling, resulting in skeletal fragility180. Evidence for
YAP/TAZ signaling in both regulating osteoprogenitor cell function during skeletal
development and coordinating osteocyte-mediated bone remodeling suggests a more
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mechanistic understanding of how YAP/TAZ activity regulates bone function could
contribute new insights into the heterogeneity and/or etiology of both metabolic and
developmental skeletal diseases.
1.7

Specific Aims
This study uses a comprehensive approach to identify the contributions of YAP and

TAZ to bone growth, remodeling, and fracture repair. Using three novel, transgenic
conditional knockout mouse model approaches, the combinatorial roles of YAP versus
TAZ as well as the dual roles of YAP and TAZ together are identified at multiple stages of
the osteogenic lineage in the context of bone function. Characterizing the roles of YAP and
TAZ during each bone function (i.e. growth, remodeling, and fracture repair) were
evaluated using skeletal phenotyping techniques at multiple length-scales complemented
with a combination of in vitro assays using various osteogenic-lineage cells.
Specific Aim 1 evaluated the combinatorial roles of skeletal cell YAP and/or TAZ
during bone growth. In this aim, we targeted combinatorial YAP and/or TAZ deletion in
osteoprogenitor cells and their progeny with Osterix-Cre using an allele dose-dependent
breeding strategy. The resulting phenotype of YAP and/or TAZ deletion from Osterixexpressing cells was evaluated at three stages of post-natal growth, corresponding to early
post-natal growth and ending with early skeletal maturity. Here, we used a multifaceted
approach to measure bone growth and function on the whole bone (microCT and
mechanical

testing),

tissue

(histological

and

multiphoton

imaging),

cellular

(immunohistochemistry and primary cell isolations), and molecular (RT-qPCR) levels.
Specific Aim 2 identified the dual roles of osteocyte YAP and/or TAZ during bone
growth and remodeling. In this aim, we targeted combinatorial YAP and/or TAZ deletion
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in osteocytes with 8kb-DMP1-Cre using an allele dose dependent breeding strategy, but
subsequently only compared dual homozygous YAP/TAZ knockouts to WT control mice.
The resulting phenotype of YAP and/or TAZ deletion from 8kb-DMP1-expressing cells
was evaluated at two stages of post-natal growth, corresponding to early post-natal growth
and early skeletal maturity. Here, we again used a multifaceted approach to measure bone
remodeling and function on the whole bone (microCT and mechanical testing), tissue
(histological,

multiphoton

imaging,

and

confocal

imaging),

cellular

(immunohistochemistry and in vitro cell model), and molecular (RT-qPCR) levels.
Specific Aim 3 investigated the combinatorial roles of skeletal cell YAP and/or TAZ
during bone fracture repair. In this aim, we again targeted combinatorial YAP and/or TAZ
deletion in osteoprogenitor cells and their progeny with Osterix-Cre using two deletion
models. In the first model, we constitutively deleted YAP and/or TAZ from Osterixexpressing cells from embryonic development onward, similar to Aim 1, and evaluated
adult bone fracture repair. In the second model, we induced dual YAP/TAZ deletion from
Osterix-expressing cells following skeletal maturity, but prior to fracture and evaluated
adult bone fracture repair. Here, we used a similar multifaceted approach to measure bone
fracture repair on the whole bone (microCT and mechanical testing), tissue (histological
and multiphoton imaging), cellular (immunohistochemistry and primary cell isolations),
and molecular (RT-qPCR) levels.
1.8
1.8.1

Approach
Overall Strategy
This study characterizes the contributions of the paralogous transcriptional co-

activators, YAP and TAZ, to bone growth, remodeling, and fracture repair at two distinct
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stages of the osteogenic cell lineage. Here, we used in vivo conditional knockout mouse
models with a combinatorial deletion strategy both in early osteoprogenitors and their
progeny (using Osterix-Cre) and in late stage osteocytes (using 8kb-DMP1-Cre). The
relative contributions of YAP and/or TAZ to bone growth, remodeling and fracture repair
were evaluated at multiple, post-natal time points, with an emphasis on characterizing how
YAP and/or TAZ deletion affected bone function at multiple length scales. Each mouse
model and distinct bone function (i.e. growth, remodeling, and fracture repair) were
evaluated using a similar set of methodologies. Whole-bone architectural and mechanical
properties were evaluated using both X-ray-based microCT imaging and three-point
bending or torsional testing. Bone tissue-level characteristics were assessed using both
standard histological and whole-mount stains, but also immunohistochemical and
immunofluorescent techniques combined with multiphoton and confocal microscopy
imaging. To assess cellular behavior in response to YAP/TAZ manipulation, both primary
cell isolations and osteogenic-lineage cell models were evaluated in vitro with a
combination of functional and gene expression analyses. Our overall hypothesis is that
skeletal cell YAP and TAZ promote osteogenesis during bone growth, development, and
remodeling while their combinatorial and dual deletion will result in decreased
osteogenesis with severity depending on the targeted cell type (i.e. Osterix- vs. DMP1expressing cells) and allele dosage (e.g. single copy of TAZ vs. single copy of both YAP
and TAZ).
1.8.2

Study Design and Animal Model
This study characterizes two transgenic conditional knockout mouse models at

various stages of post-natal development in the context bone growth, remodeling and
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fracture repair. Both models were generated using Cre-loxP technology and target distinct
osteogenic cell lineage populations. In Aim 1, we use the Osterix-Cre model63 to target
combinatorial deletion of YAP and/or TAZ in osteoprogenitors and their progeny from
embryonic development onward (Figure 1-3A). In Aim 2, we used the 8kb-DMP1-Cre
model69 to target combinatorial deletion of YAP and/or TAZ in osteocytes, but
subsequently compared YAPfl/fl;TAZfl/fl and YAPfl/fl;TAZfl/fl;8kb-DMP1-Cre mice (Figure
1-3B,C). In Aim 3, we again use the Osterix-Cre model63 to target combinatorial deletion
of YAP and/or TAZ in osteoprogenitors and their progeny, using either a constitutive
deletion model (from embryonic deletion onward) or an adult onset-inducible deletion
model (following skeletal maturity) (Figure 1-3D,E). In all aims, we used a breeding
strategy targeting YAP/TAZ deletion that yielded an allele dose dependent decrease in
YAP/TAZ allele number within littermates (Figure 1-3). Sample sizes were determined a
priori by power analysis based on effect sizes and population standard deviations taken
from published phenotypic data on YAPfl/fl;TAZfl/fl mice in other tissues188, assuming a
power of 80% and α=0.05.
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Figure 1-3: Breeding strategy resulting in combinatorial allele dosage-dependent YAP/TAZ deletion.
A) For Aim 1, YAPfl/fl;TAZfl/fl were bred to YAPfl/+;TAZfl/+;Osx-Cre, resulting in an allele dosage-dependent
deletion of YAP and/or TAZ from osteoprogenitor cells and their progeny. The five experimental genotypes
shown were compared. B) For Aim 2, YAPfl/fl;TAZfl/fl were bred to YAPfl/+;TAZfl/+;8kb-DMP1-Cre, resulting
in an allele dosage-dependent deletion of YAP and/or TAZ from osteocytes. The five experimental genotypes
shown were compared initially, but subsequent analyses were performed on genotypes shown in (C). D) For
Aim 3, the same allele-dosage dependent deletion of YAP and/or TAZ from osteoprogenitor cells and their
progeny was used for constitutive deletion from embryonic development onward. The four experimental
genotypes shown were compared in this model. E) For the inducible deletion model, dual homozygous
YAP/TAZ knockout mice (YAPcKOi;TAZcKOi) were compared to both WT littermate control mice
(YAPWT;TAZWT) and separately bred Osterix-Cre (Osx-Cre) control mice.
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In Aim 1 we combinatorially deleted YAP and/or TAZ from embryonic
development onward in osteoprogenitors and their progeny using Osterix-Cre and
evaluated bone growth at various stages of post-natal development. At P0 and P10, we
evaluated bone growth using a combination of microCT, whole-mount skeletal
preparations, and histological approaches. At P28, we evaluated bone formation rate using
flourochrome-labeling of actively mineralizing bone surfaces. At P56, we evaluated bone
architecture, mechanical, and matrix composition properties using microCT, three-point
bend testing, histology, and second-harmonic generated imaging.
In Aim 2 we combinatorially deleted YAP and/or TAZ in osteocytes using 8kbDMP1-Cre and evaluated bone remodeling at various stages of post-natal development. At
P0, we evaluated skeletal formation using whole-mount skeletal preparations. At P28, we
evaluated bone formation using flourochrome-labeling of actively mineralizing bone
surfaces and osteocyte lacunar-canalicular network formation. At P84, we evaluated bone
architecture, mechanical, and matrix composition properties with similar methods as Aim
1, but further analyzed osteocyte expression using immunohistochemistry.
In Aim 3, we combinatorially deleted YAP and/or TAZ from embryonic
development onward in osteoprogenitors and their progeny using Osterix-Cre and also
induced dual YAP/TAZ deletion after skeletal maturity using the tetracycline-sensitive
element of the Osterix-Cre model. In both deletion models, adult bone fracture repair was
evaluated in skeletally mature mice 18-21 weeks of age. In the constitutive deletion model,
fracture healing was evaluated 14 days post fracture (dpf) and 42 dpf with a combination
of microCT and torsional testing. In the inducible deletion model, fracture healing was

28

evaluated 4, 7 and 14 dpf with a combination of microCT, immunohistochemistry,
immunofluorescence and second-harmonic generated imaging.
1.9

Chapter Overview
Chapter 2 will describe how YAP and/or TAZ in osteoprogenitor cells and their

progeny contribute to matrix formation and organization during bone growth. Chapter 3
will describe how YAP and TAZ in osteocytes coordinate both osteocyte-intrinsic and
osteocyte-extrinsic functions during bone remodeling. Chapter 4 will describe how YAP
and/or TAZ in osteoprogenitor cells and their progeny contribute to the development,
activation and differentiation capabilities of periosteal osteoprogenitors during bone
fracture repair. Chapter 5 will summarize the conclusions of the previous chapters and
provide future directions for this area of research.
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CHAPTER 2: SKELETAL CELL YAP AND TAZ COMBINATORIALLY
PROMOTE BONE DEVELOPMENT
2.1

Abstract
The functions of the paralogous transcriptional co-activators Yes-associated protein

(YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) in bone are
controversial. Each has been observed to either promote or inhibit osteogenesis in vitro,
with reports of both equivalent and divergent functions. Their combinatorial roles in bone
physiology are unknown. Here we report that combinatorial YAP/TAZ deletion from
skeletal lineage cells, using Osterix-Cre, caused an osteogenesis imperfecta-like phenotype
with severity dependent on allele dosage and greater phenotypic expressivity with
homozygous TAZ vs. YAP ablation. YAP/TAZ deletion decreased bone accrual and
reduced intrinsic bone material properties through impaired collagen content and
organization. These structural and material defects produced spontaneous fractures,
particularly in mice with homozygous TAZ deletion, and caused neonatal lethality in dual
homozygous knockouts. At the cellular level in vivo, YAP/TAZ ablation reduced
osteoblast activity and increased osteoclast activity, in an allele dosage-dependent manner,
impairing bone accrual and remodeling. Transcriptionally, YAP/TAZ deletion and small
molecule inhibition of YAP/TAZ interaction with the transcriptional co-effector TEAD
reduced osteogenic and collagen-related gene expression both in vivo and in vitro.
Together, these data demonstrate that YAP and TAZ combinatorially promote bone
development through regulation of osteoblast activity, matrix quality, and osteoclastic
remodeling.
*This chapter is modified from publication in FASEB J (DOI: 10.1096/fj.201700872R). Authors: Kegelman
CD, Mason DE, Dawahare JH, Horan DJ, Vigil GD, Howard SS, Robling AG, Bellido TM, Boerckel JD.
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2.2

Introduction
Bone is a living hierarchical composite whose form and function depend not only

on tissue structure, but also matrix composition and organization. Each of these
components is controlled during development by skeletal cell lineage progression and by
dynamic regulation of bone deposition and remodeling. Various genetic, hormonal, or
environmental abnormalities can impair these processes, leading to debilitating diseases
including osteoporosis and osteogenesis imperfecta. However, the molecular mechanisms
that govern cell fate and matrix production in bone remain poorly understood, limiting
therapeutic intervention. Several transcriptional programs have been described as essential
regulators of bone development, but current understanding is insufficient to fully explain
the heterogeneity found in congenital and acquired bone diseases52,200,201. In this study, we
sought to define the functions of the paralogous transcriptional co-activators YAP and TAZ
in bone development.
Yes-associated protein (YAP) and Transcriptional co-activator with PDZ-binding
motif (TAZ; also known as WWTR1) display either equivalent or divergent functions,
depending on cell type and context131. While YAP and TAZ possess transcription
activation domains, they lack DNA-binding domains and require interaction with cofactors for transcriptional activity121. Their most potent and well-studied interactions are
with the transcriptional enhancer activator-domain (TEAD) family proteins, which
themselves lack activation domains, providing specificity for YAP/TAZ-TEAD
signaling126. However, other co-effectors are also known, including Runx2122, β-catenin114–
116

, and Smad2/3117,118, each of which contributes to bone development and osteoprogenitor

lineage progression76–78,202,203. Thus, independent pathways that regulate coincident
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activation of these various binding partners could provide additional layers of contextual
specificity in bone. Further, as paralogs, the YAP and TAZ proteins also possess structural
differences (reviewed in Ref.132) that enable distinct protein interactions to confer unique
physiological functions of YAP versus TAZ. Notably, global YAP deletion in mice is
embryonic lethal (E8.5) due to impaired yolk sac vasculogenesis204, while the global TAZ
knockout lives to maturity with modest skeletal defects and polycystic kidney disease205,
demonstrating conclusive gene-specific functions. However, in other contexts, they exhibit
clear functional homology, with either protein capable of compensation for the other188,206.
Roles for YAP and TAZ in osteogenesis were first described in 2004 and 2005,
respectively112,113. YAP was reported to suppress osteoblastic differentiation through
sequestration and transcriptional repression of Runx2112, while TAZ was identified as a
Runx2 co-activator and an inhibitor of the adipogenic nuclear receptor, PPARγ113,157. A
subsequent study found that overexpression of a constitutively-active YAP mutant in
marrow stromal cells (MSCs) promoted osteogenic differentiation even under conditions
more favorable for adipogenesis150. In contrast, another report found that YAP
overexpression inhibited osteogenesis in MSCs by suppressing activation of WNT target
genes147. The role of TAZ in osteogenic differentiation in vitro is similarly complicated,
with reports demonstrating both inhibition148 and induction160 of osteogenic differentiation
by modulating the canonical WNT pathway. In vivo, osteoblast-specific overexpression of
TAZ promoted bone formation with higher expression levels of Runx2 expression175, while
YAP overexpression in chondrocytes impaired cartilage template formation during
endochondral bone development181. Together, these observations suggest the importance
of YAP and TAZ in bone, but the conflicting evidence remains unresolved and their
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combinatorial roles in bone physiology remain unknown. To address these questions, we
implemented a combinatorial deletion approach in vivo to evaluate the influence of allele
dosage-dependent YAP/TAZ deletion on bone development.
2.3
2.3.1

Methods
Animals
Mice harboring loxP-flanked exon 3 alleles in both YAP and TAZ on a mixed

C57BL/6J background were kindly provided by Dr. Eric Olson (University of Texas
Southwestern Medical Center). Tetracycline responsive (tetOFF) B6.Cg-Tg(Sp/7tTA,tetO-EGFP/Cre)1AMc/J (Osterix-Cre) mice from The Jackson Laboratory (Bar
Harbor, MA, USA) were raised, bred, and evaluated without tetracycline administration to
induce constitutive gene recombination in osteoprogenitor cells and their progeny from
embryonic development onward63.
Mice with homozygous floxed alleles for both YAP and TAZ (YAPfl/fl;TAZfl/fl)
were mated with double heterozygous conditional knockout mice (YAPfl/+;TAZfl/+;OsxCre) to produce eight possible genotypes in each litter, but only Cre-positive and
YAPfl/fl;TAZfl/fl animals were compared (Table 2-1). Both male and female mice were
evaluated, with YAPfl/fl;TAZfl/fl mice serving as littermate control mice (WT). The different
analyses were performed in both male and female young mice at postnatal day 0 (P0),
postnatal day 10 (P10), postnatal day 28 (P28), and postnatal day 56 (P56). All mice were
fed regular chow ad libitum and housed in cages containing 2-5 animals each. Mice were
maintained at constant 25°C on a 12-hour light/dark cycle. Mice were tail or ear clipped
after weaning or prior to euthanasia and genotyped by an external service (Transnetyx, Inc.,
Cordoba, TN, USA). All protocols were approved by the Institutional Animal Care and
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Use Committees at the University of Notre Dame and the University of Pennsylvania and
in adherence to federal guidelines for animal care.
Table 2-1: Experimental genotypes & abbreviations (Aim 1)

2.3.2

Genotype

Abbreviation

Yapfl/fl;Tazfl/fl

YAPWT;TAZWT

Yapfl/+;Tazfl/+;Osx-CretetOff

YAPcHET;TAZcHET

Yapfl/fl;Tazfl/+;Osx-CretetOff

YAPcKO;TAZcHET

Yapfl/+;Tazfl/fl;Osx-CretetOff

YAPcHET;TAZcKO

Yapfl/fl;Tazfl/fl;Osx-CretetOff

YAPcKO;TAZcKO

Skeletal preparations
Skeletal preparations were stained with Alcian blue (A3157; Sigma-Aldrich, St.

Louis, MO, USA) and Alizarin red (A5533; Sigma-Aldrich, St. Louis, MO, USA) as
described previously207.
2.3.3

Microcomputed tomography
Micro-computed tomography (microCT) was performed according to published

guidelines208. Harvested femora from P56 mice were stored at -20°C until evaluation.
Frozen specimens were thawed and imaged using a vivaCT 80 scanner (Scanco Medical,
Zurich, Switzerland) to determine trabecular and cortical femoral bone architecture prior
to mechanical testing. The mid-diaphysis and distal femur were imaged with an X-ray
intensity of 114 µA, energy of 70 kVp, integration time of 300 ms, and resolution of 10
µm. Mid-diaphyseal and distal femoral 2D tomograms were manually contoured, stacked
and binarized by applying a Gaussian filter (sigma =1, support =1) at a threshold value of
550 mg HA/cm3. Eight mice were analyzed per group except for the YAPcKO;TAZcKO
genotype. Investigators were blinded to animal genotype during scan quantification.
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2.3.4

Mechanical testing
Following microCT scanning, femurs from P56 mice were tested in three point

bending to failure. Femurs were loaded with the condyles facing down onto the bending
fixtures with a lower span length of 4.4 mm, which attenuated the effect of femur length
on the measured mechanical properties. The upper fixture was aligned with the middiaphysis. The femora were loaded to failure at a rate of 0.5 mm/s using the ElectroForce
3220 Series testing system (TA Instruments, New Castle, DE, USA). Stiffness, maximum
load to failure, work to maximum load and work to failure were quantified using a custom
MATLAB script170. Eight mice were analyzed per group except for the YAPcKO;TAZcKO
genotype. Investigators were blinded to animal genotype during data quantification.
2.3.5

Histology, immunohistochemistry, and immunofluorescence
Femurs and tibias from P10, P28, and P56 mice were fixed with 10% neutral

buffered formalin for 48 hours and decalcified following standard procedures. Paraffin
sections (5 µm thickness) for were processed for either immunohistochemistry or
histology. Primary antibodies were compared to IgG control sections. Anti-Osterix (abcam,
Eugene, OR, USA: Cat# ab22552, 1:250), anti-YAP (Cell Signaling, Danvers, MA, USA:
Cat# 14074, 1:400), anti-TAZ (Cell Signaling, Danvers, MA, USA: Cat# 4883, 1:400)
were applied overnight. Colorimetric detection using the DAB Peroxidase HRP-linked
Substrate Kit (Vector Labs, Burlingame, CA, USA) allowed for immunohistochemical
detection of YAP, TAZ, or Osterix-positive cells. Hematoxylin and eosin stains (H&E),
Safranin O/Fast Green (Saf-O), Tartrate-resistant acid phosphatase (TRAP), and
Picrosirius Red stains were used.
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Methyl-methacrylate-embedded bones from P28 mice injected with Calcein (Sigma
#: C0875-25G) and Alizarin Complexone (Sigma #:A3882-25G ) were processed for
dynamic bone histomorphometry. Using a diamond-embedded wire saw (Histo-saw;
Delaware Diamond Knives, Wilmington, DE, USA), transverse sections (40 µm) were cut
from the midshaft and ground to a final thickness of 20 µm. The slice sections were
mounted on slides, and three sections per limb were analyzed using OsteomeasureTM
(OsteoMetrics, Decatur, GA, USA).
2.3.6

Imaging and histomorphometric analysis
Histological and immunohistochemical sections were imaged either on a 90i

Upright/Widefield Research Microscope (Nikon Instruments, Melville, NY, USA) at the
4x, 10x, 20x, and 40x objectives or an Axio Observer Z1 (Zeiss) at the 20x and 40x
objectives. Osteoblast number per bone surface and osteocyte number per bone area were
quantified using OsteomeasureTM (OsteoMetrics, Decatur, GA, USA) and ImageJ (NIH,
Bethesda, MD, USA) on H&E stained sections in the cortical bone compartment using 36 separate fields of view per mouse. Osteoclast surface per bone surface was quantified on
TRAP stained sections in the cancellous bone compartment using 3 separate fields of view
per mouse. Hypertrophic chondrocyte zone percent thickness (HZ thickness %) was
calculated using ImageJ (NIH, Bethesda, MD, USA) by measuring three separate lines
across the area of positive Saf-O staining in the center metaphyseal region, normalized to
the respective length of the total growth plate within each line, and averaged together for
each mouse.
The samples tested in three-point bending were stained with Picrosirius Red and
imaged under polarized light using an Eclipse ME600 Microscope (Nikon Instruments,
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Melville, NY, USA) at the 20x objective while second harmonic image microscopy (SHG)
images were taken on a multiphoton-enabled Fluoview Research Microscope (Olympus,
Center Valley, PA, USA) at a fundamental wavelength of 875nm with the 25x objective
on sections oriented in the same direction for all groups. All SHG images were quantified
using ImageJ and reported as mean pixel intensity within the cortical region relative to WT
bone. Mean pixel intensities across four separate regions of interest within each image of
the cortex were averaged as technical replicates for a given sample.
Dynamic bone histomorphometry sections of P28 femurs were imaged on an Axio
Observer Z1 (Zeiss) at the 20x, 40x, and 63x objectives. Dynamic bone histomorphometry
parameters were quantified using OsteomeasureTM (OsteoMetrics). The following primary
data were collected: total bone surface length (BS); single label perimeter (sL.Pm); double
label perimeter (dL.Pm); and double label width (dL.Ith). From primary data, we derived
mineralizing surface (MS/BS = [1/2sL.Pm+dL.Pm]/B.Pm ×100; %); mineral apposition
rate (MAR = dL.Ith/5 days; µm/day) and bone formation rate (BFR/BS = MAR × MS/BS;
µm3/µm2 per day). Eight mice were analyzed per group except for the YAPcKO;TAZcKO
genotype. Investigators were blinded to animal genotype during image acquisition and
quantification of all histology and immunofluorescent images.
2.3.7

Marrow stromal cell isolation and culture
Mouse bone marrow stromal cells (MSCs) were isolated from either WT or Osterix

conditional YAP/TAZ deficient mice and cultured at 37°C and 5% O2 in media
supplemented with FGF-2, as described previously209. Briefly, mice were anesthetized by
isoflurane inhalation (2%) and euthanized via cervical dislocation. Long bone samples
were dissected and then marrow cavities were flushed out into a tissue culture plastic flask
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for 3-5 days. MSCs were cultured at 5% O2 in Dulbecco's Modified Eagle's Medium
(DMEM) with 10% FBS, 10 ng/ml bFGF (Austral Biologicals, San Ramon, CA, cat # GF030-5), 1% penicillin-streptomycin, and 1 µg/ml doxycycline.
During passaging, culture media was removed and the cells were quickly rinsed
once with 4mL of TrypLE Express Enzyme (Thermo-Fisher Scientific, Philadelphia, PA,
USA, cat# 12605036) by rolling the trypsin over the plate to allow the senescent cells from
the cultures to initially detach209. These senescent cells were then discarded prior to
standard passaging of the MSCs. MSCs were then seeded, at 21% O2, into 6-well plates (9
x 103 cells/cm2) containing 30 mL osteogenic induction media, which included 2 mg/ml bglycerophosphate, 50 µM dexamethasone, and 3.75 mg/ml ascorbic acid to the previously
described media without doxycycline of FGF-2. Osteogenic media was changed every
other day prior to RNA isolation.
2.3.8

UMR-106 cell culture
Osteoblast-like UMR-106 cells (UMRs) were cultured in DMEM containing 4 mM

L-glutamine, 4500 mg/L glucose, 1 mM sodium pyruvate, and 1500 mg/L sodium
bicarbonate and 10% FBS according to American Type Culture Collection (ATCC,
Manassas, VA, USA: Catalog #: 30-2002) recommendations. UMRs at 50 % confluence in
96-well plates were transfected in antibiotic-free media for four hours with four previously
described luciferase reporter constructs: 1) Runx2-responsive 6xOSE2, 2) 657 bp
Osteocalcin promoter210, 3) TEAD-responsive 8XGTIIC (Addgene, Cambridge, MA,
USA) and a control renilla plasmid, kindly provided by Dr. Munir Tanas (University of
Iowa).
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Forty-eight hours after transfection, UMRs were treated with either DMSO, 0.5
µM, or 1 µM verteporfin (VP) for 4 hours then in serum-free conditions for 3 hours. All
VP experiments were carried out in the dark to prevent photoactivation. Cells were then
lysed immediately using the Dual-Luciferase Reporter Assay System according to
manufactures instructions (Promega, Madison, WI, USA). Luciferase activity was
measured on a VICTOR 3 (Perkin Elmer, Waltham, MA, USA) plate reader and
normalized to baseline renilla activity as previously described211. Separately cultured
UMR-106 cells were seeded (4 x 103 cells/cm2) onto 6-well plates and simultaneously
treated with either DMSO, 0.5 µM, or 1µM VP and cultured for 4 hours and then under
serum-free conditions for 3 hours prior to RNA isolation.
2.3.9

Verteporfin delivery in vivo
Six littermate control (four male and two female) mice (YAPWT;TAZWT) were aged

until 16 weeks. Three mice each (two males and one female each) were assigned to
verteporfin (VP) or vehicle control (dimethyl sulfoxide, DMSO) groups. Briefly, DMSOsolubilized VP was diluted in 0.9% saline and injected intraperitoneally at 100 mg/kg every
other for day for 2 weeks. Control animals received corresponding injections of DMSO in
0.9% saline. Livers and femurs from both VP-treated and DMSO-treated mice were
harvested on the day of the last injection for RNA isolation.
2.3.10 RNA isolation and qPCR
Bone and liver samples were snap frozen in liquid nitrogen-cooled isopentane for
1 minute prior to storage at -80°C until processing. Tissue was then homogenized via
mortar and pestle and RNA from the sample was collected using Trizol Reagent (Life
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Technologies Inc., Carlsbad, CA, USA) followed by centrifugation in chloroform. RNA
from tissue samples and cell culture experiments were purified using the RNA Easy Kit
(Qiagen, Germantown, MD, USA) and quantified by spectrophotometry using a NanoDrop
2000 (Thermo-Fisher Scientific, Philadelphia, PA, USA). Reverse transcriptase
polymerase chain reaction (RT-PCR) was performed on 0.1-0.5 μg/μl concentration of
RNA using the TaqMan Reverse Transcription Kit (Thermo-Fisher Scientific,
Philadelphia, PA, USA). Quantitative polymerase chain reaction (qPCR) assessed RNA
amount using a CFX Connect (Bio-Rad, Hercules, CA, USA) relative to the internal control
of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Data are presented using the
DDCt method. Six mice per group were used except for the YAPcKO;TAZcKO genotype.
Specific mouse and rat primer sequences are listed (Table 2-2).
Table 2-2: qPCR primers (Aim 1)
A) Mouse primers used for qPCR B) Rat primers used for qPCR

A) Mouse gene

Primer Sequence (5’ to 3’)

Gapdh

F
R

TCACTGCCACCCAGAAGAC
TGTAGGCCATGAGGTCCAC

Yap

F
R

TGGACGTGGAGTCTGTGTTG
AAGCGGAACAACGATGGACA

Taz

F
R

GTCCATCACTTCCACCTC
TTGACGCATCCTAATCCT

Col1a1

F
R

GCTCCTCTTAGGGGCCACT
CCACGTCTCACCATTGGGG

Col1a2

F
R

GTAACTTCGTGCCTAGCAACA
CCTTTGTCAGAATACTGAGCAGC

Col2a1

F
R

GACTGAAGGGACACCGAG
CCAGGGATTCCATTAGAG

Col10

F
R

ATGCTGCCTCAAATACCCT
TGCCTTGTTCTCCTCTTACT

SerpinH1

F
R

AGCCGAGGTGAAGAAACCC
CATCGCCTGATATAGGCTGAAG
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Runx2

F
R

AGCCTCTTCAGCGCAGTGAC
CTGGTGCTCGGATCCCAA

Osx

F
R

CTGGGGAAAGGAGGCACAAAGAAG
GGGTTAAGGGAGCAAAGTCAGAT

Ocn

F
R

TGAGCTTAACCCTGCTTGTG
TAGGGCAGCACAGGTCCTA

Alp

F
R

GGACAGGACACACACACACA
CAAACAGGAGAGCCACTTCA

Bsp

F
R

ACAATCCGTGCCACTCACT
TTTCATCGAGAAAGCACAGG

Cyr61

F
R

CTGCGCTAAACAACTCAACGA
GCAGATCCCTTTCAGAGCGG

Ctgf

F
R

GGGCCTCTTCTGCGATTTC
ATCCAGGCAAGTGCATTGGTA

B) Rat gene

Primer Sequence (5’ to 3’)

Gapdh

F
R

CATGGCCTTCCGTGTTCCTA
GCGGCACGTCAGATCCA

Col1a1

F
R

ACAGCGTAGCCTACATGG
AAGTTCCGGTGTGACTCG

Col1a2

F
R

ATGGTGGCAGCCAGTTTG
GCTGTTCTTGCAGTGGTAGG

SerpinH1

F
R

TCATGGTGACCCGCTCCTAC
GCTTATGGGCCAAGGGCATC

Runx2

F
R

CAGGTTCAACGATCTGAGATTTGT
TGAAGACCGTTATGGTCAAAGTGA

Osx

F
R

CAGCCTGCAGCAAGTTTGG
TTTTCCCAGGGCTGTTGAGT

Alp

F
R

GAGCAGGAACAGAAGTTTGC
GTTGCAGGGTCTGGAGAGTA

Bsp

F
R

TCCTCCTCTGAAACGGTTTCC
CGAACTATCGCCATCTCCATT

Ctgf

F
R

ATCCCTGCGACCCACACAAG
CAACTGCTTTGGAAGGACTCGC
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2.3.11 Statistics and regression
All statistics and regression analyses were performed in GraphPad Prism (San Diego,
CA, USA) or using R (Version 2.13.1). Comparisons between two groups were made using
the independent t-test while comparisons between 3 or more groups were made using a
one-way ANOVA with post-hoc Bonferroni’s multiple comparisons test, if the data were
normally distributed according to D’Agostino-Pearson omnibus normality test and
homoscedastic according to Bartlett’s test. When parametric test assumptions were not met,
data were log-transformed and residuals were evaluated. If necessary, the non-parametric
Kruskal-Wallis test with post-hoc Dunn’s multiple comparisons was used. A p-value <
0.05 (adjusted for multiple comparisons) was considered significant. On the graphs,
repeated significance indicator letters (e.g., “a” vs “a”) signify P > 0.05. while groups with
distinct indicators (e.g., “a” vs “b”) signify P < 0.05. Data are represented as individual
samples with mean ± standard error of the mean (SEM). Sample sizes were selected a
priori by power analysis based on effect sizes and population standard deviations of
phenotypic differences taken from published data on YAPfl/fl;TAZfl/fl mice in other
tissues,188 assuming a power of 80% and α=0.05.
Multivariate analysis was performed following a previously described procedure, with
some modifications212. Briefly, we used an exhaustive best subsets algorithm to determine
the best predictors of maximum load and stiffness from a subset of morphological
parameters measured, which included moment of inertia (I) or section modulus (I/c), tissue
mineral density (TMD), and relative second harmonic generated (SHG) intensity based on
the Akaike’s information criterion (AIC).213 The best subsets algorithm selects the optimal
model using the Akaike’s information criterion (AIC), which gives preference to less
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complex models with fewer explanatory parameters to avoid overfitting the data213. The
overall “best” multivariate model for each predicted mechanical property was selected with
the lowest relative AIC value, indicative of having the least variables with the greatest
predictive power. AIC values were used to determine the “best” model for predicting new
data instead of R2 values, which describe how well the model fits existing data. Further,
adding additional variables can artificially increase R2 values without enhancing model
relevancy.

2.4
2.4.1

Results
YAP/TAZ expression and deletion in bone
To determine YAP/TAZ expression profiles in bone, we immunostained YAP and

TAZ in the growth plate and cancellous and cortical bone of 8-week-old C57Bl6/J mouse
femora. YAP and TAZ immunolocalized in hypertrophic chondrocytes, osteoblasts, and
osteocytes with minimal detectable expression in quiescent or proliferating chondrocytes
(Figure 2-1A). Based on these expression patterns, we chose to evaluate the physiological
roles of YAP and TAZ by combinatorial conditional ablation188 in cells of the skeletal
lineage using Osterix-Cre63. We selected a breeding strategy that yielded littermates with
variable YAP/TAZ allele dosage. To assess Cre-mediated recombination and deletion of
YAP and TAZ, we measured mRNA expression in femoral bone preparations by qPCR
(Figure 2-1B), and qualitatively observed reduced cellular expression in the growth plate
of conditional knockout mice by IHC (Figure 2-1C). YAP/TAZ expression in skeletal cells
was reduced by 50-80% by Osterix-Cre-mediated excision as measured by qPCR (Figure
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2-1B).

Figure 2-1: YAP/TAZ expression and deletion in skeletal cells.
In vivo YAP/TAZ expression and deletion efficiency were assessed by immunohistochemistry (IHC) and
quantitative (qPCR). A) YAP/TAZ were expressed in hypertrophic chondrocytes, osteoblasts, and osteocytes
in bone. Scale bars in the first column are 50 microns for the growth plate, and 100 microns for magnified
images of trabecular and cortical bone. B) YAP and TAZ transcript expression in Osterix-conditional
knockout mice in femoral bone lysates. C) Qualitative comparison of IHC for YAP and TAZ expression in
Osterix-conditional cKO growth plates. Scale bars in the first column are 50 microns.

2.4.2

Neonatal lethality and hypermineralization
All Osterix-conditional knockouts and littermate controls were born at expected

Mendelian ratios, but dual homozygous conditional deletion (YAPcKO;TAZcKO) caused
neonatal asphyxiation secondary to ribcage malformation and fracture (Figure 2-2A-C),
resulting in 75% mortality at postnatal day 0 (P0) and 99% by P7 (Figure 2-2B). Only one
female YAPcKO;TAZcKO mouse lived to P56 for each endpoint analysis. YAPcKO;TAZcKO
neonates exhibited spinal scoliosis, cranial vault deformity, and spontaneous fractures of
the ribs, tibia, femur, radius and ulna (Figure 2-2A,C-E). Spontaneous extremity fractures
were not present in other genotypes at P0 (Figure 2-2A). YAPcKO;TAZcKO mice displayed
reduced whole-skeleton bone volume (Figure 2-2F; p < 0.05, ANOVA) and significantly
elevated bone tissue mineral density (Figure 2-2G; p < 0.01, ANOVA) compared to
littermate control mice. Osterix-conditional YAP/TAZ deletion also significantly reduced
birth weight and intact femoral length in an allele dosage-dependent manner (Figure 2-3).
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Males and females exhibited similar phenotypes in both growth deficits and P0 skeletal
morphology (Figure 2-3).

Figure 2-2: Combinatorial YAP/TAZ ablation from Osterix-expressing cells caused allele dosagedependent perinatal skeletal deformity and lethality.
Skeletal structures of littermate mice were evaluated at postnatal day 0 (P0). A) Whole body skeletal
preparations of Osterix-conditional YAP/TAZ knockouts and controls stained with Alcian blue/Alizarin red
and microCT reconstructions reveal progressive skeletal malformation with decreasing allele dosage. B)
Survival curves for each genotype show 99% lethality of YAPcKO;TAZcKO mice by P56. C-E) Skeletal
preparations and microCT reconstructions of rib cages, hindlimbs, and femora, respectively, illustrate
spontaneous perinatal fractures in YAPcKO;TAZcKO mice. F) P0 whole skeleton bone volume was
significantly altered by dual homozygous YAP/TAZ deletion. G) P0 whole skeleton tissue mineral density
(TMD increased with YAP/TAZ allele deletion. Data are presented as individual samples with lines
corresponding to the mean and standard error of the mean (SEM). Sample sizes, n = 7-15.
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Figure 2-3: Allele dose dependent YAP/TAZ ablation from Osterix-expressing cells in 8-week-old mice
reduced overall long bone growth independent of sex.
Allele-dosage-dependent YAP/TAZ ablation from Osterix-expressing cells reduced body mass in (A,B) male
and (D,E) female mice with similar trends in (C,F) survival curves for each sex by P56. Reduced femoral
length in (G) males and (H) females. * indicates death of male YAPcKO;TAZcKO mouse at P10, “a” indicates
difference between YAPcHET;TAZcHET and WT, “b” indicates difference between YAPcKO;TAZcHET and WT,
“c” indicates difference between YAPcHET;TAZcKO and WT, “d” indicates difference between
YAPcKO;TAZcKO and WT. Sample sizes, n = 8 for both sexes and genotypes at except n = 1 for
YAPcKO;TAZcKO male and n = 2 for YAPcKO;TAZcKO females. I) P0 bone volumes reduced similarly between
sexes with # indicating lower bone volumes in YAPcKO;TAZcKO mice for both sexes. Sample sizes, n = 7-15
per genotype at P0.
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2.4.3

Spontaneous neonatal long bone fractures & defective endochondral bone
formation
A single copy of either gene rescued neonatal lethality, with 83 and 85% of

YAPcHET;TAZcKO and YAPcKO;TAZcHET mice surviving to terminal analysis at P56,
respectively. However, between P1 and P10, both YAPcHET;TAZcKO and YAPcKO;TAZcHET
mice sustained spontaneous femoral and other bone fractures (Figure 2-4A-B), with
significantly increased femoral fracture incidence in the YAPcHET;TAZcKO mice (p<0.01,
χ2 test; Figure 2-4C). Fractures healed by endochondral repair in all groups, though
YAPcHET;TAZcKO and YAPcKO;TAZcKO calluses exhibited empty lacunae in the
hypertrophic transition zone, suggesting increased hypertrophic chondrocyte death or
insufficient progenitor cell recruitment (Figure 2-4C c.f. Figure 2-4D). Consistently,
staining of Osterix-positive cells was qualitatively reduced in the transition zone of the
YAPcKO;TAZcKO growth plate, but differences in the thickness of the resting (RZ),
proliferating (PZ), and hypertrophic (HZ) zones of the growth plate did not reach statistical
significance at either P10 (p>0.05, Figure 2-4E-G) or P56 (p>0.05, Figure 2-5A,B).
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Figure 2-4: YAP/TAZ ablation from Osterix-expressing cells induced spontaneous neonatal femoral
fractures and impaired endochondral bone formation.
A) Representative radiographs with matched (B) microCT reconstructions of femoral fracture calluses at
P10. C) Quantification of the number of mice with femoral fractures demonstrated significantly increased
fracture incidence in YAPcHET;TAZcKO mice. D) Safranin-O/fast green staining of mid-diaphysis bone collar
and (E) growth plates of matched P10 femora split into resting zone (RZ), proliferating zone (PZ), and
hypertrophic zone (HZ). Scale bar = 50 µm. F) Histomorphometric quantification of P10 hypertrophic zone
thickness as percentage of total growth plate thickness (HZ thickness %). G) Representative micrographs of
P10 distal femur growth plates immunostained for osterix-positive cells (brown). Scale bar = 25 µm. Data
presented as individual samples with lines corresponding to the mean and standard error of the mean (SEM).
Sample sizes, n = 3-4 except YAPcKO;TAZcKO n = 1.

Figure 2-5: Allele-dose dependent YAP/TAZ ablation from Osterix-expressing cells in 8-weeks-old mice
does not significantly alter growth plate morphology.
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A) Safranin-O/fast green staining of P56 femoral growth plates with inset of larger field of view. Scale bar =
50 µm. B) Quantification of P56 hypertrophic zone thickness as a percentage of total growth plate thickness
in the femoral metaphyseal region (HZ thickness %). Data presented as individual samples with lines
corresponding to the mean and standard error of the mean (SEM). Sample sizes, n = 8 mice except
YAPcKO;TAZcKO n = 1.

2.4.4

Reduced cortical and cancellous microarchitectural properties
YAP/TAZ deletion from osteoblast precursor cells and their progeny altered

cancellous (Figure 2-6A,B) and cortical bone (Figure 2-6C,D) in adolescent mice (P56)
according to allele dosage. Distal femur metaphyseal cancellous bone exhibited reduced
trabecular bone volume fraction (BV/TV), thickness (Tb.Th), and number (Tb.N), and
increased spacing (Tb.Sp) and structural model index (SMI, indicative of more rod-like
trabeculae) (Figure 2-6B, Figure 2-7A-C). The cumulative distribution of trabecular
thicknesses shifted in an allele dosage-dependent manner, toward reduced numbers of both
small and large trabeculae (Figure 2-7B). Volumetric bone mineral density was
significantly reduced, suggesting no differences in local tissue mineral density proportional
to the decrease in trabecular bone volume (Figure 2-6B). Mid-diaphyseal femoral cortical
bone (Figure 2-6C,D, Figure 2-7D,E) similarly exhibited reduced thickness (Ct.Th), area
(B.Ar), and moment of inertia (I) in cKO mice, attributable both to reduced periosteal and
endocortical bone accumulation, as indicated by significant reductions in endocortical
perimeter (Ec.Pm), periosteal perimeter (Ps.Pm), and bone area (B.Ar). Cortical tissue
mineral density (Ct.TMD) was not significantly altered.
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Figure 2-6: YAP/TAZ ablation altered bone microarchitectural properties in a manner dependent on allele
dosage.
Femora from 8 weeks-old Osterix-conditional YAP/TAZ littermates were evaluated by microCT analysis.
A) Representative microCT reconstructions of distal metaphyseal cancellous bone, arranged in decreasing
allele dosage. B) Cancellous bone microarchitectural parameters were impaired according to YAP/TAZ allele
dosage: bone volume fraction (BV/TV), trabecular thickness (Tb.Th), number (Tb.N) and spacing (Tb.Sp),
volumetric bone mineral density (vBMD), and structural model index (SMI). C) Representative microCT
reconstructions of the mid-diaphyseal cortex, arranged in decreasing allele dosage. D) Cortical crosssectional properties were reduced in cKO mice: bone area (B.Ar), endocortical perimeter (Ec.Pm), periosteal
perimeter (Ps.Pm), cortical thickness (Ct.Th), moment of inertia in the direction of bending (I), and cortical
tissue mineral density (Ct.TMD). Data are presented as individual samples with lines corresponding to the
mean and standard error of the mean (SEM). Sample sizes, n= 8 mice except YAPcKO;TAZcKO n = 1. Scale
bars indicate 1 mm for 2D microCT slice reconstructions.
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Figure 2-7: Allele-dose dependent YAP/TAZ ablation from Osterix-expressing cells in 8-week-old mice
altered bone microarchitecture.
Femora from 8 weeks-old Osterix-conditional YAP/TAZ littermates were evaluated by microCT analysis.
A) Representative 3D microCT reconstructions of distal metaphyseal cancellous bone, arranged in decreasing
allele dosage. B) Trabecular thickness histogram distributions (Tb.Th). C) Total tissue area and D) medullary
area of cortical bone from the mid-diaphysis. Sample sizes, n= 8 except YAPcKO;TAZcKO n = 1.

2.4.5

Reduced intrinsic bone mechanical properties and matrix collagen content and
microstructure
In general, extrinsic bone properties (e.g., failure load, bending stiffness) depend

on both the intrinsic mechanical properties of the bone matrix and the bone amount and
cross-sectional distribution. To determine whether Osterix-conditional YAP/TAZ deletion
impaired bone matrix quality, we performed three-point bend testing to failure on each
femur previously analyzed by microCT (Figure 2-8A,B). YAP/TAZ deletion reduced
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stiffness, maximum force at failure, work to maximum load, and work to failure (Figure 28C-F). Since the assumptions of Euler-Bernoulli beam theory are decidedly not met in
three-point bend testing of mouse long bones214,215, we performed an analysis of covariance
(ANCOVA) using linear regression (Figure 2-8G,H) to decouple the contributions of bone
quantity and distribution from the mechanical behavior216. If the variability in extrinsic
mechanical properties is best predicted by individual regression lines for each genotype,
this would indicate differences in intrinsic matrix mechanical properties between
genotypes; however, a best-fit by a single regression line for all groups would indicate that
differences in extrinsic behavior are sufficiently described merely by changes in bone
geometry216. We found that individual regression lines for each genotype best predicted
maximum load at failure, indicating significant differences in intrinsic failure properties
(Figure 2-8G). In contrast, a single regression line best fit the stiffness data (Figure 2-8H),
indicating that the differences in stiffness can be attributed to changes in moment of inertia
rather than intrinsic matrix elastic properties.
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Figure 2-8: YAP/TAZ ablation reduced intrinsic bone failure properties.
Femora from 8-weeks-old osterix-conditional YAP/TAZ littermates were tested in (A) three point bending
to failure. B) Representative, average load-displacement curves collected during testing. C-F) YAP/TAZ
deletion reduced extrinsic mechanical properties measured from the load-displacement curves including (C)
maximum load, (D) stiffness, (E) work to maximum load and (F) work to failure. ANCOVA analysis
accounting for bone geometry revealed significant differences in (G) intrinsic failure properties, but not (H)
intrinsic elastic properties. Data are presented as individual samples with lines corresponding to the mean
and standard error of the mean (SEM). Sample sizes, n = 8, except YAPcKO;TAZcKO, n = 1.

As a composite material, quasi-static bone mechanical behavior is determined
predominantly by its two primary matrix components: mineral and collagen. We noted
above that femora from mice with Osterix-conditional YAP/TAZ deletion did not exhibit
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differences in mineralization (Figure 2-6D). Next, to characterize the bone matrix collagen
in these same samples, we performed polarized light microscopy of Picrosirius red-stained
sections (Figure 2-9A) and second harmonic imaging microscopy (SHG, Figure 2-9B)217.
Both approaches revealed that YAP/TAZ deletion significantly reduced local collagen
content and organization (Figure 2-9C). Therefore, to determine the contributions of
geometry, mineralization, and collagen content and microstructure to bone mechanical
behavior, we performed a best-subsets correlation analysis to identify significant predictors
based on Akaike’s information criterion (AIC)212,213. For both elastic (Figure 2-9D) and
failure (Figure 2-9E) properties, bone tissue mineral density was not a significant predictor;
however, moment of inertia and SHG intensity significantly improved model capability to
explain variation with reduced AIC (Figure 2-10). Addition of tissue mineral density
(TMD) to the models did not improve predictive power as measured by AIC (Figure 2-10).

Figure 2-9: YAP/TAZ ablation reduced bone matrix collagen content and organization.
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Imaging of matrix collagen was performed on femora from 8 weeks-old osterix-conditional YAP/TAZ
littermates. Representative (A) polarized light and (B) second harmonic generation (SHG) microscopy
images from cortical bone tissue sections of three-point bend tested femora. C) Second harmonic generated
(SHG) intensity, relative to WT, was reduced according to allele-dosage. Best subsets regression analyses
indicating significant contributions of both bone geometry and collagen content and microstructure, but not
tissue mineral density, to both (D) elastic and (E) failure mechanical properties. Sample sizes, n = 8 except
YAPcKO;TAZcKO n = 1. Scale bars indicate 100 μm and 25 μm in Picrosirius red and SHG images,
respectively.

Figure 2-10: Best subsets analysis on morphological parameters from YAP/TAZ ablation in Osterixexpressing cells from 8-week-old mice demonstrated increased predictiveness by accounting for collagen
content and organization.
Within the mice with Osx-driven deletion of YAP/TAZ, we compared experimental ultimate load (Fmax) with
predicted model values with (A) only moment of inertia as a predictor, (B) moment of inertia and second
harmonic generated signal intensity, or (C) moment of inertia, second harmonic generated signal intensity,
and tissue mineral density. Similarly, we compared experimental to predicted stiffness using (D-F) the same
predictors, respectively. Akaike’s information criterion (AIC) was at a minimum for both ultimate load and
stiffness with geometry and SHG as independent parameters, suggesting optimal predictive power by
geometry and SHG. Sample sizes n = 8, except YAPcKO;TAZcKO n = 1.

Static histomorphometric analysis of Osterix-conditional YAP/TAZ-deficient P56
femora revealed an allele dose-dependent decrease in periosteal osteoblast number per
bone surface (Ob.N/BS), but a dose-dependent increase in osteoclast surface per bone
surface (Oc.S/BS) in the metaphyseal secondary spongiosa (Figure 2-11A,B,D-E). Cortical
osteocyte density (Ot.N/B.Ar) was not significantly altered (Figure 2-11A,F). Dynamic
histomorphometric analysis of Osterix-conditional YAP/TAZ deficient P28 femora
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revealed no significant differences in mineralizing surface percentage (MS/BS), while
mineral apposition rate (MAR) was significantly reduced, according to allele dosage
(Figure 2-11C,G,H). Differences in bone formation rate (BFR/BS) did not reach statistical
significance (Figure 2-11C,I). YAP/TAZ deletion qualitatively reduced fluorescent
labeling of epiphyseal and metaphyseal cancellous bone compartments (Figure 2-12).

Figure 2-11: YAP/TAZ ablation reduced osteoblast numbers and increased osteoclast activity.
Femora were evaluated by static and dynamic histomorphometry from Osterix-conditional YAP/TAZ
deletion. A) Representative micrographs of P56 mid-diaphyseal cortical bone stained by H&E from the
Osterix-conditional YAP/TAZ deletion. B) Representative micrographs of P56 metaphyseal cancellous bone
stained by TRAP from the Osterix-conditional YAP/TAZ deletion. C) Representative micrographs of double
fluorochrome-labeled P28 femoral cortices. Static histomorphometric quantification of (D) osteoblast per
bone surface (Ob.N/BS) and (E) osteocyte number per bone area (Ot.N/B.Ar) quantified in the mid-diaphysis
and (F) the osteoclast surface per bone surface (Oc.S/BS) quantified in the metaphyseal region. Dynamic
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histomorphometric quantification of (G) mineralizing surface percentage (MS/BS), (H) mineral apposition
rate (MAR) and (I) bone formation rate (BFR/BS). Data presented as individual samples with lines
corresponding to the mean and standard error of the mean (SEM). Sample sizes n = 8, except YAPcKO;TAZcKO
n = 1. Scale bars indicate 25, 50, and 100 μm in H&E, TRAP, and double labeled micrographs, respectively.

Figure 2-12: YAP/TAZ ablation qualitatively reduced mineralized bone formation in cancellous
compartments.
Femora were evaluated by dynamic histomorphometry from Osterix-conditional YAP/TAZ deletion. A)
Qualitative comparison of micrographs from double fluorochrome labeled P28 femoral cortices. Sample sizes
n = 8, except YAPcKO;TAZcKO n = 1. Scale bar indicate 200 μm.

2.4.6

YAP/TAZ-deletion and acute YAP/TAZ-TEAD inhibition reduced osteogenic
and collagen-related gene expression

To identify potential YAP/TAZ transcriptional targets, we evaluated expression of
candidate genes known to regulate osteogenesis or whose mutations cause osteogenesis
imperfecta in bone marrow stromal cells (BM-MSCs) isolated from WT and Osterixconditional YAPcKO;TAZcKO mice. For all tested genes, mRNA expression levels were
equivalent prior to osteogenic induction, verifying Osterix-dependence of gene
recombination (Figure 2-13). However, after seven days in osteogenic media, Osterixconditional Cre-mediated recombination evaluated by qPCR significantly reduced TAZ
mRNA expression, while the reduction in YAP expression did not reach statistical
significance (Figure 2-14A,B). However, mRNA expression of canonical YAP/TAZ target
genes, Cyr61 and Ctgf, was significantly reduced (Figure 2-15A,B). Of the collagen-related
genes, mRNA expression of Col1a1 and SerpinH1, but not Col1a2, collagen type II (Col2)
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or collagen type 10 (Col10) was significantly reduced in YAP/TAZ cKO cells (Figure 214C-E, Figure 2-15C,D). Of the osteogenic genes, mRNA expression of osteocalcin (Ocn),
alkaline phosphatase (Alp), and bone sialoprotein (Bsp) were significantly reduced, but
expression of Runx2 and Osterix were not altered (Figure 2-14F-J).
We next sought to determine whether this gene regulation was dependent on
YAP/TAZ-TEAD in osteoblast-like cells using a small molecule inhibitor, verteporfin
(VP), which blocks YAP/TAZ interaction with TEAD218. We found that VP treatment of
osteoblast-like UMR-106 cells reduced expression of the known YAP/TAZ-TEAD target
gene, CTGF, concomitant with reduced YAP/TAZ-TEAD-sensitive synthetic promoter
activity (8xGTIIC-lux) (Figure 2-14K). mRNA expression of OI-related genes Col1a1 and
Col1a2 was reduced by YAP/TAZ-TEAD inhibition, while differences in SerpinH1
expression did not reach statistical significance (Figure 2-14L). VP treatment did not alter
Runx2 transcriptional activity (OSE2-lux) or Runx2 and Osterix expression levels, but
reduced Ocn promoter activity (Ocn-657 bp-lux) concomitant with reduced expression of
Bsp and Alp mRNA (Figure 2-14M,N).
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Figure 2-13: Osterix-mediated YAP/TAZ deletion did not occur prior to osteogenic induction.
MSCs were isolated from Osterix-conditional YAPcKO;TAZcKO mice and cultured under osteogenic
conditions for zero days. Expression levels, normalized to GAPDH, were evaluated for (A) YAP and (B)
TAZ along with collagen–related genes, (C) Col1a1, (D) Col1a2, and (E) SerpinH1 and key upstream
osteogenic transcription factors, (F) Runx2 and (G) Osterix (Osx), and downstream osteogenic genes, (H)
osteocalcin (Ocn), (I) alkaline phosphatase (Alp), and (J) bone sialoprotein (Bsp). Sample sizes n = 3-6.

59

Figure 2-14: YAP/TAZ deletion and acute inhibition of YAP/TAZ-TEAD with verteporfin reduced
osteogenic and collagen-related gene expression in vitro.
MSCs were isolated from Osterix-conditional YAPcKO;TAZcKO mice and cultured under osteogenic
conditions. Expression levels, normalized to GAPDH, were evaluated for (A) YAP and (B) TAZ along with
collagen–related genes, (C) Col1a1, (D) Col1a2, and (E) SerpinH1 and key upstream osteogenic transcription
factors, (F) Runx2 and (G) Osterix, and downstream osteogenic genes, (H) osteocalcin (Ocn), (I) alkaline
phosphatase (Alp), and (J) bone sialoprotein (Bsp). Osteoblast-like UMR-106 cells were treated with the
inhibitor Verteporfin (VP), to block interaction of YAP/TAZ with TEAD. K) Effectiveness was assessed by
mRNA expression of the canonical YAP/TAZ-TEAD target gene CTGF and synthetic TEAD (8xGTIIC)
reporter activity. 8xGTIIC reporter activity was normalized to renilla luciferase expression and expressed as
fold vs. DMSO. VP treatment dose dependently reduced mRNA levels of (L) Col1a1, Col1a2, and SerpinH1
in UMR-106 cells in comparison to DMSO. M) The activity of the Runx2 (6xOSE2) reporter activity was
not altered following VP-treatment, but the activity of the 657 bp Ocn promoter was reduced following VP
treatment. VP treatment dose dependently reduced mRNA levels of (N) Bsp and Alp, but not Runx2 and
Osterix (Osx) in UMR-106 cells in comparison to DMSO. Sample sizes, n = 3-4.
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Figure 2-15: YAP/TAZ deletion reduced canonical downstream targets but not collagen type2-a1 or
collagen 10 gene expression in vitro.
MSCs were isolated from Osterix-conditional YAPcKO;TAZcKO mice and cultured under osteogenic
conditions for seven days. Expression levels, normalized to GAPDH, were evaluated for (A) Cyr61, (B) Ctgf,
(C) Col2a1 and (D) Col10. Sample sizes n = 3.

To determine whether YAP and TAZ regulate expression of these genes in vivo, we
performed quantitative real-time PCR amplification of mRNA transcripts isolated from
femoral cortical bone preparations. Osterix-conditional YAP/TAZ deletion significantly
reduced Col1a1 and SerpinH1 expression in a manner dependent on allele dosage (Figure
2-16A,B). No differences in Col1a2 (Fig 2-17A) or Col2a1 or Col10 (Figure 2-17B,C)
expression were observed. Similarly, gene expression of osteogenic transcripts, Runx2,
Osx, Ocn, Alp and Bsp did not exhibit any statistical differences in expression levels in
vivo (Figure 2-17D-G). Next, we evaluated whether YAP/TAZ-TEAD regulate the
identified collagen-related candidate genes in vivo by acute YAP/TAZ inhibition in WT
mice by verteporfin (VP) injection. VP delivery (100mg/kg i.p. injection every other day
for two weeks) significantly reduced expression of CTGF and SerpinH1 in liver tissue in
vivo, but reductions in Col1a1 expression in liver and CTGF, Col1a1, and SerpinH1 in
bone did not reach statistical significance (Figure 2-16C,D).
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Figure 2-16: YAP/TAZ deletion and acute inhibition of YAP/TAZ-TEAD with verteporfin reduced
collagen-related gene expression in vivo.
Femoral cortical bone from Osterix-conditional YAP/TAZ-deficient mice were harvested to quantify mRNA
expression. Expression levels, normalized to GAPDH, were evaluated in Osterix-conditional YAP/TAZdeficient cortical bone for (A) Col1a1 and (B) SerpinH1. 16-week-old wild type mice received intraperitoneal
injections of VP (100 mg/kg) every two days for two weeks. VP treatment did not significantly reduce mRNA
expression levels in (C) bone, but differences in (D) CTGF and SerpinH1 were detected in VP-treated livers.
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Figure 2-17: YAP/TAZ deletion did not significantly reduce collagen type1-a2, collagen type2-a1,
collagen 10 and downstream osteogenic gene expression in vivo.
Femoral cortical bone from Osterix-conditional YAP/TAZ-deficient mice were harvested to quantify mRNA
expression. Expression levels, normalized to GAPDH, were evaluated in Osterix-conditional YAP/TAZdeficient cortical bone for (A) Col1a2, (B) Col2a1, (C) Col10, (D) Runx2, (E) Osx, (F) Alp, (G) Ocn, and
(H) Bsp. Sample sizes n = 4-6 per group except YAPcKO;TAZcKO n = 1.

2.5

Discussion
Reports

on

the

roles

of

YAP

and

TAZ

in

bone

are

contradictory112,113,147,148,150,157,160,175,219–221. To resolve these apparent conflicts in a
physiologic context, we performed combinatorial conditional YAP/TAZ deletion in mice
to dissect the roles of YAP and TAZ in the cells of the osteoblast lineage, from the
precursors to terminal osteocytes, using Osterix-Cre. Our data reveal that YAP and TAZ
have combinatorial roles in promoting osteogenesis by regulating bone formation,
remodeling, and matrix mechanical properties.
Bone cell-conditional YAP/TAZ deletion caused skeletal defects similar to
osteogenesis imperfecta (OI), with severity dependent on allele dosage. OI is a highly
heterogeneous group of inherited genetic diseases characterized by bone fragility and
deformity, whose severity varies from mildly increased fracture risk to perinatal lethality16.
YAP/TAZ conditional knockout mice mimicked clinical OI222 and several established OI
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mouse models194–196 with reduced bone volume in both cancellous and cortical
compartments. For example, the human Col1a1 minigene mouse194,195, which expresses a
human transgene containing a clinically-observed mutation in pro-α1(I) collagen, dosedependently reproduces the phenotypes seen in Osterix-conditional YAP/TAZ knockouts,
including neonatal lethality at high transgene dose and spontaneous femoral fractures and
reduced failure, but not elastic, bone material properties at moderate dose. Similarly, the
naturally-occurring oim mouse, caused by a frameshift mutation in pro-α2(I) collagen, also
features reduced bone mechanical properties and increased fracture incidence with elevated
mineral density,196,223 a product of increased mean tissue age.
In addition, multivariate regression analyses revealed intrinsic matrix mechanical
property deficiencies in YAP/TAZ cKO mice similar to the oim mouse, also attributable to
defects in local collagen content and organization223,224. Similarly, conditioned medium
from osteoprogenitor cells isolated from oim mice increased osteoclast formation in
vitro225, consistent with our observation of increased osteoclast activity in Osterixconditional YAP/TAZ knockout bone. This suggests altered osteoclast recruitment and/or
activation as a result of defective skeletal cell communication. Because global YAP
deletion is embryonic lethal in animal models, loss-of-function mutations in YAP/TAZ are
unlikely to be a cause in human OI; however, many pathways including TGFbSmad2/3117,118 and WNT-b-catenin115,116 converge on YAP/TAZ, which could place this
signaling axis upstream of the human disease. Further research will be required to evaluate
whether YAP/TAZ signaling is causally linked to clinical OI. The elucidation of this
pathway in bone may contribute new insights into the heterogeneity and/or etiology of the
disease.
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Mice possessing a single copy of either gene in Osterix-expressing cells rescued
the lethality found in dual homozygous knockouts, indicating mutual compensatory
function. However, mice with homozygous deletion of TAZ (i.e., YAPcHET;TAZcKO)
exhibited consistently increased phenotypic expressivity compared to YAPcKO;TAZcHET
for all outcome measures, including bone formation, osteoclast activity, and bone quality.
This suggests that either TAZ is the more potent of the two paralogs in bone, or that the
two floxed loci exhibited differential efficiency of Cre-mediated excision. This latter
possibility is supported by the greater reduction in TAZ expression observed in
differentiating MSCs isolated from YAPfl/f;TAZfl/fl;Osx-Cre mice; however, in vivo,
mRNA and protein levels of YAP and TAZ were similarly reduced. Thus, further study
will be required to elucidate potentially distinct co-effectors or transcriptional efficiency
for YAP vs. TAZ in bone. A recent report demonstrated a unique binding mode of TAZ to
TEAD4 based on crystal structure, suggesting a potential difference in regulatory function
of TAZ vs. YAP226. In addition, the Osterix-Cre transgene exhibits some non-skeletal cell
targeting, including potential recombination in muscle73 and causes defects in craniofacial
development72; however, we did not observe differential YAP/TAZ expression in skeletal
muscle, and the allele dosage-dependent response establishes YAP/TAZ specificity.
Together, these data demonstrate a critical combinatorial role for both YAP and TAZ in
bone development and combinatorial function, evidenced by the rescue of neonatal
lethality by a single intact allele of either gene.
A recent study found that YAP overexpression in developing chondrocytes, under
control of the Col2a1 promoter impaired bone development181. This appears to contradict
our results; however, this study was not designed to isolate the role of YAP in the skeletal
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lineage and featured YAP overexpression in the cartilaginous anlage as well as the
osteoblast precursors. YAP has elsewhere been reported to negatively regulate
chondrogenesis227, and changes in anlage formation may therefore alter bone development
independent of defects in osteogenic cells. Further, the developmental phenotype appeared
only in homozygously-overexpressed transgenics, which points to the limitations of
overexpression approaches for tightly regulated transcriptional regulators that may exhibit
non-physiologic transcriptional activity at high concentrations. Consistent with our
observations that YAP and TAZ have compensatory roles, they did not observe statistically
significant effects of Col2a1-conditional YAP deletion on skeletal development181.
Similarly, Yang et al. overexpressed TAZ in collagen I-expressing cells and observed
increased bone formation175. This is consistent with the present data and the phenotype of
the global homozygous TAZ knockout, which also presents bone development defects205.
Synthesis of these studies indicates the importance of dual and combinatorial loss-offunction approaches to interrogate YAP/TAZ compensatory function.
Bone cell-conditional YAP/TAZ deletion produced an allele dosage-dependent
phenotype characterized by defects in both osteogenesis and matrix composition,
associated with reduced osteogenic and collagen-related gene expression. These
transcriptional patterns were consistent in vitro and in vivo. YAP/TAZ deletion reduced
osteogenic gene induction in isolated osteoprogenitors and reduced osteoblast numbers and
mineral apposition rates in vivo, indicating that YAP/TAZ deletion impaired osteoblast
differentiation and activation. Further, reduced collagen content and organization in vivo
and impaired expression of Col1a1 and the endoplasmic reticulum-associated collagen
chaperone, SerpinH1, suggest that YAP/TAZ regulate collagen production. Together, these
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findings support a convergent, pro-osteogenic function for both YAP and
TAZ113,150,157,160,175.
YAP and TAZ control gene expression through formation of transcriptional
complexes with other transcription factors. These include TEAD1-4 as well as Runx2,
among others 114–116117,118. Runx2 has previously been identified as a YAP/TAZ co-effector
in osteogenesis in vitro112,113,157, but the role of TEAD in bone is unclear. To determine
whether TEAD could be involved in YAP/TAZ regulation of osteogenesis- and collagenrelated genes, we evaluated the effects of disrupting the YAP/TAZ-TEAD interaction using
the small molecule inhibitor, verteporfin (VP), in vitro and in vivo. Quantification of
YAP/TAZ-TEAD transcriptional activity and canonical downstream gene expression
showed that VP treatment significantly inhibited YAP/TAZ-TEAD activity. Analysis of
published ChIP-seq data on the UCSC Genome Browser228 reveals that TEAD is capable
of binding its canonical recognition sequence (3’-ACATTCCA-5’) in the promoter region
of both Col1a1 and SerpinH1, suggesting the possibility of direct regulation. However, as
YAP/TAZ are known to regulate gene expression through both promoter and enhancer
binding, further research using chromatin immunoprecipitation combined with targeted
mutagenesis will be required to isolate the binding domains and associated co-effectors. In
contrast, VP treatment had no effect on Runx2 transcriptional reporter activity or direct
Runx2 target genes (i.e., autoregulatory Runx2 or Osterix) either in vitro or in vivo. Despite
this, expression of mature osteoblast markers was decreased by VP treatment, concomitant
with Osteocalcin promoter activity, suggesting that YAP/TAZ-TEAD may be involved in
both osteogenic and collagen-related gene regulation. In vivo, verteporfin treatment
significantly reduced Col1a1 in the liver, but did not significantly alter gene expression in
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bone, likely due to the small sample size and the four-fold less efficient biodistribution of
porphyrins to bone compared to liver229,230. Verteporfin may also exhibit off-target
effects231, but both VP treatment and YAP/TAZ-conditional deletion produced consistent
gene expression profiles.
Taken together, these data demonstrate that YAP and TAZ have combinatorial roles
in promoting skeletal development by regulating osteoblast activity, osteoclast-mediated
remodeling, and matrix composition.
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CHAPTER 3: YAP AND TAZ MEDIATE PERILACUNAR/CANALICULAR
REMODELING
3.1

Abstract

Bone fragility fractures are caused by low bone mass or impaired bone quality.
Osteoblast/osteoclast coordination determines bone mass, but the factors that control bone
quality are poorly understood. Osteocytes regulate osteoblast and osteoclast activity on
bone surfaces but can also directly reorganize the bone matrix to improve bone quality
through perilacunar/canalicular remodeling; however, the molecular mechanisms remain
unclear. We previously found that deleting the transcriptional regulators Yes-associated
protein (YAP) and Transcriptional co-activator with PDZ-motif (TAZ) from osteoblastlineage cells caused lethality in mice due to skeletal fragility. Here, we tested the
hypothesis that YAP and TAZ regulate osteocyte-mediated bone remodeling by
conditional ablation of both YAP and TAZ from mouse osteocytes using 8kb-DMP1-Cre.
Osteocyte-conditional YAP/TAZ deletion reduced bone mass and dysregulated matrix
collagen content and organization, which together decreased bone mechanical properties.
Further, YAP/TAZ deletion impaired osteocyte perilacunar/canalicular remodeling by
reducing canalicular network density, length, and branching, as well as perilacunar
fluorochrome-labeled mineral deposition. Consistent with recent studies identifying TGFb as a key inducer of osteocyte expression of matrix-remodeling enzymes, YAP/TAZ
deletion in vivo decreased osteocyte expression of matrix proteases MMP13, MMP14, and
CTSK. In vitro, pharmacologic inhibition of YAP/TAZ transcriptional activity in
osteocyte-like cells abrogated TGF-b-induced matrix protease gene expression. Together,
these data show that YAP and TAZ control bone matrix accrual, organization, and
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mechanical properties by regulating osteocyte-mediated bone remodeling. Elucidating the
signaling pathways that control perilacunar/canalicular remodeling may enable future
therapeutic targeting of bone quality to reverse skeletal fragility.
*This chapter is modified from publication in JBMR (DOI: 10.1002/jbmr.3876). Authors: Kegelman CD,
Coulombe JC, Jordan KM, Horan DJ, Qin L, Robling AG, Bellido TM, Boerckel JD.

3.2

Introduction
Skeletal fragility diseases are characterized by decreased bone strength. Bone

strength is determined by both the quantity and quality of the bone, both of which are
necessary to explain fracture susceptibility232–234. Decreased bone mass is a hallmark of
osteoporosis, but defects in bone geometry, microarchitecture, porosity, or matrix material
properties are significant contributors to bone fragility235. Both bone quantity and quality
are influenced by bone remodeling, a tightly coordinated process by which old, damaged
bone is resorbed and new, strong bone is deposited. Imbalanced bone remodeling, either
by excessive bone resorption or decreased bone formation can impair bone quantity and
quality6,236. Understanding the mechanisms that control bone remodeling is both
scientifically and therapeutically valuable.
The most abundant cell type in bone, osteocytes regulate bone remodeling26,27. As
terminally differentiated osteoblasts, osteocytes reside within lacunae in the mineralized
bone matrix, and extend dendritic processes through an interconnected network of microchannels called canaliculi that permeate the bone matrix28,29,237. In humans, this
lacunar/canalicular network contains an estimated 3.7 trillion dendritic projections and
covers more than 215 m2 of bone surface area238. Through this widespread network,
osteocyte-derived molecules reach the bone surfaces and regulate bone remodeling by
coordinating osteoblast/osteoclast coupled remodeling30,31. In addition, osteocytes directly
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resorb and deposit bone in their surrounding bone matrix via perilacunar/canalicular
remodeling32,35,36. However, the molecular mechanisms by which osteocytes control bone
remodeling remain poorly understood.
Osteoblast/osteoclast coordinated bone remodeling is regulated in part through the
CCN family of matricellular growth factors, cysteine-rich angiogenic inducer-61 (CYR61,
CCN1) and connective tissue growth factor (CTGF, CCN2)239,240. CYR61 and CTGF have
been

implicated

in

activation

of

osteoblastogenesis241–244

and

inhibition

of

osteoclastogenesis245. Both CYR61 and CTGF are downstream gene targets of the
paralogous transcriptional regulators Yes associated protein (YAP) and Transcriptional coactivator with PDZ-binding motif (TAZ)126,246. YAP and TAZ are the key effector proteins
of the Hippo signaling pathway and regulate important biological functions including organ
size determination, tissue regeneration, and cancer119,120. Transcriptional complex
formation of nuclear YAP and/or TAZ with the transcriptional enhancer activator domain
(TEAD) family proteins is required to induce expression of CYR61 and CTGF126,247.
In addition to paracrine regulation of osteoblast/osteoclast activity, osteocytes
directly remodel the bone matrix through perilacunar/canalicular remodeling. Osteocyte
perilacunar/canalicular remodeling is regulated by the TGF-b signaling pathway106. The
TGF-b and YAP/TAZ signaling pathways are known to interact in a variety of cell types
including cancer cells, fibroblasts, and epithelial cells117,118,248,249, and the mechanisms by
which TGF-b regulate YAP and TAZ continue to emerge. For example, YAP/TAZ form
complexes with the R-SMAD proteins to co-activate TGF-b/SMAD-target gene
expression117,118. Independent of the R-SMAD proteins, YAP/TAZ interact with additional
transcriptional co-factors, such as AP-1 and MRTF, to regulate TGF-b/SMAD-target gene
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expression248,249. Taken together, these observations position YAP and TAZ as potential
mediators of TGF-b-mediated bone remodeling in osteocytes.
Here, we conditionally ablated both YAP and TAZ from DMP1-expressing cells and
evaluated bone remodeling. In vivo, we found that osteocyte YAP and TAZ regulate
perilacunar/canalicular remodeling as well as coordinate osteoblast/osteoclast activity. In
vitro, YAP/TAZ inhibition abrogated TGF-b-induced expression of matrix proteases
required for osteocyte perilacunar/canalicular remodeling and expression of the
matricellular growth factors Cyr61 and Ctgf. Together, these data demonstrate that
osteocyte YAP and TAZ control bone matrix accrual, organization, and mechanical
properties by regulating osteocyte-mediated bone remodeling.

3.3
3.3.1

Methods
Animals
Mice harboring loxP-flanked exon 3 alleles in both YAP and TAZ on a mixed

C57BL/6J genetic background were kindly provided by Dr. Eric Olson (University of
Texas Southwestern Medical Center). Osteocytes were targeted using Cre-recombination
under the control of an 8kb fragment of the dentin matrix protein-1 promoter (8kb-DMP1Cre)69. All mice were fed regular chow (PicoLab Rodent Diet, Cat#: 0007688, LabDiet) ad
libitum and housed in cages containing 2-5 animals each. Mice were maintained at constant
25°C on a 12-hour light/dark cycle.
Mice with homozygous floxed alleles for both YAP and TAZ (YAPfl/fl;TAZfl/fl)
were mated with double heterozygous conditional knockout mice (YAPfl/+;TAZfl/+;DMP1-
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Cre) to produce eight possible genotypes in each litter, but only the genotypes in (Table 31) were compared. Mice were tail or ear clipped after weaning or prior to euthanasia and
genotyped by an external service (Transnetyx Inc.). Both male and female mice were
evaluated with YAPfl/fl;TAZfl/fl mice serving as littermate controls (WT). The different
analyses were performed in both male and female young mice at either postnatal day 28
(P28) or postnatal day 84 (P84) as indicated. All protocols were approved by the
Institutional Animal Care and Use Committees at the University of Notre Dame and the
University of Pennsylvania. All animal procedures were performed in adherence to federal
guidelines for animal care and conform to the Animal Research: Reporting of In Vivo
Experiments (ARRIVE) guidelines.
Table 3-1: Experimental genotypes & abbreviations (Aim 2)

3.3.2

Genotype

Abbreviation

Yapfl/fl;Tazfl/fl

YAPWT;TAZWT

Yapfl/+;Tazfl/+;DMP1cre/+

YAPcHET;TAZcHET

Yapfl/fl;Tazfl/+;DMP1cre/+

YAPcKO;TAZcHET

Yapfl/+;Tazfl/fl;DMP1cre/+

YAPcHET;TAZcKO

Yapfl/fl;Tazfl/fl;DMP1cre/+

YAPcKO;TAZcKO

Microcomputed tomography
Micro-computed tomography (microCT) was performed according to published

guidelines208. Harvested femurs from P84 mice were stored at -20°C until evaluation.
Frozen specimens were thawed and imaged using a vivaCT 80 scanner (Scanco Medical)
to determine trabecular and cortical femoral bone architecture prior to mechanical testing.
The mid-diaphysis and distal femur were imaged with an X-ray intensity of 114 µA, energy
of 70 kVp, integration time of 300 ms, and resolution of 10 µm. Mid-diaphyseal and distal

73

femoral 2D tomograms were manually contoured, stacked and binarized by applying a
Gaussian filter (sigma =1, support =1) at a threshold value of 550 mg HA/cm3. Eight mice
were analyzed per group. Investigators were blinded to animal genotype during scan
quantification.
3.3.3

Mechanical testing
Following microCT scanning, femurs from P84 mice were tested in three-point

bending to failure. Femurs were loaded with the condyles facing down onto the bending
fixtures with a support span length of 4.4 mm, which attenuated the effect of femur length
on the measured mechanical properties. The upper fixture was aligned with the middiaphysis. The femurs were loaded to failure at a rate of 0.5 mm/s using the ElectroForce
3220 Series testing system (TA Instruments). Stiffness, maximum load to failure, work to
maximum load and work to failure were quantified using a custom MATLAB script170.
Eight mice were analyzed per group. Investigators were blinded to animal genotype during
data quantification.
3.3.4

Osteocyte lacunae visualization and quantification
Nano-computed tomography (nanoCT) was used to evaluate the morphological

characteristics of osteocyte lacunae in the proximal tibia (Xradia Versa XRM-520, Zeiss,
Dublin, CA). Tibiae from P84 mice were harvested and removed of all non-osseous tissue.
Samples were scanned in 70% EtOH, in custom-made sample holders that oriented the
samples vertically on the stage. Tibiae were originally scanned with a 4x objective to
determine regions of interest. A 650 µm3 region of bone was located on the anterior medial
aspect of the tibia, 8 mm from the tibiofibular junction (TFJ). Nano-computed tomography
images image were collected in the region of interest using a 20x objective with energy
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settings of 40 V, 3.0 W, using the Air Filter and 3,201 projections. To obtain a constant
resolution of 0.6 µm voxel for all the samples, the source and detector distance were varied
between 5.8 and 8.5 mm from the sample, and excitation ranged from 6 - 8 seconds
contingent on resulting intensity values.
Dragonfly 3.6 (Object Research Systems (ORS) Inc, Montreal, QC) was used for
segmentation of bone types and osteocyte lacunae regions. Cortical and trabecular bone
were manually segmented. Osteocyte lacunae were identified and segmented in three
dimensions using a global Otsu threshold, defined for each sample to most closely match
grayscale images250. Threshold values were not statistically different between genotypes
(31,382 ± 1,080 for YAPWT;TAZWT and 31,032 ± 1,168 for YAPcKO;TAZcKO; p = 0.83).
Voids that were too small or too large (< 50 µm3 and > 1,500 µm3)251–253 to be an osteocyte
lacuna were removed. Osteocyte volume, surface area, and aspect ratio were measured for
each osteocyte. Additionally, custom python code based on previous work251,254,255 was
implemented to analyze osteocyte lacunar shape measures, oblateness and stretch.
Oblateness and stretch are calculated from the eigenvalues of the shape tensor for each
individual osteocyte lacuna. Lacunar oblateness is defined as the “plateness” of a lacuna
and ranges from [−1,1], where −1 corresponds to a perfect rod (strongly prolate), and 1 to
a perfect plate (strongly oblate)251.
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(Eq. 1)

Similarly, lacunar stretch measures the sphericity of the osteocyte lacunae. Lacunar stretch
is evaluated between [0,1], where 0 corresponds to a perfectly spherical, and 1 to an
infinitely stretched object251.
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(Eq. 2)

3.3.5

Histology, immunohistochemistry, and immunofluorescence
Femurs and tibias from P28 and P84 mice were fixed with 10% neutral buffered

formalin for 48 hours at 4°C and decalcified for 4 weeks with 0.25M EDTA (pH 7.4) at
4°C. Paraffin sections (5 µm thickness) were processed for either immunohistochemistry
or histology. Primary antibodies were compared to both normal rabbit sera IgG control
sections. For immunostaining, anti-CTSK (1:75, ab19027; abcam), anti-MMP13 (1:100,
ab39012; abcam), anti-MMP14 (1:100, ab38971; abcam), anti-YAP (1:200, 14074; Cell
Signaling), and anti-TAZ (1:200 NB110-58359; Novus Biologicals) primary antibodies
were applied overnight. Next, sections were incubated with corresponding biotinylated
secondary antibody, avidin-conjugated peroxidase, and diaminobenzidine substrate
chromogen

system

(329ANK-60;

Innovex

Biosciences),

which

allowed

for

immunohistochemical detection of positively stained cells. Hematoxylin and eosin stains
(H&E), Tartrate-resistant acid phosphatase (TRAP), Picrosirius Red, and silver nitrate
stains were used to stain for osteoblasts, osteoclasts, collagen, and the osteocyte
lacunar/canalicular network as previously shown256,257.
Femurs from P28 mice were fixed with 10% neutral buffered formalin for 48 hours
at 4°C, transferred to 30% sucrose in PBS overnight at 4°C, and then embedded in O.C.T.
compound (Tissue-Tek). Thin sections (7 µm thickness) were made from undecalcified
femurs using cryofilm IIC tape (Section Lab Co. Ltd.) as previously described258 and
processed for immunofluorescence. Taped sections were glued to microscope slides using
chitosan adhesive glue, rehydrated and then decalcified with 0.25M EDTA (pH 7.4) for 5
minutes prior to immunofluorescence staining. Terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) assays were then performed using the Click-iT Plus
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TUNEL Assay kit (C10618; Invitrogen) according to the manufacturer’s instructions.
Thick sections (20 µm thickness), were processed similarly and stained for F-actin with
Alexa Fluor 488-conjugated phalloidin (1:50, Life Technologies) for confocal imaging.
Femurs from P28 mice injected with Calcein (C0875-25G; Sigma-Aldrich) at P21
and Alizarin Complexone (A3882-25G; Sigma Aldrich) at P26 were embedded in methylmethacrylate and processed for dynamic bone histomorphometry. Using a diamondembedded wire saw (Delaware Diamond Knives), transverse sections (40 µm) were cut
from the midshaft and ground to a final thickness of 20 µm. The slice sections were
mounted on slides, and three sections per limb were analyzed.
3.3.6

Imaging and histomorphometric analysis
Histological and immunohistochemical sections were imaged on either a 90i

Upright/Widefield Research Microscope (Nikon Instruments) at the 20x and 40x objectives
or an Axio Observer Z1 (Zeiss) at the 20x, 40x, and 63x objectives. Quantification of
paraffin immunohistochemistry and histology was performed using ImageJ (NIH) and
OsteomeasureTM (OsteoMetrics). To determine the number of positively immunostained
cells, 3 fields of view per mouse per antibody were manually scored as either positive or
negative and reported as percentage positively stained lacunae per total number of lacunae
using ImageJ (NIH). To determine canalicular length, primary canaliculi emanating from
each lacuna and extending as a single, unbranched process106 were traced with ImageJ
(NIH). The mean length was taken from at least 5 osteocytes per field within the midcortex, with 3 fields per mouse and 6 mice per group106. Osteoblast number per bone
surface, osteocyte number per bone area, and osteoclast surface per bone surface were
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quantified using OsteomeasureTM (OsteoMetrics) on H&E and TRAP stained sections in
the metaphyseal cancellous bone with 8 mice per group.
The samples tested in three-point bending were stained with Picrosirius Red to
construct a multivariate regression model that included collagen organization and content
as a predictor of mechanical behavior. These samples were imaged both under polarized
light using an Eclipse ME600 Microscope (Nikon Instruments) at the 20x objective and
using second harmonic generated (SHG) microscopy. SHG images were taken on a
multiphoton-enabled Fluoview Research Microscope (Olympus) at a fundamental
wavelength of 875 nm with the 25x objective on sections oriented in the same direction for
all groups. All SHG images were quantified using ImageJ (NIH) and reported as mean
pixel intensity within the mid-cortical region relative to WT bone. Mean pixel intensities
across four separate regions of interest within each image of the cortex were averaged as
technical replicates for a given sample.
Confocal images were acquired using an LSM 710 confocal (Zeiss) with the 63x
objective on 20-micron thick sections. 15-micron thick z-stack images were acquired using
a step size of 0.5 microns. Three separate regions of interest within the mid-cortex were
averaged as technical replicates for a given animal sample. All confocal image stacks were
quantified using ImageJ (NIH). Stacks were smoothed by applying a Gaussian filter (sigma
= 0.3), then skeletonized using the Skeletonize3D function. The AnalyzeSkeleton2D/3D
function was then used to quantify mean branch length, number of branches, and number
of junctions259. Six YAPWT;TAZWT and four YAPcKO;TAZcKO mice were analyzed.
Immunofluorescence sections of P28 femurs were imaged on an Axio Observer Z1
(Zeiss) at the 20x, 40x, and 63x objectives. To determine the number of positively TUNEL-
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stained lacunae, 3 fields of view per mouse in the metaphyseal cancellous bone were
manually scored as either positive or negative and reported as percent positively stained
per total number of lacunae scored in ImageJ (NIH). Dynamic bone histomorphometry
parameters were quantified using OsteomeasureTM (OsteoMetrics). The following primary
data were collected: total bone surface length (BS); single label perimeter (sL.Pm); double
label perimeter (dL.Pm); and double label width (dL.Ith). From primary data, we derived
mineralizing surface (MS/BS = [1/2sL.Pm+dL.Pm]/B.Pm ×100; %); mineral apposition
rate (MAR = dL.Ith/5 days; µm/day) and bone formation rate (BFR/BS = MAR × MS/BS;
µm3/µm2 per day). Six mice were analyzed per group. Investigators were blinded to animal
genotype

during

image

acquisition

and

quantification

of

all

histology,

immunohistochemistry, and immunofluorescent images.
3.3.7

Cell culture
IDG-SW3 cells were cultured in a-MEM supplemented with 10% fetal bovine

serum, 1% antibiotic/antimycotic (15240062; Gibco) and 1 U/mL INF-g (PMC4031;
Invitrogen) at 33°C. OCY454 cells were cultured in a-minimum essential media (a-MEM)
supplemented with 10% fetal bovine serum and 1% antibiotic/antimycotic (Gibco) at 33°C.
Prior to treatment, OCY454 cells were differentiated for 12 days at 37°C while IDG-SW3
cells were differentiated for 21 days at 37°C in a-MEM supplemented with 10% fetal
bovine serum (100-106; Gemini Bio-Products), 1% antibiotic/antimycotic (15240062;
Gibco), 50 µg/ml ascorbic acid (A-4544; Sigma-Aldrich), and 4 mM b-glycerophosphate
(G-9422; Sigma-Aldrich) without INF-g. Prior to treatment on the last day of
differentiation, both OCY454 and IDG-SW3 cells were treated with 3 µM verteporfin
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(SML0534; Sigma-Aldrich) overnight in 1% fetal bovine serum. The next morning, the
media was changed and supplemented with 3 µM verteporfin and 5ng/ml TGF-b1
(HZ1011; Humanzyme) for 6 hours before mRNA isolation.
3.3.8

RNA isolation and qPCR
P84 femur samples were dissected and removed of all non-osseous tissue. The ends

were cut at the growth plate and marrow flushed before being snap-frozen in liquid
nitrogen-cooled isopentane for 1 minute prior to storage at -80°C until processing. Tissues
were then homogenized via mortar and pestle and RNA from the sample was collected
using Trizol Reagent (15596026; Life Technologies) followed by centrifugation in
chloroform. RNA from femur tissue and cell culture experiments were purified using the
RNA Easy Kit (74106; Qiagen) and quantified by spectrophotometry using a NanoDrop
2000 (Thermo-Fisher Scientific). Reverse transcriptase polymerase chain reaction (RTPCR) was performed on 0.1-0.5 μg/μl concentration of RNA using the High-Capacity
cDNA Reverse Transcription Kit (4368814; Thermo-Fisher Scientific). Quantitative
polymerase chain reaction (qPCR) assessed RNA amount using a StepOnePlusTM RealTime PCR System (Thermo-Fisher Scientific) relative to the internal control of 18S
ribosomal RNA (18S rRNA). Data are presented using the DDCt method. Six mice per
group were used. Specific mouse primer sequences are listed (Table 3-2).
Table 3-2: qPCR primers (Aim 2)
Mouse primers used for qPCR

Gene

Primer Sequence (5’ to 3’)

18S rRNA

F CGAACGTCTGCCCTATCAAC
R GGCCTCGAAAGAGTCCTGTA

Yap

F TGGACGTGGAGTCTGTGTTG
R AAGCGGAACAACGATGGACA
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3.3.9

Taz

F GTCCATCACTTCCACCTC
R TTGACGCATCCTAATCCT

Col1a1

F GCTCCTCTTAGGGGCCACT
R CCACGTCTCACCATTGGGG

Alp

F GGACAGGACACACACACACA
R CAAACAGGAGAGCCACTTCA

Ocn

F TGAGCTTAACCCTGCTTGTG
R TAGGGCAGCACAGGTCCTA

Bsp

F ACAATCCGTGCCACTCACT
R TTTCATCGAGAAAGCACAGG

Dmp1

F GAACAGTGAGTCATCAGAAG
R AAAGGTATCATCTCCACTGTC

Ctsk

F GAGGGCCAACTCAAGAAGAA
R GCCGTGGCGTTATACATACA

Mmp13

F CGGGAATCCTGAAGAAGTCTACA
R CTAAGCCAAAGAAAGATTGCATTTC

Mmp14

F AGGAGACGGAGGTGATCATCATTG
R GTCCCATGGCGTCTGAAGA

Sost

F TCCTCCTGAGAACAACCAGAC
R TGTCAGGAAGCGGGTGTAGTG

Phex

F TCATTGATACCAGACTCTACC
R CAATGGTTTTCTTCCTCTCG

Serpine1

F CAGATGACCACAGCGGGGAA
R GGCATGAGCTGTGCCCTTCT

Opg

F AGAGCAAACCTTCCAGCTGC
R CTGCTCTGTGGTGAGGTTCG

Rankl

F CCAAGATCTCTAACATGACG
R CACCATCGCTGAAGATAGT

Statistics and regression
Sample sizes were selected a priori by power analyses based on effect sizes and

population standard deviations taken from published data on YAPfl/fl;TAZfl/fl mice in other
tissues188, assuming a power of 80% and α=0.05. All statistics and regression analyses were
performed in GraphPad Prism or using R (Version 3.5.1). Repeated-measures ANOVA
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with post hoc Tukey’s HSD comparison test was performed using R (Version 3.5.1) for
osteocyte lacunae quantification. All other comparisons between two groups were made
using the two-tailed student’s t-test, provided the data were normally distributed according
to D’Agostino-Pearson omnibus normality test and homoscedastic according to Bartlett’s
test in GraphPad Prism. When parametric test assumptions were not met, data were logtransformed, and residuals were evaluated. If necessary, the non-parametric MannWhitney test was used. A p-value < 0.05 was considered significant. Post-hoc power
analyses were performed using R (Version 3.5.1) for phenotypic results as indicated. Data
are presented as bars and individual samples with lines corresponding to the mean and
standard error of the mean (SEM).
Multivariate regression analyses were performed as described previously212, using
R (Version 3.5.1) with some modifications170. Briefly, we used an exhaustive best subsets
algorithm to determine the best predictors of maximum load and stiffness from a subset of
morphological parameters measured, which included moment of inertia (I) or section
modulus (I/c), microCT-measured tissue mineral density (TMD), second harmonic
generated (SHG) intensity, and femur length. The best subsets algorithm selects the optimal
model using the Akaike’s information criterion (AIC), which gives preference to less
complex models with fewer explanatory parameters to avoid overfitting the data213. The
overall “best” multivariate model for each predicted mechanical property was selected with
the lowest relative AIC value, indicative of having the least variables with the greatest
predictive power. AIC values were used to determine the “best” model for predicting new
data instead of R2 values, which describe how well the model fits existing data. Further,
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adding additional variables can artificially increase R2 values without enhancing model
relevancy.

3.4
3.4.1

Results
DMP1-Cre conditionally ablates YAP and TAZ primarily in osteocytes
To determine the roles of YAP and TAZ in osteocyte-mediated bone remodeling,

we used Cre-lox to selectively delete YAP and TAZ from 8kb-DMP1-Cre expressing
cells69,260. We used a breeding strategy that generated YAP/TAZ allele dosage-dependent
DMP1-conditional knockouts170. All genotypes (Table 3-1) appeared at expected
Mendelian ratios. By early skeletal maturity (P84), YAP/TAZ allele dosage-dependent
DMP1-conditional deletion did not significantly alter body mass in either males or females
(Figure 3-1A). YAP/TAZ deletion reduced femoral length at P84 only in double
homozygous knockouts, for both sexes (Figure 3-2A,B; Figure 3-1B). A single copy of
either gene was sufficient to rescue this defect. Therefore, for further analyses, we selected
littermate YAPfl/fl;TAZfl/fl wild type (YAPWT;TAZWT) and YAPfl/fl;TAZfl/fl;8kb-DMP1-Cre
conditional double knockout (YAPcKO;TAZcKO) mice for comparison.
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Figure 3-1: Combinatorial YAP/TAZ ablation with 8kb-DMP1-Cre is functionally redundant and does
not recombine in growth plate chondrocytes.
A) Body masses from mice with allele-dose dependent YAP/TAZ ablation from DMP1-expressing cells until
P84. B) Femoral lengths from mice with allele-dose dependent YAP/TAZ ablation from DMP1-expressing
cells at P84 for both males and females. C) Histomorphometric quantification of P84 growth plate thickness.
HZ = hypertrophic zone. PZ = proliferating zone. D) Representative micrograph of P84 wild type
(YAPWT;TAZWT) growth plate. E) Representative micrograph of P84 conditional double knockout
(YAPcKO;TAZcKO) growth plate. F) Representative micrographs of chondrocyte immunostaining for IgG
control, YAP, and TAZ in YAPWT;TAZWT femurs at P28. G) Representative micrographs of growth plate
chondrocyte immunostaining for IgG control, YAP, and TAZ in YAPcKO;TAZcKO femurs at P28. Body mass
data presented as mean with lines corresponding to the standard error of the mean (SEM). Sample sizes, N =
6-22 per sex per group. Femoral length data presented as a box and whiskers plots with whiskers
corresponding to maximum and minimum values. Sample sizes, N = 2-10 per sex per group. Growth plate
thickness percentage data presented as bars with lines corresponding to the mean and standard error of the
mean (SEM). Sample sizes, N = 6 per group. Scale bars equal 50 µm in all images.
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Figure 3-2: 8kb-DMP1-Cre selectively ablated YAP/TAZ expression from osteocytes.
A) Representative radiographs for P84 wild type (YAPWT;TAZWT) and B) conditional double knockout
(YAPcKO;TAZcKO) mice. C) P84 femur microCT reconstructions and D) quantification of femoral lengths. EJ) Recombination efficiency and specificity was assessed by measurement of YAP and TAZ protein and
mRNA expression. E) Representative micrographs of osteocyte (Ocy) immunostaining for IgG control, YAP,
and TAZ in YAPWT;TAZWT and YAPcKO;TAZcKO femurs at P28. F) Representative micrographs of osteoblast
(Ob) immunostaining for IgG control, YAP, and TAZ in YAPWT;TAZWT and YAPcKO;TAZcKO femurs at P28.
G) YAP protein expression in osteocytes (Ocy) and osteoblasts (Ob) from femoral sections at P28. H) Yap
mRNA expression, relative to 18S rRNA, from femoral bone preparations at P84. I) TAZ protein expression
in osteocytes (Ocy) and osteoblasts (Ob) from femoral sections at P28. J) Taz mRNA expression, relative to
18S rRNA, from femoral bone preparations at P84. Data are presented with individual samples in scatterplots
and bars corresponding to the mean and standard error of the mean (SEM). N = 5-6 per group for qPCR and
N = 4-6 per group for IHC. Brown arrows indicate positive osteocytes. Blue arrows indicate negative
osteocytes. Scale bars equal 1 mm in microCT reconstructions and 30 µm in all images.
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To analyze the specificity of 8kb-DMP1-Cre-mediated YAP/TAZ deletion, we
evaluated YAP/TAZ expression in osteocytes, osteoblasts, and growth plate chondrocytes.
YAP mRNA expression was significantly reduced by 67% in YAPcKO;TAZcKO femoral
bone preparations (Figure 3-2C). YAP cellular expression was significantly reduced in
osteocytes (58% reduction), but not osteoblasts (0% reduction; p = 0.98) (Figure 3-2G).
Similarly, TAZ mRNA expression was significantly reduced by 72% in YAPcKO;TAZcKO
femoral bone preparations (Figure 3-2F), and TAZ cellular expression was significantly
reduced in osteocytes (79% reduction), but not osteoblasts (6% reduction; p = 0.12) (Figure
3-2H). The reduction in YAPcKO;TAZcKO growth plate thickness did not reach statistical
significance within the hypertrophic zone (16% reduction; p = 0.26), the proliferating zone
(12% reduction; p = 0.39), or total growth plate thickness (13% reduction; p = 0.27; Figure
3-1C). Further, YAPcKO;TAZcKO growth plate chondrocytes did not show differential
expression of YAP or TAZ in either proliferating or hypertrophic zones (Figure 3-1D-G).
3.4.2

DMP1-conditional YAP/TAZ deletion impaired bone accrual
Dual homozygous YAP/TAZ deletion from DMP1-expressing cells reduced bone

accrual and microarchitectural parameters in both the cancellous and cortical
compartments of P84 femurs. In metaphyseal cancellous bone, conditional YAP/TAZ
deletion significantly reduced bone volume fraction, trabecular number, and thickness and
increased trabecular spacing and structural model index (Figure 3-3A-F). In middiaphyseal femoral cortical bone, conditional YAP/TAZ deletion reduced cortical
thickness and bone area without changing medullary area (Figure 3-3G-I; Figure 3-4).
Differences in tissue mineral density (p = 0.24), periosteal perimeter (p = 0.15), and
moment of inertia (p = 0.08) were not statistically significant (Figure 3-3J-L).
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Figure 3-3:YAP/TAZ ablation from DMP1-expressing cells altered bone microarchitecture.
A) Representative microCT reconstructions of distal metaphysis of P84 femurs. Quantification of cancellous
bone microarchitecture: (B) bone volume fraction (BV/TV), (C) trabecular thickness (Tb.Th), (D) number
(Tb.N), (E) spacing (Tb.Sp), and (F) structural model index (SMI). G) Representative microCT
reconstructions of mid-diaphysis cortical microarchitecture in P84 femurs. Quantification of cortical
microarchitectural properties: (H) cortical thickness (Ct.Th), (I) bone area (B.Ar), (J) periosteal perimeter
(Ps.Pm), (K) moment of inertia in the direction of bending (I), and (L) cortical tissue mineral density
(Ct.TMD). Data are presented with individual samples in scatterplots and bars corresponding to the mean
and standard error of the mean (SEM). Sample sizes, N = 8. Scale bars indicate 1 mm for microCT
reconstructions.
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Figure 3-4:YAP/TAZ ablation from DMP1-expressing cells altered bone microarchitecture.
A) Representative microCT reconstructions of distal metaphyseal microarchitecture in P84 femurs. B)
Quantification of trabecular thickness distributions in cancellous bone. C-E) Quantification of cortical
microarchitectural properties: (C) total area, (D) medullary area (Me.Ar), and (E) endocortical perimeter
(Ec.Pm). Data are presented as bars and individual samples with lines corresponding to the mean and standard
error of the mean (SEM). Sample sizes, N = 8 per group.

To determine if the low bone mass phenotype resulted from decreased bone
formation and/or increased bone resorption, we evaluated osteoblast and osteoclast
activity. Conditional YAP/TAZ deletion increased osteoclast surface per bone surface
(Figure 3-5A,B) and decreased osteoblast number per bone surface (Figure 3-5C,D) in P84
distal femur metaphyseal cancellous bone. YAP/TAZ deletion decreased bone formation
rate, reducing both mineralizing surface percentage and mineral apposition rate at P28 in
distal femur metaphyseal cancellous bone (Figure 3-5E-H). In the cortical compartment,
YAP/TAZ deletion similarly reduced osteoblast number per endosteal bone surface (Figure
3-6A,B) and decreased bone formation rate by reducing mineral apposition rate without
altering mineralizing surface percentage (Figure 3-6C-F).
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Figure 3-5:YAP/TAZ ablation from DMP1-expressiong cells increased osteoclast activity and decreased
osteoblast activity.
A) Representative high magnification micrographs with insets of low magnification micrographs of P84
cancellous metaphyseal bone (outlined in black) stained by TRAP. B) Quantification of osteoclast surface
per bone surface (Oc.S/BS). C) Representative high magnification micrographs with insets of low
magnification micrographs of P84 cancellous metaphyseal bone (outlined in black) stained by H+E. D)
Quantification of osteoblast number per bone surface (Ob.N/BS). E) Representative high magnification
micrographs with insets of low magnification micrographs of double fluorochrome labeled P28 cancellous
metaphyseal bone (outlined in white). F-H) Quantification of (F) mineralizing surface percentage (MS/BS),
(G) mineral apposition rate (MAR) and (H) bone formation rate (BFR/BS). I-J) Femoral bone preparations
from P84 mice were harvested to quantify mRNA expression. Expression levels, normalized to 18S rRNA,
were evaluated for (I) cysteine-rich angiogenic inducer 61 (Cyr61) and (J) connective tissue growth factor
(Ctgf). Data are presented with individual samples in scatterplots and bars corresponding to the mean and
standard error of the mean (SEM). Sample sizes N = 6-8. Scale bars indicate 15 µm in all images.
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Figure 3-6: YAP/TAZ ablation from DMP1-expressing cells altered cortical osteoblast number and
function.
A) Representative micrographs of P84 cancellous metaphyseal bone stained by H+E. B) Quantification of
osteoblast number per bone surface (Ob.N/BS). C) Representative micrographs of double fluorochrome
labeled cortical bone in P28 femurs. D-F) Quantification of (D) mineralizing surface percentage (MS/BS),
(E) mineral apposition rate (MAR) and (F) bone formation rate (BFR/BS). Data are presented as bars and
individual samples with lines corresponding to the mean and standard error of the mean (SEM). Sample sizes
N = 6-8. Scale bars indicate 50 µm in all images.

Further, YAP/TAZ deletion significantly reduced mRNA expression of YAP/TAZTEAD target genes, Cyr61 and Ctgf in femoral bone at P84 (Figure 3-5I,J). However,
YAP/TAZ deletion did not alter sclerostin (SOST), receptor activator of nuclear factor
kappa-B ligand (Rankl) or osteoprotegerin (Opg) transcript expression (Figure 3-7).
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Figure 3-7: YAP/TAZ ablation from DMP1-expressing cells did not affect bone turnover markers.
A-C) Femoral bone preparations from P84 mice were harvested to quantify mRNA expression. Expression
levels, normalized to 18S rRNA, were evaluated for (A) sclerostin (Sost), (B) receptor activator of nuclear
factor kappa-B ligand (Rankl), and (C) osteoprotegerin (Opg), Data are presented as bars and individual
samples with lines corresponding to the mean and standard error of the mean (SEM). Sample sizes, N = 5-6
per group.

3.4.3

DMP1-conditional YAP/TAZ deletion impaired bone mechanical properties and
matrix collagen composition
To determine whether YAP/TAZ deletion impaired functional mechanical

properties, we tested P84 femurs in three-point bending to failure (Figure 3-8A).
Conditional YAP/TAZ deletion did not significantly reduce maximum load to failure
(Figure 3-8B; p = 0.07) but significantly reduced bending stiffness, work to maximum load
and work to failure (Figure 3-8C-E).
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Figure 3-8:YAP/TAZ ablation from DMP1-expressing cells impaired bone mechanical behavior by
altering bone geometry and matrix collagen.
A) P84 femurs were tested in three-point bending to failure. B-E) Quantification of (B) maximum load to
failure, (C) bending stiffness, (D) work to max load, and (E) work to failure. F) Representative micrographs
of polarized light microscopy and second harmonic generated (SHG) images of cortical bone from the P84
femurs tested in three-point bending. G-H) Quantification of (G) SHG intensity normalized to wild type. H)
Best-subset multivariate regression model predicting experimental bending stiffness (K) using moment of
inertia and SHG intensity as predictors. Data are presented with individual samples in scatterplots and bars
corresponding to the mean and standard error of the mean (SEM). Sample sizes, N = 8 per group. Scale bars
equal 100 and 25 µm in the Picrosirius red and SHG, respectively.
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Intrinsic bone material properties are determined, in part, by collagen content and
organization170. To test whether osteocyte YAP/TAZ regulate the local collagen matrix,
we performed polarized light and second harmonic generation (SHG) microscopy (Figure
3-8F). YAP/TAZ deletion qualitatively reduced Picrosirius red staining and significantly
reduced SHG intensity per bone area, indicative of both collagen content and organization
(Figure 3-8G). Both cross sectional bone geometry (section modulus and moment of
inertia) and collagen matrix content and organization significantly contributed to bone
stiffness according to a multivariate best-subsets regression analysis using the Akaike’s
information criterion (AIC), which selects the model with the lowest number of predictors
with the greatest predictive power170,213. Neither microCT-measured tissue mineral density
nor femur length contributed to the overall best model according to AIC for stiffness and
maximum load to failure (Figure 3-8H, Figure 3-9).

Figure 3-9: Best subsets analysis on morphological parameters from YAP/TAZ ablation in DMP1expressiong cells demonstrated increased goodness of fit for stiffness by accounting for collagen content
and organization.
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Using the femurs that were scanned by microCT, tested in three-point bending, and imaged using SHG,
experimental ultimate load (Fmax) values were compared with predicted values from the top three “best”
multivariate models in order from left to right. Models were ranked based on their relative Akaike’s
information criterion (AIC) value with the lowest AIC being the “best.” The three “best” multivariate models
for ultimate load were A) only section modulus (I/c), (B) I/c and second harmonic generated signal intensity
(SHG), and (C) I/c and tissue mineral density (TMD) as predictors. Similarly, (K) were (D) moment of inertia
(I) and SHG, (E) I, SHG and femur length, and (C) I and femur length as predictors. Sample sizes, N = 8 per
group.

3.4.4

DMP1-conditional YAP/TAZ deletion impaired the osteocyte canalicular
network, but not lacunar morphology
We initially hypothesized that the primary function of YAP/TAZ in osteocytes was

to regulate expression of genes that control osteocyte-osteoblast and -osteoclast
communication, such as secreted factors CYR61 and CTGF. However, the reduced bone
mechanical properties and disorganized collagen matrix in mice lacking YAP/TAZ from
osteocytes phenocopied matrix metalloproteinase-13 (MMP13) knockout mice, which had
defective collagen organization as a result of impaired perilacunar/canalicular
remodeling33. This led us to ask whether YAP/TAZ deletion from osteocytes impaired
perilacunar/canalicular remodeling.
Conditional YAP/TAZ deletion did not significantly alter osteocyte density but
increased empty lacunae percentage in cancellous metaphyseal bone (Figure 3-10A-C).
Accordingly, conditional YAP/TAZ deletion increased the number of TUNEL-positive
lacunae, suggesting an increase in osteocyte apoptosis within the cancellous bone
compartment (Figure 3-10D-E). Conditional YAP/TAZ deletion significantly reduced
canalicular density and mean process length, measured in silver nitrate-stained, midcortical bone sections (Figure 3-10F-H).
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Figure 3-10: YAP/TAZ ablation from DMP1-expressing cells increased osteocyte apoptosis and reduced
canalicular number and length.
A) Representative micrographs of P84 cancellous metaphyseal bone stained by H+E. B-C) Quantification of
(B) osteocyte number per bone area (Ot.N/B.Ar), and (C) percentage of empty lacunae. D) Representative
immunofluorescence micrographs of P28 cancellous metaphyseal bone stained with TUNEL positive cells
(red) and DAPI (blue). E) Quantification of the percentage of TUNEL positive lacunae. F) Representative
micrographs of P84 mid-cortical bone silver stained for the osteocyte canalicular network. G-H)
Quantification of (G) canalicular density per cell and (H) average canalicular length. Data are presented with
individual samples in scatterplots and bars corresponding to the mean and standard error of the mean (SEM).
Sample sizes, N = 6-8 per group. Scale bars equal 15 µm all images.

As the canalicular system is a three-dimensional network of branched cell processes
that physically connect osteocytes to their neighbors238, we next quantified the 3D
canalicular network by laser scanning confocal microscopy of the osteocyte actin
cytoskeleton, labeled with phalloidin (Figure 3-11A). YAP/TAZ deletion significantly
reduced branch length (Figure 3-11B,C), number of branches per cell (Figure 3-11D), and
number of junctions per cell (Figure 3-11E).
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Figure 3-11: YAP/TAZ ablation from DMP1-expressing cells reduced canalicular network length and
branching, but not lacunar morphology in 3D.
A) Representative 15-micron thick confocal reconstructions of phalloidin-stained osteocyte F-actin
cytoskeletons in cortical bone at P28. B) Average distributions of branch length. C-E) Quantification of (C)
average branch length, (D) number of branches, and (E) number of junctions. F) Representative lacunar
morphologies in 3D in cancellous bone from P84 tibiae using X-ray microscopy (XRM). G) Average
distributions of lacunar volume. H-J) Quantification of (H) average lacuna volume, (I) oblateness, and (J)
stretch. Data are presented with individual samples in scatterplots and bars corresponding to the mean and
standard error of the mean (SEM). Sample sizes, N = 4-6 for confocal network analysis and N = 8 for XRM.
Each side of scale parallelograms equal 10 µm for both confocal and XRM.

To determine the effect of YAP/TAZ deletion on osteocyte lacunar morphology,
we performed high resolution (0.6 um voxel) X-Ray microscopy (XRM) imaging of both
cortical and cancellous bone in the proximal tibia metaphysis (Figure 3-11F). YAP/TAZ
deletion did not significantly alter lacuna volume (Figure 3-11G,H) or shape (Figure 311I,J), as significant interaction factors were observed between sex, bone compartment,
and genotype for all lacunar morphology parameters. Using post-hoc multiple
comparisons, no differences in lacunar parameters were observed between genotypes
within either a single sex or bone compartment.

96

3.4.5

DMP1-conditional YAP/TAZ deletion reduced osteocyte-mediated bone matrix
remodeling
Perilacunar/canalicular remodeling involves both the deposition and degradation of

the bone matrix directly surrounding the osteocytes. Prior studies used 3H-proline pulses
and tetracycline labeling to identify osteocyte lacunae as sites of active collagen deposition
and mineralization35,261,262. Here, we measured collagen I gene expression and
fluorochrome incorporation in osteocyte lacunae to assess peri-osteocyte matrix
deposition. Conditional YAP/TAZ deletion reduced the percentage of Calcein-labeled
osteocyte lacunae (Figure 3-12A,B) and reduced transcript expression of Col1a1 (Figure
3-12C). However, YAP/TAZ deletion did not alter expression of either osteogenic genes,
including alkaline phosphatase (Alp), osteocalcin (Ocn), and bone sialoprotein (Bsp), or
osteocyte-marker genes, dentin matrix protein-1 (Dmp1) or phosphate-regulating neutral
endopeptidase, X-linked (Phex) (Figure 3-13).
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Figure 3-12:YAP/TAZ ablation from DMP1-expressing cells reduced osteocyte-mediated bone
remodeling.
A) Representative double fluorochrome-labeled osteocytes (white) in cortical bone from P28 femurs (Calcein
label injected at P21). B-C) Quantification of (B) Calcein labeled lacunae and (C) relative transcript
expression for collagen1a1 (Col1a1) in P84 femoral bone preparations. D) Representative micrographs of
cancellous metaphyseal bone from P84 femurs immunostained for cathepsin K (CTSK). E-F) Quantification
of (E) CTSK immunostained lacunae and (F) relative transcript expression for Ctsk in P84 femoral bone
preparations. G) Representative micrographs of cancellous metaphyseal bone from P84 femurs
immunostained for matrix metalloproteinase 13 (MMP13). E-F) Quantification of (E) MMP13
immunostained lacunae and (F) relative transcript expression for Mmp13 in P84 femoral bone preparations.
J) Representative micrographs of cancellous metaphyseal bone from P84 femurs immunostained for matrix
metalloproteinase 14 (MMP14). K-L) Quantification of (K) MMP14 immunostained lacunae and (L) relative
transcript expression for Mmp14 in P84 femoral bone preparations. Data are presented with individual
samples in scatterplots and bars corresponding to the mean and standard error of the mean (SEM). Sample
sizes, n = 6-8. Scale bars equal 15 µm in all images.
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Figure 3-13: YAP/TAZ deletion did not alter osteogenic or osteocyte-marker gene expression.
A-E) Femoral bone preparations from P84 mice were harvested to quantify mRNA expression. Expression
levels, normalized to 18S rRNA, were evaluated for (A) alkaline phosphatase (Alp), (B) osteocalcin (Ocn),
(C) bone sialoprotein (Bsp), (D) dentin matrix protein 1 (Dmp1), and (E) phosphate-regulating neutral
endopeptidase (Phex). Data are presented as bars and individual samples with lines corresponding to the
mean and standard error of the mean (SEM). Sample sizes, N = 6 per group.

In addition to local matrix deposition, osteocytes also locally degrade their
extracellular matrix. Many of the matrix metalloproteinases and other enzymes employed
by osteoclasts to resorb bone are also expressed by osteocytes and are critical to
perilacunar/canalicular remodeling

32–34

. Therefore, to test whether YAP/TAZ regulate

direct matrix remodeling by osteocytes, we measured mRNA and protein expression of the
matrix proteases, cathepsin K (CTSK), matrix metalloproteinase-13 (MMP13), and matrix
metalloproteinase-14 (MMP14). Conditional YAP/TAZ deletion reduced the percentage
of osteocytes that stained positive for CTSK (Figure 3-12D,E), MMP13 (Figure 3-12G,H),
and MMP14 (Figure 3-12J,K) and decreased mRNA expression of Ctsk (Figure 3-12F),
Mmp13 (Figure 3-12I), and Mmp14 (Figure 3-12L) in vivo.
3.4.6

YAP/TAZ inhibition abrogated TGF-b-induced gene expression in vitro
Though unexplored in osteocytes, YAP and TAZ are known to mediate TGF-b

signaling in a variety of other cell types117,118,248,249. Further, either pharmacologic
inhibition or genetic ablation of TGF-b receptors from osteocytes caused defective

99

perilacunar/canalicular remodeling and associated gene expression106. Therefore, we next
tested whether YAP/TAZ mediate TGF-b signaling, Cyr61/Ctgf expression, and
perilacunar/canalicular remodeling-associated gene expression in osteocytes by treating
two osteocyte-like cell lines with combinatorial TGF-b and/or verteporfin (VP) treatment.
VP is a small molecule inhibitor that physically blocks the interaction of YAP and TAZ
with their transcriptional co-effectors, particularly the TEAD transcription factors,
preventing YAP/TAZ-TEAD transcriptional activity170,218.
We first used mouse osteocyte-derived IDG-SW3 cells, which carry a DMP1 cisregulatory system driving GFP expression, as a marker of living osteocytes263,264. As shown
previously, IDG-SW3 cells exhibited robust DMP1-GFP transgene expression after 21
days of in vitro osteocytic differentiation (Figure 3-14A). Beginning at day 20, cells were
treated with vehicle (DMSO) or 3 µM verteporfin (Figure 3-14A). At day 21, cells were
treated with 5 ng/ml TGF-b or PBS vehicle for 6 hours and gene expression was evaluated
by qPCR. Similar experiments were conducted in mouse osteocyte-derived OCY454
cells265 (Figure 3-15A).
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Figure 3-14:Inhibition of YAP/TAZ-TEAD with verteporfin (VP) reduced TGF-b-induced PLR gene
expression in vitro.
A) Osteocyte-like IDG-SW3 cells were differentiated for 21 days, with osteocyte differentiation reported by
DMP1-GFP transgene expression. Cells were combinatorially treated with inhibitor verteporfin (VP) and/or
5 ng/ml TGFb1 at day 21. B-G) mRNA expression, normalized to 18S rRNA, was evaluated for (B) serpin
family E member 1 (SerpinE1), (C) cysteine-rich angiogenic inducer 61 (Cyr61), (D) connective tissue
growth factor (Ctgf), (E) cathepsin K (Ctsk), (F) matrix metalloproteinase-13 (Mmp13), and (G) matrix
metalloproteinase-14 (Mmp14). Relative expression was expressed as fold vs. vehicle (PBS + DMSO)-treated
cells. Data are presented with individual samples in scatterplots and bars corresponding to the mean and
standard error of the mean (SEM). Sample sizes, N = 3. Scale bars equal 75 mm.

First, to test whether verteporfin blocked TGF-b-induced YAP/TAZ signaling, we
evaluated expression of serpin family E member 1 (SerpinE1) and expression of known
osteoblast/osteoclast paracrine signaling factors, Cyr61 and Ctgf. Each of these genes are
established TGF-b-inducible, YAP/TAZ-TEAD target genes126,246,266,267. As expected,

101

TGF-b robustly induced SerpinE1, Cyr61, and Ctgf mRNA expression, which was
abrogated by verteporfin treatment (Figure 3-14B-D). Next, to test whether YAP/TAZ
mediate TGF-b induction of genes associated with perilacunar/canalicular remodeling, we
quantified mRNA expression of Ctsk, Mmp13, and Mmp14. TGF-b significantly induced
expression of Mmp13 and Mmp14, but not Ctsk, in IDG-SW3 cells, and verteporfin
treatment abrogated expression of all three genes (Figure 3-14E-G). In OCY454 cells,
verteporfin similarly abrogated TGF-b induced expression of Ctgf, Cyr61 and SerpinE1
mRNA (Figure 3-15B-D) as well as Mmp14 and Ctsk, but not Mmp13 (Figure 3-15E-G).

Figure 3-15:Inhibition of YAP/TAZ-TEAD with verteporfin (VP) reduced TGF-b-induced remodeling
gene expression in OCY454 cells.
A) Osteocyte-like cells, OCY454, were differentiated for 12 days. Cells were combinatorially treated with
inhibitor verteporfin (VP) and 5 ng/ml TGF-b1 at day 12. B-G) mRNA expression, normalized to 18S rRNA,
was evaluated for (B) serpin family E member 1 (SerpinE1), (C) cysteine-rich angiogenic inducer 61 (Cyr61),
(D) connective tissue growth factor (Ctgf), (E) cathepsin K (Ctsk), (F) matrix metalloproteinase-13 (Mmp13),
and (G) matrix metalloproteinase-14 (Mmp14). Relative expression was expressed as fold vs. vehicle (PBS
+ DMSO)-treated cells. Data are presented as bars and individual samples with lines corresponding to the
mean and standard error of the mean (SEM). Sample sizes, N = 3.
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Finally, we evaluated Sost, Opg, and Rankl expression in both IDG-SW3 and
OCY454

cells

as

potential

YAP/TAZ-regulated

mediators

of

osteocyte-

osteoblast/osteoclast signaling. In IDG-SW3 cells, both verteporfin and TGF-b
significantly reduced Sost transcript expression, while verteporfin abrogated TGF-binduced Rankl and Opg expression (Figure 3-16A-C). In OCY454 cells, verteporfin
abrogated TGF-b-induced Opg and reduced Sost expression, but did not significantly alter
Rankl expression (Figure 3-16D-F). In contrast to IDG-SW3 cells, treatment of OCY454
cells with TGF-b alone significantly reduced Rankl transcript expression (Figure 3-16E).

Figure 3-16: Combinatorial verteporfin (VP) and TGF-b treatment altered bone turnover-related gene
expression in vitro.
Osteocyte-like IDG-SW3 cells were differentiated for 21 days and combinatorially treated with inhibitor
verteporfin (VP) and/or 5 ng/ml TGFb1 at day 21. A-C) mRNA expression, normalized to 18S rRNA, was
evaluated for (A) sclerostin (Sost), (B) receptor activator of nuclear factor kappa-B ligand (Rankl), and (C)
osteoprotegerin (Opg). Osteocyte-like cells, OCY454, were differentiated for 12 days. Cells were
combinatorially treated with inhibitor verteporfin (VP) and 5 ng/ml TGF-b1 at day 12. D-F) mRNA
expression, normalized to 18S rRNA, was evaluated for (D) sclerostin (Sost), (E) receptor activator of nuclear
factor kappa-B ligand (Rankl), and (F) osteoprotegerin (Opg). Relative expression was expressed as fold vs.
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vehicle (PBS + DMSO)-treated cells. Data are presented as bars and individual samples with lines
corresponding to the mean and standard error of the mean (SEM). Sample sizes, N = 3.

3.5

Discussion
This study identifies new roles of the transcriptional regulators, YAP and TAZ, to

enhance our understanding of how osteocyte-mediated bone remodeling contributes to
skeletal fragility. Here, we show that YAP and TAZ control bone matrix accrual,
organization, and mechanical properties by regulating both perilacunar/canalicular
remodeling and osteoblast/osteoclast activity, potentially through TGF-b signaling in
osteocytes. Osteocyte-conditional YAP/TAZ deletion reduced bone mass by decreasing
osteoblast number and activity and increasing osteoclast activity, but also impaired
osteocyte-intrinsic pericellular matrix deposition and degradation, impairing canalicular
network connectivity without altering lacunar morphology. In vitro, we found that
YAP/TAZ activity was required for TGF-b1 induction of matricellular growth factors
involved in paracrine signaling from osteocytes to osteoblasts/osteoclasts and matrix
proteases necessary for perilacunar/canalicular remodeling. Together, these data identify
the transcriptional co-activators YAP and TAZ as key mediators of bone remodeling.
The roles of YAP and TAZ in skeletal-lineage cells are beginning to be clarified.
Previously, we reported that dual YAP/TAZ deletion from osteoprogenitor cells and their
progeny using Osterix-Cre mimicked severe cases of osteogenesis imperfecta170. We
identified a combinatorial role for YAP and TAZ in promoting osteoblast number and
activity and suppressing osteoclast activity170. Similarly, YAP deletion later in the
osteoblast lineage, from committed osteoblasts using Osteocalcin-Cre, significantly
reduced bone formation, further supporting a role for YAP in promoting osteogenesis in
vivo177. That study did not observe changes in osteoclast activity, potentially due to
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compensatory effects of TAZ or the Cre line used177. We show here that 8kb-DMP1-Creconditional YAP/TAZ deletion from osteocytes also reduced osteoblast number and
activity and increased osteoclast activity. Consistent with our data268, Xiong et al. found
that YAP/TAZ deletion using 10kb-DMP1-Cre reduced bone formation and increased
osteoclast numbers171. The YAP/TAZ-TEAD target, CTGF was previously reported to
directly bind to RANKL and OPG to induce osteoclast differentiation in vitro269, but
neither the present study nor Xiong et al.171 observed significant changes in transcript
expression of Sost or Opg/Rankl in vivo. Our in vitro experiments in osteocyte-like IDGSW3 and OCY454 cells did not reveal consistent regulation of Sost, Opg, or Rankl by
YAP/TAZ-TEAD, warranting further mechanistic studies.
Here, we found that YAP/TAZ deletion in vivo and inhibition in vitro reduced
osteocyte expression of the matricellular growth factors, Cyr61 and Ctgf. Both CYR61 and
CTGF are induced by TGF-b266,267 and are transcriptionally regulated directly by the
YAP/TAZ-TEAD complex126,246. CYR61 and CTGF are expressed by osteocytes239 and
have been implicated in both osteoblastogenesis243,244 and osteoclastogenesis245,270. During
osteoblastogenesis in vitro, CYR61 enhances mesenchymal stem cell migration and
regulates

WNT3A-induced

osteogenic

differentiation243.

CTGF

also

enhances

osteoblastogenesis in vitro, in part by inhibiting Notch signaling and inducing HES-1
transcription and NFAT transactivation244. In vivo deletion of CTGF in Osteocalcinexpressing cells led to a mild low bone mass phenotype in male mice without alterations
in osteoblast or osteoclast numbers271. Similarly, deletion of CYR61 at various stages of
the osteoblast lineage (Osterix-Cre, Collagen1(2.3kb)-Cre, and Osteocalcin-Cre) resulted
in low bone mass phenotypes of similar severity, suggesting mature osteoblasts/osteocytes
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are the primary source of CYR61 in bone240. Deletion of CYR61 from Osteocalcinexpressing mature osteoblasts also increased osteoclast numbers in vivo240, consistent with
the effects of osteocyte-conditional YAP/TAZ deletion here. CYR61 inhibits
osteoclastogenesis in vitro through a RANKL-independent mechanism245, while CTGF has
been observed to promote osteoclast-precursor fusion through interaction with dendritic
cell-specific transmembrane protein (DC-STAMP)270. Future studies will be required to
dissect the varied mechanisms by which osteocytes direct osteoblast/osteoclast-mediated
remodeling, but these data identify a role for YAP/TAZ in osteocyte-mediated promotion
of osteoblast activity and suppression of osteoclast activity and implicate a TGF-b–
YAP/TAZ-TEAD signaling axis in CYR61 and CTGF expression by osteocytes.
In addition to regulating osteocyte-mediated coordination of osteoblasts and
osteoclasts, we found that YAP/TAZ deletion also impaired perilacunar/canalicular
remodeling of the bone matrix directly by osteocytes. TGF-b signaling is an osteocyteintrinsic regulator of perilacunar/canalicular remodeling106. Here, we found that DMP1conditional YAP/TAZ deletion phenocopied the effects of both DMP1-conditional TGF-b
receptor deletion and pharmacologic inhibition, which impaired canalicular network length
and reduced expression of matrix-degrading enzymes required for perilacunar/canalicular
remodeling (i.e. MMP13, MMP14, and CTSK) without altering lacunar morphology106, as
observed here. Confirming the function of these regulated genes, DMP1-conditional
YAP/TAZ deletion also partially phenocopied knockout mouse models of these important
matrix proteases. First, global knockout of MMP13 in mice osteocyte inhibited
perilacunar/canalicular remodeling by reducing collagen organization, flourochromelabeled mineral deposition around osteocytes, and canalicular network connectivity with
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similar effect sizes to DMP1-conditional YAP/TAZ deletion33. Second, global knockout of
MMP14 in mice significantly reduced canalicular network development and maintenance,
reducing osteocyte processes density and length34. Notably, targeted deletion of MMP14
in skeletal lineage cells using Dermo1-Cre reduced YAP/TAZ activity in osteocytes220,
suggesting a potential feedback loop between matrix protease activity and matrix
mechanotransduction. Lastly, global knockout of CTSK in mice impaired bone matrix
collagen organization that increased bone fragility in spite of high bone mass and increased
osteoclast activity272. We therefore pose the working hypothesis that YAP and TAZ act
downstream of TGF-b to mediate perilacunar/canalicular remodeling in osteocytes; further
investigation will be required to test this in vivo.
Perilacunar/canalicular remodeling and osteoblast/osteoclast-mediated remodeling
coordinately determine skeletal strength6,236. Compromised bone strength caused by
defects in bone mass and/or quality results in fragility fracture6,235,236. Bone quantity is
primarily regulated by the balance of bone turnover rate while quality includes matrix
composition and microarchitectural geometry6,235. Both of these factors contribute to the
pathogenesis of skeletal fragility diseases such as osteoporosis, Paget’s disease, and
osteogenesis imperfecta6. Here, we found that osteocyte-conditional YAP/TAZ deletion
decreased bone mass and altered collagen matrix content and organization, producing
moderate defects in bone mechanical behavior. Osteocyte-specific YAP/TAZ knockouts
did not exhibit the spontaneous bone fractures prevalent in mice lacking YAP/TAZ in the
full osteoblast lineage170, but their defects correspond with the increased bone fragility
described in other models of defective perilacunar/canalicular remodeling33,106. Agerelated decreases in canalicular network connectivity are associated with microdamage
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accumulation that contributes to age-associated skeletal fragility199, further suggesting a
contribution of the canalicular network to bone strength.
This study has several limitations. First, small sample sizes (N = 4-8) produced
under-powered analyses for some outcome measures. Post-hoc power analyses for
indicated perilacunar/canalicular phenotypic results are shown in Table 3-3.
Table 3-3: Post-hoc power analyses.
Power analyses for perilacunar/canalicular phenotypic results.

Figure Panel

Parameter

Power

Figure 4C

Stiffness

0.99

Figure 5G

Canalicular length

0.99

Figure 6C

Branch length

0.95

Figure7B

Calcein+ lacunae

0.92

Figure 7C

Col1a1 mRNA

0.74

Figure7E

CTSK+ lacunae

0.86

Figure 7F

Ctsk mRNA

0.96

Figure7H

MMP13+ lacunae

0.83

Figure 7I

Mmp13 mRNA

0.99

Figure7K

MMP14+ lacunae

0.74

Figure 7L

Mmp14 mRNA

0.83

Power ranged from 0.74 to 0.99. Thus, not all the studies performed had enough
power to compare sex as a variable, though our initial assessment of skeletal phenotype did
not show a significant effect of sex. Second, two different age of mice were used (P28 and
P84). Both timepoints represent young mice with robust osteocyte canalicular networks
avoiding the potentially confounding effects of age-related canalicular network
deterioration199. However, significant changes in development and bone growth occur in
mice between P28 and P84; future studies will characterize the extent of canalicular
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development during post-natal growth. Third, recent reports suggest that both the 8-kb and
10-kb DMP1 promoter fragments used to drive Cre recombinase expression for conditional
ablation in osteocytes can also induce recombination in mature osteoblasts, and other cell
types, depending on the sensitivity of the floxed alleles69,70,273,274. Although we observed
minimal recombination in osteoblasts and growth plate chondrocytes, the 8-kb DMP1-Cre
model used here is not an inducible model, and potential targeting of earlier stage
osteogenic cells could still contribute to the developmental changes observed. Fourth, our
data suggest that YAP/TAZ act downstream of TGF-b in osteocytes, but continued study
will be required to determine whether YAP and TAZ act downstream of TGF-b in vivo and
to define the transcriptional mechanisms by which YAP and TAZ regulate
perilacunar/canalicular remodeling genes. Finally, osteocytes are the key mechanosensing
cells in bone275, and YAP and TAZ are important mediators of mechanotransduction in
many cell types150; however, the putative roles of YAP and TAZ in osteocyte
mechanotransduction

are

unknown.

As

mechanical

loading

also

induces

perilacunar/canalicular remodeling276, continued investigation is warranted.
In conclusion, this study identifies the transcriptional co-activators, YAP and TAZ,
as regulators of bone quantity and quality that mediate osteocyte regulation of
osteoblast/osteoclast activity and perilacunar/canalicular remodeling. Specifically,
osteocyte YAP and TAZ are required for the expression of paracrine growth factors that
regulate osteoblast/osteoclast coupled remodeling (i.e., Cyr61, Ctgf) and the effector
enzymes that enable perilacunar/canalicular remodeling. Further elucidation of the
mechanisms by which the TGF-b and YAP/TAZ signaling pathways interact to regulate
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osteocyte function may help guide the development of targeted therapies for the treatment
of skeletal fragility diseases.
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CHAPTER 4: YAP AND TAZ PROMOTE PERIOSTEAL OSTEOBLAST
PRECURSOR EXPANSION AND DIFFERENTIATION FOR FRACTURE
REPAIR
4.1

Abstract
In response to bone fracture, periosteal progenitor cells proliferate, expand, and

differentiate to form cartilage and bone in the fracture callus. These cellular functions
require the coordinated activation of multiple transcriptional programs, and the
transcriptional regulators Yes-associated protein (YAP) and transcriptional co-activator
with PDZ-binding motif (TAZ) regulate osteochondroprogenitor activation during
endochondral bone development. However, recent observations raise important
distinctions between the signaling mechanisms used to control bone morphogenesis and
repair. Here, we tested the hypothesis that YAP and TAZ regulate osteochondroprogenitor
activation during endochondral bone fracture healing in mice. Constitutive YAP and/or
TAZ deletion from Osterix-expressing cells impaired both cartilage callus formation and
subsequent mineralization. However, this could be explained either by direct defects in
osteochondroprogenitor differentiation after fracture, or by developmental deficiencies in
the progenitor cell pool prior to fracture. Consistent with the second possibility, we found
that developmental YAP/TAZ deletion produced long bones with impaired periosteal
thickness and cellularity. Therefore, to remove the contributions of developmental history,
we next generated adult onset-inducible knockout mice (using Osx1-CretetOff) in which
YAP and TAZ were deleted prior to fracture, but after normal development. Adult onsetinduced YAP/TAZ deletion had no effect on cartilaginous callus formation, but impaired
bone formation at 14 days post-fracture (dpf). Earlier, at 4 dpf, adult onset-induced
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YAP/TAZ deletion impaired the proliferation and expansion of osteoblast precursor cells
located in the shoulder of the callus. Further, activated periosteal cells isolated from this
region at 4 dpf exhibited impaired osteogenic differentiation in vitro upon YAP/TAZ
deletion. Finally, confirming the effects on osteoblast function in vivo, adult onset-induced
YAP/TAZ deletion impaired intramembranous bone formation in the callus shoulder at 7
dpf. Together, these data show that YAP and TAZ promote the expansion and
differentiation of periosteal osteoblast precursors to accelerate bone fracture healing.

4.2

Introduction
Bone is a remarkable tissue in its capacity to heal without forming a scar, and most

bone injuries heal readily, with bone fractures healing at success rates of 90-95%277. This
is due, in part, to the maintenance of a skeletal stem cell population capable of
recapitulating many aspects of embryological programs for adult tissue regeneration37. As
in development, bone formation during fracture repair can occur through both direct
intramembranous

ossification

and

endochondral

ossification

via

a

cartilage

intermediate39,40,43. However, the source, niche, and molecular regulation of the progenitor
cells responsible for bone fracture repair are distinct from those that produce the skeleton
during development37,278. In the embryo, mesodermal mesenchymal progenitors in the limb
bud form a template of the skeletal elements, while bone fracture healing initiates by
expansion and differentiation of osteochondroprogenitor cells resident in the bone-lining
periosteum39,40,50. Understanding the mechanisms that regulate the proliferation and
differentiation of these cells will be critical to develop new therapeutic strategies for
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accelerating fracture repair and regenerating challenging bone injuries that cannot heal on
their own.
To define the roles of the molecular mediators that regulate adult periosteal
progenitor cell function, we must decouple the developmental history of the
osteochondroprogenitor cells that come to reside in the periosteum from the regenerative
function of these cells after fracture to accurately evaluate their contribution to responding
to injury in the adult. For example, a recent study in which PDGFRb was deleted from
Osterix-expressing cells found no notable defects in skeletal development, but severe
impairment of fracture healing279, demonstrating contextual distinctions between
development and fracture repair. Further, skeletal cell- and bone-specific gene deletion
during development may alter the number, location, or niche of progenitor cells that, during
injury, are activated for skeletal regeneration58. In this study, we assessed the effects of
conditional gene deletion from osteochondroprogenitors on endochondral bone fracture
repair, with deletion performed either constitutively during development or inducibly after
normal development to skeletal maturity prior to fracture. Several types of inducible CreloxP systems exist to temporally regulate Cre-mediated gene recombination, including the
interferon-responsive Mx1 promoter280, tamoxifen-inducible mutated estrogen- and
progesterone-receptors281, and tetracycline-controlled systems282.

Here, we used the

Osterix-CretetOff (Osx-Cre) mouse in which Cre-recombinase is driven by the Osterix
promoter and temporally controlled by tetracycline (or its more stable derivative,
doxycycline)63. Osx-Cre is expressed in hypertrophic chondrocytes and osteoprogenitors,
including those of the primary ossification center in the embryo as well as the periosteum
in the adult63,283.
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Periosteal cell expansion and differentiation require the coordinated activation of
multiple transcriptional programs, and the transcriptional regulators, Yes-associated
protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) have
recently emerged as critical mediators of osteoblast progenitor proliferation and
differentiation during bone development170,171,177. Previously, we found that constitutive
homozygous deletion of both YAP and TAZ from Osterix-expressing cells caused severe
skeletal fragility and neonatal lethality170. Mice with a single allele of either YAP or TAZ
survived, but sustained spontaneous long bone fractures due to both reduced bone mass
and defects in bone matrix collagen that caused weaker bone mechanical properties170.
Despite fracture, the neonatal limbs exhibited natural reduction284 and eventually healed
through callus formation 170. However, the roles of YAP and TAZ in periosteal progenitor
cell function and their contributions to bone fracture healing are unknown.
Here, we conditionally deleted YAP and/or TAZ from Osterix-expressing cells
using either constitutive or tetOFF-inducible deletion and evaluated adult endochondral
bone fracture healing. We found that constitutive YAP and/or TAZ deletion impaired both
callus formation and subsequent mineralization, due to developmental deficiencies in the
progenitor cell pool prior to fracture. In contrast, adult onset-induced YAP/TAZ deletion
had no effect on cartilaginous callus formation, but impaired both the proliferation of
osteoblast precursor cells located in the shoulder of the callus and their osteogenic
differentiation, both, in vitro and in vivo. Together, these data show that YAP and TAZ
promote the expansion and differentiation of periosteal osteoblast precursors to accelerate
bone fracture healing.
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4.3
4.3.1

Methods
Animals
Mice harboring loxP-flanked exon 3 alleles in both YAP and TAZ on a mixed

C57BL/6J genetic background were kindly provided by Dr. Eric Olson (University of
Texas Southwestern Medical Center). Tetracycline responsive (tetOFF) B6.Cg-Tg(Sp/7tTA,tetO-EGFP/Cre)1AMc/J (Osx-CretetOff) mice from The Jackson Laboratory (Bar
Harbor, MA, USA) were used to generate two mouse models in which we conditionally
deleted YAP and/or TAZ from Osterix-expressing cells (Table 4-1). In both mouse models,
tetracycline (or its more stable derivative, doxycycline) administration prevents
tetracycline-controlled transactivator protein (tTA) binding to the tetracycline-responsive
promoter element (TRE) in the promoter of the Cre transgene, allowing Cre expression
only in the absence of doxycycline63 for temporal control of Osx-Cre-mediated gene
deletion.
Table 4-1: Experimental fracture healing models, genotypes, and abbreviations (Aim 3)

Deletion Model

Genotype

Abbreviation

Yap ;Taz

YAPWT;TAZWT

Yapfl/+;Tazfl/+;Osx-CretetOff

YAPcHET;TAZcHET

Yapfl/fl;Tazfl/+;Osx-CretetOff

YAPcKO;TAZcHET

Yapfl/+;Tazfl/fl;Osx-CretetOff

YAPcHET;TAZcKO

Yapfl/fl;Tazfl/fl;Osx-CretetOff

YAPcKO;TAZcKO

Osx-CretetOff

Osx:Cre

Yap ;Taz
Yapfl/fl;Tazfl/fl;
Osx-CretetOff

YAPWT;TAZWT

fl/fl

Constitutive

Inducible

fl/fl

fl/fl

fl/fl

YAPcKOi;TAZcKOi

In our first study, we evaluated constitutive allele dose-dependent deletion of YAP
and/or TAZ in skeletally mature mice 16-21 weeks of age (Table 4-1). Mice with
homozygous floxed alleles for both YAP and TAZ (YAPfl/fl;TAZfl/fl) were mated with

115

double heterozygous conditional knockout mice (YAPfl/+;TAZfl/+;Osx-Cre) to produce
eight possible genotypes in each litter, but only Cre-positive and YAPfl/fl;TAZfl/fl animals
were compared (Table 4-1). Here, the littermate YAPfl/fl;TAZfl/fl mice were considered the
control genotype. All of these mice were bred, raised, and evaluated without tetracycline
administration to induce gene recombination in Osterix-Cre-expressing cells from
embryonic development onward, for the duration of the analyses in the constitutive deletion
model.
In our second study, we allowed mice to develop to skeletal maturity and induced
homozygous YAP/TAZ deletion two weeks prior to fracture at 16-18 weeks of age (Table
4-1). In the inducible deletion model, both littermate YAPfl/fl;TAZfl/fl (YAPWT;TAZWT )
mice and separately bred Osx-CretetOff mice were evaluated as control genotypes (Table 41). All mice were bred and raised until skeletal maturity with doxycycline in their drinking
water to prevent Cre-mediated gene recombination. For all in vivo fracture healing
assessments, doxycycline was removed two weeks prior to fracture surgery and normal
drinking water was provided for the remainder of the study. For periosteal progenitor cell
isolations from fractured limbs, doxycycline was provided for both YAPWT;TAZWT and
YAPcKOi;TAZcKOi mice throughout skeletal development and the duration of the fracture
healing experiment.
In both studies, mice were tail or ear clipped after weaning or prior to euthanasia
and genotyped by an external service (Transnetyx, Inc.). All mice were fed regular chow
(PicoLab Rodent Diet, Cat#: 0007688, LabDiet) ad libitum and housed in cages containing
2-5 animals each. Mice were maintained at constant 25°C on a 12-hour light/dark cycle.
Both male and female mice were evaluated with the same fracture healing procedure for
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both the constitutive and inducible deletion models of fracture healing (Table 4-1). All
protocols were approved by the Institutional Animal Care and Use Committees at the
University of Notre Dame and the University of Pennsylvania. All animal procedures were
performed in adherence to federal guidelines for animal care and conform to the Animal
Research: Reporting of In Vivo Experiments (ARRIVE) guidelines.

4.3.2

Open femoral fracture model and timepoints
An open, unilateral, and intramedullary pin-stabilized femoral fracture model was

used to study bone repair in both the inducible and constitutive deletion studies. Femora
were surgically exposed and manually fractured by applying a bending moment, but
stabilized with an intramedullary pin285. For the surgical procedure, animals were
anesthetized using isoflurane (1-5%), all hair was removed from the surgical site, and the
area was cleansed with sterile water followed by betadine. A 25-gauge needle was inserted
in a retrograde manner into the intramedullary canal of the right femur286. Subsequently,
the muscle surrounding the same femur was blunt dissected to expose the femoral midshaft
and a reproducible fracture was created by applying a three-point bending moment in the
femur containing the intramedullary pin. The contralateral leg was left intact. Any animals
that displayed intramedullary pin displacement or fractures that were comminuted or too
oblique were removed. The mice were allowed to recover under a heating lamp and after
awakening returned to their cages and allowed to ambulate freely. In the constitutive
deletion model, mice were euthanized at 14 days post-fracture (dpf) and 42 dpf. In the
inducible deletion model, mice were euthanized at 4 dpf, 7 dpf, and 14 dpf. At 4 dpf, mice
were injected intraperitoneally with 5-ethynyl-2’-deoxyuridine (EdU; E10187; Invitrogen)
at 10 mg/kg 3 hours prior to euthanasia to assay cellular proliferation.
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4.3.3

Microcomputed tomography
Micro-computed tomography (microCT) was performed according to published

guidelines208 on two separate systems. In the constitutive deletion study, 14 and 42 dpf
fractured limbs were dissected free from surrounding musculature and the intramedullary
pins were removed. Samples from 14 and 42 dpf limbs were wrapped in PBS-soaked gauze
and frozen at -20°C. When removed from the freezer, bones were allowed to thaw while
being imaged using a µCT 35 system (Scanco Medical). Samples from 14 and 42 dpf bone
were imaged with an X-ray intensity of 114 µA, energy of 70 kVp, integration time of 200
ms, and resolution of 15µm. Based on the precedent set in a similar fracture healing
study286,287, we defined the fracture callus mineralization threshold as 50% of the mineral
density that we used to segment intact cortical bone under these conditions on this system.
2D tomograms of the fracture calluses both excluding and including the intact cortical bone
were manually contoured, stacked and binarized by applying a Gaussian filter (sigma =0.8,
support =1) at a threshold of 345 mg HA/cm3. 3D quantification of the mineralized callus
excluding the intact bone were reported as total callus volume, percent callus
mineralization, and volumetric bone mineral density. Five to eight mice were analyzed per
group. Investigators were blinded to animal genotype during scan quantification.
In the inducible deletion study, 7 and 14 dpf limbs were dissected free from
surrounding musculature and the intramedullary pins were removed. Bones from 7 and 14
dpf were then snap-frozen in liquid nitrogen-cooled isopentane for 1-minute, wrapped in
gauze and imaged on a vivaCT 80 system (Scanco Medical). Samples from 7 and 14 dpf
were imaged with an X-ray intensity of 114 µA, energy of 70 kVp, integration time of 200
ms, and resolution of 15µm. We again defined the fracture callus mineralization threshold
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as 50% of the mineral density that we used to segment intact cortical bone under these
conditions on this system. 2D tomograms of the fracture calluses both excluding and
including the intact cortical bone were manually contoured, stacked and binarized by
applying a Gaussian filter (sigma =0.8, support =1) at a threshold of 254 mg HA/cm3. 3D
quantification of the mineralized callus excluding the intact bone were reported as total
callus volume, percent callus mineralization, and volumetric bone mineral density. Six to
eight mice were analyzed per group. Investigators were blinded to animal genotype during
scan quantification.
To assess the cross-sectional bone distributions on the scans from both systems, the
“Bone Midshaft” evaluation script (Scanco Medical) was used to quantify polar moment
of inertia (pMOI)288. Limbs from 14 dpf in the constitutive deletion model and 14 dpf from
the inducible deletion model were evaluated on each system using a negative, nonphysiological threshold so as to include all parts of the callus in the “Bone Midshaft”
evaluation. Limbs from 42 dpf were scanned on the µCT 35 system were evaluated using
the same threshold for mineralized tissue above (345 mg HA/cm3). In both cases, pMOI
values for all groups were binned into 25 equal distance bins from the center of the fracture
using a custom MATLAB script and presented as the mean with error bars corresponding
to the standard deviation (SD).

4.3.4

Mechanical testing
Following microCT scanning, 14 and 42 dpf limbs from the constitutive deletion

model were tested in torsion to failure. For torsional testing, we used fixtures and a custom
potting apparatus that allowed us to reproducibly align and pot the fractured limbs in
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polymethylmethacrylate bone cement. After the fractured limbs were potted, they were
loaded in torsion at a rate of 1°/s until failure using a custom-designed micro-torsional
testing system. Recorded torque-rotation data were normalized by gauge length on a persample basis289. Torsional rigidity, maximum torque to failure, work to maximum torque
and work to failure were quantified from the normalized torque-rotation data using a
custom MATLAB script170. Five to eight mice were analyzed per group per timepoint.
Investigators were blinded to animal genotype during data quantification.
4.3.5

Histology, immunohistochemistry, and immunofluorescence
Limbs from 7 and 14 dpf were fixed with 10% neutral buffered formalin for 48

hours and decalcified for 4 weeks with 0.25M EDTA (pH 7.4) at 4°C. Paraffin sections (5
µm thickness) were processed for either immunohistochemistry or histology. Primary
antibodies were compared to normal rabbit sera IgG control sections. For immunostaining,
anti-OSX (1:500, ab22552; abcam), anti-YAP (1:500, 14074; Cell Signaling), and antiTAZ (1:250 NB110-58359; Novus Biologicals) primary antibodies were applied overnight.
Next, sections were incubated with corresponding biotinylated secondary antibody, avidinconjugated peroxidase, and diaminobenzidine substrate chromogen system (329ANK-60;
Innovex Biosciences), which allowed for immunohistochemical detection of positively
stained cells. Hematoxylin and eosin stains (H&E), Safranin-O, and Picrosirius Red stains
were used to stain for bone, cartilage, and collagen.
Limbs from 4 dpf and intact femora were fixed with 10% neutral buffered formalin
for 48 hours at 4°C, transferred to 30% sucrose in PBS overnight at 4°C, and then
embedded in O.C.T. compound (Tissue-Tek). Thin sections (7 µm thickness) were made
from undecalcified fractured femurs using cryofilm IIC tape (Section Lab Co. Ltd.) as
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previously described258 and processed for immunofluorescence and/or aqueous H&E
staining. Taped sections were glued to microscope slides using a UV-adhesive glue,
rehydrated and then decalcified with 0.25M EDTA (pH 7.4) for 3 minutes prior to staining.
5-ethynyl-2’-deoxyuridine (EdU)) staining were performed using the Click-iT Plus EdU
Assay kit (C10339; Invitrogen) according to the manufacturer’s instructions.
4.3.6

Imaging and histomorphometric analysis
Histological and immunohistochemical sections were imaged on either on an Axio

Observer Z1 (Zeiss) at the 10x and 25x objectives or using an Axioscan microscope (Zeiss)
at the 10x and 20x objective. Quantification of paraffin immunohistochemistry and
histology was performed using ImageJ (NIH). To determine the number of positively
immunostained cells, 4 regions of interest per sample per antibody were manually scored
as either positive or negative and reported as percentage positively stained osteoblasts,
osteocytes, and chondrocytes per total number of each cell type using ImageJ (NIH). Bone
and cartilage area per callus area were calculated using ImageJ (NIH) on histological
sections with 3-4 mice per group per timepoint.
Samples from 7 and 14 dpf were stained with Picrosirius Red and imaged under
polarized light using an Axioscan microscope (Zeiss) at the 20x objective and using second
harmonic generated (SHG) microscopy. SHG images were taken on a TCS SP8
Multiphoton Confocal microscope (Leica) at a fundamental wavelength of 880 nm with
the 10x and 40x objective on sections oriented in the same direction for all groups. All
SHG images were quantified using ImageJ (NIH) and reported as mean pixel intensity
within the cortical and callus region relative to WT bone. Mean pixel intensities across four
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separate regions of interests were averaged as technical replicates for a given sample within
either the callus or cortex area with 3-4 mice per group.
Immunofluorescence sections of 4 dpf limbs were imaged on an Axio Observer Z1
(Zeiss) at the 5x, 10x, and 25x objectives. To determine the number of positively EdUstained periosteal cells, 4 regions of interest were outlined per mouse 1-3 mm from the
fracture on the periosteal cortical bone290. Images were manually scored as either positive
or negative, averaged together from each of the 4 regions and reported as percent positively
stained per total number of periosteal cells in ImageJ (NIH). Periosteal area and average
thickness from these same 4 regions of interested were outlined in ImageJ (NIH) using
both immunofluorescence and aqueous H&E sections and averaged together with 6-9 mice
per group.

4.3.7

Periosteal cell isolation and osteogenic differentiation
Mouse periosteal cells were isolated from either WT or Osterix-conditional

YAP/TAZ deficient (YAPcKOi;TAZcKOi) femurs on 4 dpf and cultured at 37°C and 5% O2,
as described previously291. Briefly, mice were anesthetized by carbon dioxide inhalation
and euthanized via cervical dislocation. Fractured limbs were carefully dissected of all nonosseous tissue, the epiphyses were then removed, and marrow cavities were flushed. The
periosteum was scraped and enzymatically digested for 1 hour at 37°C on an orbital shaker
(0.5 mg/ml collagenase P, 2mg/ml hyaluronidase in PBS). Following washing, 2 x 104
cells/cm2 were seeded in growth medium (a-MEM, 10% FBS, 1% penicillin-streptomycin,
and 1ug/ml doxycycline) and cultured in 5% oxygen for the first 4 days. Half of the media
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was changed on day 4 and cultures were then incubated in 21% O2. Primary cells reached
confluence by day 7 and were passaged once into osteogenic differentiation experiments.
Passage 1 periosteal cells were then seeded at 21% O2 into 24-well plates (15 x 103
cells/cm2) and cultured in growth medium. After reaching confluence, primary periosteal
cell cultures were induced towards osteogenic differentiation (50 µg/mL ascorbic acid and
4mM b-glycerophosphate) for 21 days. Osteogenic media was changed every other day
prior to RNA isolation and alizarin red staining for mineral deposition at 21 days.

4.3.8

RNA isolation and qPCR
Limbs from 7 and 14 dpf were carefully dissected and removed of all non-osseous

tissue. The intramedullary pin was removed, and marrow flushed before being snap-frozen
in liquid nitrogen-cooled isopentane for 1 minute prior to microCT imaging and storage at
-80°C until processing. Tissues were then homogenized via mortar and pestle and RNA
from the sample was collected using Trizol Reagent (15596026; Life Technologies)
followed by centrifugation in chloroform. RNA from fractured limb tissue and cell culture
experiments were purified using the RNA Easy Kit (74106; Qiagen) and quantified by
spectrophotometry using a NanoDrop 2000 (Thermo-Fisher Scientific). Reverse
transcriptase polymerase chain reaction (RT-PCR) was performed on 0.1-0.5 μg/μl
concentration of RNA using the High-Capacity cDNA Reverse Transcription Kit
(4368814; Thermo-Fisher Scientific). Quantitative polymerase chain reaction (qPCR)
assessed RNA amount using a StepOnePlusTM Real-Time PCR System (Thermo-Fisher
Scientific) relative to the internal control of 18S ribosomal RNA (18S rRNA). Data are
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presented using the DDCt method. Six mice per group were used. Specific mouse primer
sequences are listed (Table 4-2).
Table 4-2: qPCR primers (Aim 3)
Mouse primers used for qPCR

Gene

Primer Sequence (5’ to 3’)

18S rRNA

F CGAACGTCTGCCCTATCAAC
R GGCCTCGAAAGAGTCCTGTA

Yap

F GATGTCTCAGGAATTGAGAAC
R CTGTATCCATTTCATCCACAC

Taz

F GGATACAGGTGAAAATTCCG
R GATTACAGCCAGGTTAGAAAG

Sox9

F AGTACCCGCATCTGCACAAC
R ACGAAGGGTCTCTTCTCGCT

Acan

F CCTGCTACTTCATCGACCCC
R AGATGCTGTTGACTCGAACCT

Col2a1

F GACTGAAGGGACACCGAG
R CCAGGGATTCCATTAGAG

Col10

F ATGCTGCCTCAAATACCCT
R TGCCTTGTTCTCCTCTTACT

Vegfa

F TAGAGTACATCTTCAAGCCG
R TCTTTCTTTGGTCTGCATTC

Runx2

F AGCCTCTTCAGCGCAGTGAC
R CTGGTGCTCGGATCCCAA

Col1a1

F GCTCCTCTTAGGGGCCACT
R CCACGTCTCACCATTGGGG

Col1a2

F GCTCCTCTTAGGGGCCACT
R CCACGTCTCACCATTGGGG

SerpinH1

F AGCCGAGGTGAAGAAACCC
R CATCGCCTGATATAGGCTGAAG

Osx

F CTGGGGAAAGGAGGCACAAAGAAG
R GGGTTAAGGGAGCAAAGTCAGAT

Alp

F GGACAGGACACACACACACA
R CAAACAGGAGAGCCACTTCA

Bsp

F ACAATCCGTGCCACTCACT
R TTTCATCGAGAAAGCACAGG

Cyr61

F CTGCGCTAAACAACTCAACGA
R GCAGATCCCTTTCAGAGCGG
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Ctgf

4.3.9

F GGGCCTCTTCTGCGATTTC
R ATCCAGGCAAGTGCATTGGTA

Statistics and regression
Sample sizes were selected a priori by power analyses based on effect sizes and

population standard deviations taken from published data on YAPfl/fl;TAZfl/fl mice in other
tissues188, assuming a power of 80% and α=0.05. All statistics and power analyses were
performed in GraphPad Prism. Comparisons between two groups were made using the
independent t-test while comparisons between 3 or more groups were made using a oneway ANOVA with post-hoc Tukey’s multiple comparisons test, if the data were normally
distributed according to D’Agostino-Pearson omnibus normality test and homoscedastic
according to Bartlett’s test. When parametric test assumptions were not met, data were logtransformed, and residuals were evaluated. If necessary, either the non-parametric KruskalWallis test with post-hoc Dunn’s multiple comparisons or the non-parametric MannWhitney test were used. A p-value < 0.05 (adjusted for multiple comparisons) was
considered significant. On the graphs, repeated significance indicator letters (e.g., “a” vs
“a”) signify P > 0.05. while groups with distinct indicators (e.g., “a” vs “b”) signify P <
0.05. Summary data are presented as bars, with independent samples indicated in scatter
plots and error bars representing standard error of the mean (SEM). Distributions of pMOI
were binned and presented as individual samples with lines corresponding to the mean and
standard deviation (SD).
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4.4
4.4.1

Results
Constitutive Osterix-conditional YAP and/or TAZ deletion impaired
endochondral fracture repair
To determine the roles of YAP and TAZ in endochondral fracture repair, we used

Cre-lox to delete YAP and/or TAZ from Osterix-Cre expressing cells from embryonic
development onward63. We selected a breeding strategy that generated YAP/TAZ allele
dosage-dependent Osterix-conditional knockouts and compared four genotypes (Table 41)170. Homozygous YAP/TAZ knockout mice were not evaluated due to perinatal lethality
170

. We then evaluated adult bone fracture repair at 14- and 42-days post fracture (dpf).
All genotypes exhibited callus formation by 14 dpf (Figure 4-1A). However,

constitutive YAP and/or TAZ deletion reduced total callus volume and mineralized callus
percentage (i.e. BV/TV) at 14 dpf in an allele dosage-dependent manner (Figure 4-1B,C).
Similarly, constitutive YAP and/or TAZ deletion also reduced mineralized tissue volume
and volumetric mineral density at 14 dpf (Figure 4-2A,B). We then tested 14 dpf limbs in
torsion to failure and observed a similar reduction in maximum torque to failure and
torsional rigidity (Figure 4-1D,E). However, work to max torque and work to failure did
not reach statistically significant differences between genotypes (Figure 4-2C,D).
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Figure 4-1: Constitutive, combinatorial YAP/TAZ deletion from Osterix-expressing cells impaired
endochondral fracture repair.
A) MicroCT reconstructions at 14 days post-fracture (dpf). Quantification of 14 dpf callus architecture: (B)
total callus volume and (C) mineralized callus percentage. Quantification of 14 dpf callus mechanical testing
in torsion to failure: (D) maximum torque and (E) torsional rigidity. F) MicroCT reconstructions at 42 dpf.
Quantification of 42 dpf callus architecture: (G) total callus volume and (H) mineralized callus percentage.
Quantification of 42 dpf callus mechanical testing in torsion to failure: (I) maximum torque and (J) torsional
rigidity. Data are presented as individual samples in scatterplots and bars corresponding to the mean and
standard error of the mean (SEM). Sample sizes, N = 5-8. Scale bars indicate 1 mm for microCT
reconstructions.

127

At 42 dpf, all genotypes similarly underwent hard callus remodeling (Figure 4-1F).
However, constitutive YAP and/or TAZ deletion again reduced mineralized callus
percentage, maximum torque to failure, and torsional rigidity, but at this timepoint
differences in total callus volume did not reach statistical significance (Figure 4-1G-J). At
42 dpf, constitutive YAP and/or TAZ deletion reduced volumetric mineral density, but did
not significantly reduce mineralized tissue volume, work to maximum torque, or work to
failure (Figure 4-2E-H).

Figure 4-2: Constitutive, combinatorial YAP/TAZ deletion from Osterix-expressing cells impaired
endochondral fracture repair, but not callus toughness.
14 and 42 dpf calluses were analyzed using microCT and torsion testing to failure. Quantification of 14 dpf
callus architecture: (A) total mineralized tissue volume and (B) volumetric mineral density. Quantification
of 14 dpf callus mechanical testing in torsion to failure: (C) work to maximum torque and (D) work to failure.
Quantification of 42 dpf callus architecture: (E) total mineralized tissue volume and (F) volumetric mineral
density. Quantification of 42 dpf callus mechanical testing in torsion to failure: (G) work to maximum torque
and (H) work to failure. Data are presented as individual samples in scatterplots and bars corresponding to
the mean and standard error of the mean (SEM). Sample sizes, N = 5-8.

4.4.2

Constitutive Osterix-conditional YAP and/or TAZ deletion reduced callus
formation
To determine the distribution of the callus, including cartilage and bone, at 14 dpf,

we quantified total callus polar moment of inertia (Figure 4-3A). Independent of bone
formation, constitutive YAP/TAZ deletion reduced callus formation, particularly in the
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YAPcHET;TAZcKO mice, which are homozygous for TAZ deletion and heterozygous for
YAP deletion (Fig. 4-3B). At 42 dpf, similar results were observed where the polar moment
of inertia distribution of mineralized tissue within the callus were reduced in the
YAPcHET;TAZcKO mice (Figure 4-4A,B). At 42 dpf, we performed an analysis of covariance
(ANCOVA) using linear regression to decouple the contributions of callus mineralization
and geometric distribution from the mechanical behavior170,216, since constitutive
YAP/TAZ deletion reduced both callus mineralization and geometry. We found that
individual regression lines for each genotype best predicted maximum torque to failure and
torsional rigidity, suggesting that differences in connectivity or composition also contribute
to mechanical behavior (Figure 4-4C,D).

Figure 4-3: Constitutive, combinatorial YAP/TAZ deletion from Osterix-expressing cells reduced overall
callus size.
A) MicroCT reconstructions at 14 dpf showing longitudinal cut-planes within the callus. Dotted lines indicate
the callus boundary. B) Polar moment of inertia distributions of the entire callus for each of the YAP/TAZ
allele dose-dependent knockout genotypes. Data were binned into 25 equal distance bins from the center of
the callus and presented as dots representing the mean and error bars corresponding to the standard deviation
(SD). Sample sizes, N = 5-8. Scale bar indicates 1 mm for microCT reconstructions.
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Figure 4-4:Constitutive, combinatorial YAP/TAZ deletion from Osterix-expressing cells reduced hard
callus size and mechanical properties.
A) 42 dpf post fracture microCT reconstruction of longitudinal cut planes within the callus. Mineralized
tissue within the callus were included in polar moment of inertia analysis B) Polar moment of inertia
distributions of the mineralized limb for each of the YAP/TAZ allele dose dependent knockout genotypes.
Data were binned into 25 equal distance bins from the center of the callus and presented as dots representing
the mean and bars corresponding to the standard deviation (SD). ANCOVA analysis accounting for fractured
limb geometry revealed significant differences between genotypes in (C) failure properties and (D) elastic
properties. Sample sizes, N = 5-8. Scale bars indicate 1 mm for microCT reconstructions.

4.4.3

Constitutive Osterix-conditional YAP and/or TAZ deletion impaired periosteal
development
To determine whether developmental defects in the periosteum contributed to the

reduced callus formation, we evaluated the periosteal thickness and cellularity of intact
femurs from constitutive knockout mice. Constitutive YAP and/or TAZ deletion
significantly reduced periosteal thickness (Figure 4-5A-C). Similar to younger mice170,
constitutive YAP and/or TAZ deletion reduced periosteal cell number per bone surface in
an allele dose dependent manner (Figure 4-5D), suggesting defective periosteal progenitor
development.
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Figure 4-5: Constitutive, combinatorial YAP/TAZ deletion from Osterix-expressing cells impaired
periosteal development in intact bone.
A) Representative micrographs of 18-21 weeks-old distal cortical bone stained by aqueous H+E.
Quantification of (B) periosteal thickness, (C) periosteal area and (D) periosteal cell number per bone surface
(N.Pc /PS). Data are presented as bars and individual samples with bars corresponding to the mean and
standard error of the mean (SEM). Sample sizes N = 6-7. Scale bar indicates 50 µm for all images.

4.4.4

Inducible Osterix-conditional YAP/TAZ deletion impaired callus
mineralization, but not formation
The impairment of endochondral bone fracture healing observed in the constitutive

YAP/TAZ deletion knockout model could be a consequence of defective periosteal stem
cell supply, expansion, and/or differentiation. To address this question, we generated adultinducible, dual homozygous YAP/TAZ knockout mice (YAPcKOi;TAZcKOi) in which the
periosteal progenitor population was allowed to develop normally prior to fracture. Here,
we induced homozygous Osterix-conditional YAP/TAZ deletion two weeks prior to
fracture. During those two weeks prior to fracture, Osterix-conditional YAP/TAZ deletion
did not significantly affect periosteal cell thickness, area, or cell number (Figure 4-6A-D).
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Figure 4-6: Periosteal thickness and cellularity developed normally in adult onset-induced, Osterixconditional, homozygous YAP/TAZ knockout mice.
A) Representative micrographs of 16-18 weeks-old cortical bone stained by aqueous H&E. Dotted lines
indicate the periosteum. Quantification of (B) periosteal thickness, (C) periosteal area and (D) periosteal cell
number per bone surface (N.Pc/PS). Data are presented as individual samples in scatterplots and bars
corresponding to the mean and standard error of the mean (SEM). Sample sizes N = 8-9. Scale bars indicate
30 µm for all images.

To analyze the recombination efficiency of inducible Osterix-Cre-mediated
YAP/TAZ deletion following fracture, we evaluated YAP/TAZ expression in
chondrocytes, osteoblasts,

and

osteocytes

within

the

callus

at

14

dpf

by

immunohistochemistry and qPCR (Figure 4-7A-C). YAP cellular expression was
significantly reduced in chondrocytes (23% reduction), osteoblasts (23% reduction), and
osteocytes (26% reduction) (Figure 4-7D-F). YAP mRNA expression was reduced by 59%
in YAPcKOi;TAZcKOi callus lysate preparations (Figure 4-7G). TAZ cellular expression was
moderately reduced in chondrocytes (11% reduction; p = 0.1) and significantly reduced in
osteoblasts (18% reduction), and osteocytes (12% reduction) (Figure 4-7H-J). TAZ mRNA
expression was reduced by 49% in YAPcKOi;TAZcKOi callus lysate preparations (Figure 47K).
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Figure 4-7:Inducible, homozygous YAP/TAZ deletion from Osterix-expressing cells moderately reduced
callus YAP/TAZ expression on 14 dpf.
A-C) Representative micrographs of chondrocyte, osteoblast, and osteocyte immunostaining for YAP, TAZ,
and IgG control sections at 14 dpf. Quantification of YAP and TAZ protein expression in (D) chondrocytes,
(E) osteoblasts, and (F) osteocytes from callus sections at D14. G) Yap and Taz mRNA expression, relative
to 18S rRNA, from callus bone preparations at 14 dpf. Data are presented as individual samples in scatterplots
and bars corresponding to the mean and standard error of the mean (SEM). N = 6 per group for qPCR and N
= 3 per group for IHC. Scale bars equal 50 µm for all images.

All genotypes underwent initial callus formation by 14 dpf (Figure 4-8A). Inducible
Osterix-Cre-mediated YAP/TAZ deletion reduced mineralized callus percentage and
volumetric bone mineral density, but differences in total callus volume between groups
were not observed (Figure 4-8B-D). Further, inducible Osterix-Cre-mediated YAP/TAZ
deletion significantly increased variability in total callus volume size and the polar moment
of inertia distribution within the callus in comparison to YAPWT;TAZWT and Osx:Cre mice
(Figure 4-8B; Figure 4-9A,B).
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Figure 4-8:Inducible, homozygous YAP/TAZ deletion from Osterix-expressing cells impaired callus
mineralization, but not formation.
A) MicroCT reconstructions at 14 dpf. Quantification of 14 dpf callus architecture: (B) total callus volume,
(C) mineralized callus percentage, and (D) volumetric mineral density. Data are presented as individual
samples in scatterplots and bars corresponding to the mean and standard error of the mean (SEM). Sample
sizes, N = 6-8. Scale bars indicate 1 mm for microCT reconstructions.
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Figure 4-9: Inducible, homozygous YAP/TAZ deletion from Osterix-expressing cells increased variability
in overall callus size.
A) 14 dpf microCT reconstruction of longitudinal cut planes within the callus. Dotted lines represent how all
tissue within the callus were included in polar moment of inertia analysis B) Polar moment of inertia
distributions of the entire callus for Osx:Cre, YAPWT;TAZWT, and YAPcKOi;TAZcKOi genotypes. Data were
binned into 25 equal distance bins from the center of the callus and presented as dots representing the mean
and bars corresponding to the standard deviation (SD). Sample sizes, N = 5-8. Scale bars indicate 1 mm for
microCT reconstructions.

4.4.5

Inducible Osterix-conditional YAP/TAZ deletion did not significantly alter
cartilaginous callus formation, but reduced bone formation
As the formation of a cartilaginous callus template is a critical step during

endochondral fracture healing39,40,43, we histologically evaluated cartilage formation at 14
dpf (Figure 4-10A,B). Consistent with microCT, inducible Osterix-Cre-mediated
YAP/TAZ deletion did not affect total callus area at 14 dpf, but increased variability was
observed YAPcKOi;TAZcKOi mice (Figure 4-10C). Differences in total cartilage area and
percent cartilage area were not detected between groups (Figure 4-10D,E). However,
inducible Osterix-Cre-mediated YAP/TAZ deletion resulted in a non-significant trend
towards increase percent cartilage area at 14 dpf (p = 0.12; Figure 4-10E). At 14 dpf,
inducible Osterix-Cre-mediated YAP/TAZ deletion did not significantly alter mRNA
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expression of markers for chondrogenesis, including SRY-Box Transcription Factor 9
(Sox9) and Aggrecan (Acan), but resulted in a non-significant trend towards reduced
collagen, type II, alpha 1 (Col2a1) mRNA expression (p = 0.06; Figure 4-10F).

Figure 4-10: Inducible, homozygous YAP/TAZ deletion from Osterix-expressing cells did not significantly
alter cartilaginous callus formation at 14 dpf.
A) Micrographs of Safranin-O stained calluses at 14 dpf. Black dotted boxes outline three zoomed-in regions
of interest found for each genotype in (B). Quantification of cartilaginous callus histomorphometry at 14 dpf
of (C) total callus area, (D) cartilage area, and (E) percent cartilage area of total callus. F) Sox9, Acan, and
Col2a1 mRNA expression, relative to 18S rRNA, from callus lysate preparations at 14 dpf. Data are presented
as individual samples in scatterplots and bars corresponding to the mean and standard error of the mean
(SEM). N = 6 per group for qPCR and N = 3-4 per group for histomorphometry. Scale bars equal 50 µm for
all zoomed images and 500 µm for callus images.

Following formation of the cartilaginous callus, extensive bone formation occurs
within the callus through both intramembranous and endochondral ossification40. Thus, we
next histologically evaluated endochondral ossification and bone formation at 14 dpf
(Figure 4-11A,B).

At 14 dpf, differences in Osterix (OSX)-positive hypertrophic
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chondrocytes were not detected between groups (Figure 4-11C). At 14 dpf, the number of
OSX-positive osteoblasts per bone surface, bone area, and percent bone area were reduced
following inducible Osterix-Cre-mediated YAP/TAZ deletion (Figure 4-11D-F). Further,
inducible Osterix-Cre-mediated YAP/TAZ deletion reduced mRNA expression of markers
for hypertrophic chondrocytes, including collagen, type X, alpha 1 (Col10) and vascular
endothelial growth factor (Vegfa) (Figure 4-11J). Similarly, inducible Osterix-Cremediated YAP/TAZ deletion reduced mRNA expression of markers of collagen, including
collagen type I, alpha 1 (Col1a1) and collagen type I, alpha II (Col1a2), but not serpin
family H member 1 (SerpinH1) (Figure 4-11K). Lastly, inducible Osterix-Cre-mediated
YAP/TAZ deletion reduced mRNA expression markers of osteogenesis, including
osteoblast-specific transcription factor Osterix (Osx) and alkaline phosphatase (Alp), while
reductions in runt-related transcription factor 2 (Runx2) or bone sialoprotein (Bsp) did not
reach statistical significance (Figure 4-11L).
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Figure 4-11:Inducible, homozygous YAP/TAZ deletion from Osterix-expressing cells reduced callus bone
formation.
A) Micrographs of Picrosirius Red-stained calluses at 14 dpf. White boxes outline three regions of interest
(B) in which second harmonic generated imaging (SHG) and anti-Osterix (aOSX) immunostaining are
highlighted. Quantification of callus histomorphometry at 14 dpf of (C) the number Osterix-positive
hypertrophic chondrocytes per cartilage area (OSX+ N.HC/CA), (D) Osterix-positive osteoblasts per bone
surface (OSX+ N.Ob/BS), (E) bone area, and (F) percent bone area. Quantification of relative SHG intensity
per bone area at 14 dpf of (G) the intact cortical bone, (H) the newly formed callus bone, and (I) normalized
callus-to-intact SHG intensity. Messenger RNA was extracted from callus lysate preparations at 14 dpf and
target gene expression was normalized to 18S rRNA and quantified as fold-change relative to wild type (JL). J) Col10 and Vegfa mRNA expression. K) Col1a1, Col1a2, and SerpinH1 mRNA expression. L) Runx2,
Osx, Bsp, and Alp mRNA expression. Data are presented as individual samples in scatterplots and bars
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corresponding to the mean and standard error of the mean (SEM). N = 6 per group for qPCR and N = 3-4 per
group for histomorphometry. Scale bars indicate 50 µm for all high-power images and 500 µm for callus
images.

4.4.6

Inducible Osterix-conditional YAP/TAZ deletion reduced periosteal osteoblast
precursor expansion in vivo and osteogenic differentiation in vitro
Given the defect in osteogenesis resulting from inducible Osterix-Cre-mediated

YAP/TAZ deletion, we evaluated activated periosteal progenitors at 4 dpf in four regions
distal and proximal to the fracture line, in which periosteal osteoblast precursors are
primarily fated to form bone through direction intramembranous ossification292 (Figure 412A). At 4 dpf, inducible YAP/TAZ deletion reduced periosteal osteoprogenitor cell
expansion in terms of total area and average thickness (Figure 4-12B-D). However,
inducible YAP/TAZ deletion did not reduce the number of periosteal osteoprogenitor cells
per expanded periosteal area, but significantly reduced the percentage of proliferating,
EdU-positive periosteal osteoprogenitor cells (Figure 4-12E,F).
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Figure 4-12: Inducible, homozygous YAP/TAZ deletion from Osterix-expressing cells impaired periosteal
osteoblast precursor cell expansion and osteogenic differentiation.
A) Representation of the regions of interest in the callus “shoulder,” in which we evaluated periosteal
osteoblast precursor expansion and proliferation. B) Representative micrographs of EdU+ periosteal cells
(red) at 4 dpf, with all nuclei counterstained by DAPI (blue). White dotted lines indicate periosteal cell
expansion zone; “m” indicates muscle, “c” indicates cortical bone. Quantification of the expanded (C)
periosteal area, (D) average thickness, (E) number of periosteal cells per bone area (N.Pc/BA), and (F)
percentage of EdU-positive periosteal cells. G) Activated periosteal cells isolated from 4 dpf limbs were
cultured in osteogenic media for 21 days. H) Representative Alizarin Red staining of mineral deposition
following osteogenic induction. I) Yap, Taz, Ctgf, and Cyr61 and J) Runx2, Osx, Alp, and Bsp mRNA
expression, relative to 18S rRNA, from periosteal progenitor cell cultures following 21 days of osteogenic
induction. Data are presented as individual samples in scatterplots and bars corresponding to the mean and
standard error of the mean (SEM). N = 6-9 per group. Scale bars indicate 100 µm for all high-power EdU
images and 1 mm for high-power Alizarin Red images.
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Though unexplored in periosteal osteoprogenitor cells, YAP and TAZ are known
to mediate osteogenic differentiation in MSCs113,147,148,150,160, which originate from a
common mesenchymal embryonic lineage48. To elucidate if inducible YAP/TAZ deletion
regulated periosteal osteoprogenitor differentiation, we isolated activated periosteal
progenitor cells at 4 dpf (Figure 4-12G)290,291. Following culture for 21 days in osteogenic
media, inducible, Osterix-conditional YAP/TAZ deletion reduced mineral deposition
stained with Alizarin Red (Figure 4-12G-H). As expected, Osterix-conditional inducible
YAP/TAZ deletion in vitro reduced mRNA expression of Yap and Taz as well as their
canonical downstream target, Ctgf and Cyr61 in periosteal progenitor cells from
YAPcKOi;TAZcKOi mice (Figure 4-12I). Lastly, Osterix-conditional inducible YAP/TAZ
deletion in vitro reduced mRNA expression of osteogenic differentiation genes including,
Runx2, Col1a1, Alp, and Bsp while reductions in Osx (p = 0.05) did not reach statistical
significance (Figure 4-12H).
Given the defective periosteal osteoblast precursor expansion and osteogenic
differentiation, we evaluated bone formation in the callus at 7 dpf. Although all genotypes
underwent periosteal expansion and mineralization (Figure 4-13A), inducible Osterix-Cremediated YAP/TAZ deletion reduced mineralized callus percentage and volumetric
mineral density at 7 dpf (Figure 4-13B,C). Within regions of the callus undergoing
intramembranous bone formation (Figure 4-13D), inducible Osterix-Cre-mediated
YAP/TAZ deletion reduced OSX-positive osteoblasts per bone surface concomitant with
reduced bone percent area while resulting in a non-significant trend toward reduced bone
area (Figure 4-13E-H), consistent with our observations at 4 dpf in vivo and in vitro. At 7
dpf, significant changes in cartilaginous callus formation were not detected (Figure 4-14A-

141

F). Similarly, inducible Osterix-Cre-mediated YAP/TAZ deletion did not significantly
alter endochondral ossification or matrix collagen content and organization within the
callus (Figure 4-15A-I).

Figure 4-13: Inducible, homozygous YAP/TAZ deletion from Osterix-expressing cells impaired periosteal
osteoblast precursor bone formation.
A) MicroCT reconstructions at 7 days post-fracture (dpf). Quantification of 7 dpf callus architecture: (B)
mineralized callus percentage and (C) volumetric bone mineral density. D) Representation of the regions of
interest in the callus “shoulder,” in which we evaluated (E) anti-Osterix (aOSX) immunostaining at 7 dpf.
Quantification of callus histomorphometry at 7 dpf of (F) Osterix-positive osteoblasts per bone surface
(OSX+ N.Ob/BS). (G) bone area, and (H) percent bone area. Data are presented as individual samples in
scatterplots and bars corresponding to the mean and standard error of the mean (SEM). Sample sizes, N = 68. Scale bars indicate 1 mm for microCT reconstructions and 50 µm for micrographs.
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Figure 4-14: Inducible, homozygous YAP/TAZ deletion from Osterix-expressing cells did not
significantly alter cartilaginous callus formation at 7 dpf.
A) Micrographs of Safranin-O stained calluses at 7 dpf. Black dotted boxes outline three zoomed-in regions
of interest found for each genotype in (B). Quantification of cartilaginous callus histomorphometry at 7 dpf
of (C) total callus area, (D) cartilage area, and (E) percent cartilage area of total callus. F) Sox9, Acan, and
Col2a1 mRNA expression, relative to 18S rRNA, from callus lysate preparations at 7 dpf. Data are presented
with individual samples in scatterplots and bars corresponding to the mean and standard error of the mean
(SEM). N = 6 per group for qPCR and N = 3 per group for histomorphometry. Scale bars equal 50 µm for all
zoomed images and 500 µm for callus images.
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Figure 4-15: Inducible, homozygous YAP/TAZ deletion from Osterix-expressing cells did not significantly
alter endochondral ossification or collagen matrix composition at 7 dpf.
A) Micrographs of Picrosirius Red stained calluses at 7 dpf. White boxes outline three zoomed-in regions of
interest found for each genotype for both second harmonic generated imaging (SHG) and anti-Osterix
(aOSX) immunostaining in (B). Quantification of callus histomorphometry at 7 dpf of (C) the number
Osterix-positive hypertrophic chondrocytes per cartilage area (OSX+ N.HC/CA). Quantification of relative
SHG intensity per bone area at 7 dpf of (D) the intact cortical bone, (E) the newly formed callus bone, and
(F) normalized callus-to-intact SHG intensity. G) Col10 and Vegfa mRNA expression, relative to 18S rRNA,
from callus lysate preparations at 7 dpf. H) Col1a1, Col1a2, and SerpinH1 mRNA expression, relative to
18S rRNA, from callus lysate preparations at 7 dpf. I) Runx2, Osx, Bsp, and Alp mRNA expression, relative
to 18S rRNA, from callus lysate preparations at 7 dpf. Data are presented with individual samples in
scatterplots and bars corresponding to the mean and standard error of the mean (SEM). N = 6 per group for
qPCR and N = 3 per group for histomorphometry. Scale bars equal 50 µm for all zoomed images and 500
µm for callus images.

.
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4.5

Discussion
This study identifies new roles for the transcriptional regulators, YAP and TAZ, in

bone fracture healing, adding to our understanding of periosteal osteoblast precursor cell
regulation. Here, we show that YAP and TAZ promote expansion and osteoblastic
differentiation of periosteal osteoblast precursors to promote bone fracture healing.
Constitutive YAP and/or TAZ deletion from Osterix-expressing cells impaired bone
fracture healing by reducing both callus formation and subsequent mineralization, due in
part to developmental defects in the periosteal progenitor supply. When we allowed for the
development of a normal periosteal progenitor population prior to fracture, adult onsetinduced YAP/TAZ deletion did not impair cartilaginous callus formation, but delayed
mineralization due to impaired osteoblast precursor cells and their osteogenic
differentiation. Together, these data demonstrate that the transcriptional co-activators,
YAP and TAZ, promote the expansion and differentiation of periosteal osteoblast
precursors to accelerate bone fracture healing.
Fracture healing recapitulates many aspects of embryonic skeletal development, but
features a unique post-natal environment, resulting in contextual differences39,293. We
previously found that Osterix-conditional YAP/TAZ deletion in the embryo caused a
severe skeletal fragility phenotype170, while Xiong et al. induced Osterix-conditional
YAP/TAZ deletion at post-natal day 21 (P21) and performed skeletal phenotyping at P84,
observing increased osteoblast numbers but no measurable effect on whole bone
microarchitecture171. Our present data resolve the differences between these two studies,
establishing a critical role for YAP and TAZ in the development of the postnatal
osteoprogenitor niche and demonstrating critical roles for YAP and TAZ in osteoblast
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precursor proliferation and differentiation in a context of rapid bone formation, similar to
that which occurs during bone development, in contrast to postnatal growth and
homeostasis. The present data are further consistent with other reports. For example,
deletion of the YAP/TAZ-regulated transcription factors, Snail and Slug, from Osterixexpressing cells reduced both the proliferative potential of bone surface-associated
osteoprogenitors and osteogenic differentiation capacity of adult skeletal stem cells294.
Similarly, conditional deletion of YAP from Osteocalcin-expressing cells reduced
osteoblast progenitor cell proliferation and differentiation, further supporting a role for
YAP and TAZ in promoting osteoblast progenitor cell function 177.
Endochondral bone fracture repair includes both the formation of a cartilage
template as well as subsequent osteoblast-mediated mineralization39,295. Here, we found
that while constitutive deletion impaired callus formation, adult onset-inducible YAP/TAZ
deletion did not significantly affect cartilage formation during fracture healing. A previous
study found that YAP overexpression in developing chondrocytes, using the Col2a1
promoter, as well as deletion of MST1/2 using Dermo-Cre impaired endochondral fracture
healing181, which appears to contradict the results described here. However, both models
exhibit a developmental skeletal phenotype prior to fracture181, and in particular, observed
that YAP/TAZ negatively regulate chondrogenesis. Thus, inducible targeting models are
needed to decouple the developmental history from the process of fracture repair

296,297

.

Here, we selected the tetOFF Osterix-Cre inducible system instead of the tamoxifeninducible Osterix-CreERT2 298, as tamoxifen is rapidly cleared299, resulting in transient Creactivity300 in newly-generated Osterix-positive cells during fracture repair. Furthermore,
targeting conditional gene inactivation in chondrocytes versus osteoblast-lineage cells can
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result in drastically different phenotypes. For example, conditional deletion of Runx2 in
chondrocytes using Col2a1-Cre phenocopied global Runx2 gene inactivation with
perinatal lethality and a lack of mineralization while conditional deletion of Runx2 in
osteoblasts using 2.3kb-Col1a1-Cre resulted in a moderate low bone mass phenotype80,82.
Nonetheless,

hypertrophic chondrocytes are known to express Osterix during

endochondral ossification73,301,302 and we observed moderate Osterix-Cre-mediated
YAP/TAZ recombination in hypertrophic chondrocytes, suggesting that the relative
contributions of YAP and TAZ during endochondral ossification are potentially stagedependent170,171,177,181.

Future studies will identify the temporal and cell-specific

contributions of YAP and TAZ to bone development and repair.
Recent and ongoing studies have revealed remarkable diversity in both the cellular
identity and regulatory signals that contribute to periosteal function. Gli1303, Prx148,
aSMA304, cathepsin K305, and Osterix306 mark both overlapping and distinct periosteal
progenitor cell populations, while markers previously thought to define bone marrow
stromal cells, including CD73, CD90, CD105, PDGFRa, Gremlin 1, Cxcl12, and
Nestin48,307–310, also show high expression in the periosteal progenitors. Ongoing efforts
continue to uncover new skeletal progenitor cell populations that contribute to fracture
repair309,311–315, and the intersection of this cellular diversity with YAP/TAZ signaling
remains unclear. Here, we observed significant reductions in mRNA expression of
endochondral-, collagen-, and osteogenesis-related gene expression signatures at 14 dpf,
which can be explained either by indirect shifts in the cell populations that express these
targets or by direct YAP/TAZ-mediated transcriptional regulation of those genes. Further
research will be required to not only systematically identify the transcriptional co-effectors
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of YAP and TAZ in each cell type of interest, but also delineate the periosteal progenitor
subpopulations affected by YAP/TAZ signaling.
YAP and TAZ may regulate osteoblast precursor cell proliferation and osteogenic
differentiation through a variety of mechanisms. Conditional deletion of YAP in
osteoblasts using Osteocalcin-Cre reduced osteoblast progenitor proliferation as well as
osteogenic differentiation and proposed YAP stabilized β-catenin to promote β-cateninmediated osteogenesis177. However, evidence exists for YAP and TAZ playing both a
positive and negative role in WNT/β-catenin signaling115,148, suggesting that further
investigation into YAP/TAZ-dependent regulation of this pathway in periosteal
progenitors is needed. A similar study demonstrated that Snail and Slug form stable
protein-protein complexes with both YAP and TAZ in tandem to promote osteoprogenitor
proliferation and differentiation294. In osteoprogenitors, the Snail/Slug-YAP/TAZ axis
promotes proliferation by interacting with TEAD to enhance TEAD-dependent
transcriptional activity and downstream expression of YAP/TAZ-TEAD target genes, such
as Ctgf and Ankrd1294. In contrast, the Snail/Slug-YAP/TAZ axis promotes osteogenic
differentiation via Snail/Slug-TAZ interactions with Runx2 to promote Runx2-dependent
transcriptional activity and downstream expression of osteogenic target genes, such as
Osterix and Alp294. Accordingly, evidence for TAZ interacting with Runx2 to promote
downstream osteogenic gene expression in vitro is strong

113,157

, but YAP has been

observed to both inhibit and promote downstream osteogenic gene expression in
vitro112,316–319. Thus, future studies to identify the molecular mechanisms by which YAP
and TAZ control periosteal progenitor expansion and differentiation are needed.
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This study has several limitations. First, small sample sizes (N =3-9) produced
under-powered analyses for some outcome measures. Thus, not all the studies performed
had sufficient power to compare sex as a variable, though we did not observe sexually
dimorphic behavior for any outcome measure, and our prior assessment of YAP/TAZ
regulation of bone development did not show an effect of sex170. Second, we used an open
fracture model, which may affect the kinetics and immunology of the fracture repair
process320,321. We initially began these experiments using a closed fracture model,
following the Einhorn method322, but this produced a high percentage of comminuted
fractures in the YAP/TAZ cKO groups. We therefore moved to an open fracture model in
which the bending moment could be applied with lower kinetic energy. This observation
suggests that YAP/TAZ deletion during development impaired the bone matrix fracture
toughness, consistent with our prior report on the bone fragility phenotype170. Third, adult
onset-inducible Osterix-conditional knockout increased variability in response to fracture,
adding an additional layer of complexity to the already challenging study of endochondral
bone fracture healing biology43. The drug used to prevent Cre-mediated recombination,
doxycycline, is a tetracycline derivative. Tetracycline exhibits high affinity for exposed
mineral and is therefore commonly used as a label for dynamic bone histomorphometry323.
Potential embedding of doxycycline into the bone matrix during skeletal development and
subsequent release following fracture could impair robust Cre-recombination and reduce
the observed effect size for adult onset-inducible YAP/TAZ knockout mice. We
recommend additional study to quantify the kinetics of tetOFF inducible systems and
efficiency of Cre-mediated inducible recombination in bone. Lastly, the Osterix-Cre
transgene is known to cause defects in craniofacial development72 and in fracture callus
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formation73, depending on genetic background. However, on this background, we did not
observe differences between Osx-Cre and YAPWT;TAZWT wild type mice, demonstrating
phenotypic specificity for YAP/TAZ deletion.
In conclusion, this study identifies the transcriptional co-activators, YAP and TAZ,
as regulators of bone fracture healing that promote periosteal osteoblast precursor
proliferation and osteogenic differentiation to accelerate bone healing. Further elucidation
of the mechanisms by which YAP and TAZ control the periosteal progenitor cell response
to fracture may help guide the development of future targeted therapies to enhance bone
fracture healing.
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS
5.1
5.1.1

Chapter Conclusions
Chapter 2 Conclusions
Given the conflicting evidence for the contributions of YAP and TAZ to osteogenic

differentiation in vitro, we used an in vivo combinatorial YAP and/or TAZ deletion
approach in Chapter 2. Dual-deletion of YAP and TAZ using Osterix-Cre resulted in
perinatal lethality, while mice harboring a single copy of either YAP or TAZ survived to
adult hood. However, mice with a single copy of either YAP or TAZ both sustained
neonatal spontaneous femoral fractures, highlighting the compensatory functions of YAP
vs TAZ in promoting bone development and post-natal growth. To this end, Osterixconditional YAP and/or TAZ deletion in skeletally mature mice resulted in decreased bone
formation and matrix composition combined with increased osteoclast activity, leading to
reduced bone mechanical strength. Overall, Chapter 2 demonstrated that YAP and TAZ
combinatorially promote skeletal development and post-natal growth via regulation of
osteoblast activity, osteoclast-mediated remodeling and matrix composition.
5.1.2

Chapter 3 Conclusions
Given the severe skeletal fragility phenotype discussed in Chapter 2, we next asked

how YAP and TAZ later in the skeletal lineage (i.e. in osteocytes) regulated bone function.
In Chapter 3, we combinatorially deleted YAP and/or TAZ from osteocytes using 8kbDMP1-Cre. In contrast to combinatorial YAP/TAZ deletion in Osterix-expressing cells,
only dual, homozygous YAP/TAZ deletion in osteocytes resulted in an obvious skeletal
phenotype. Therefore, we subsequently examined how dual deletion of YAP and TAZ
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affected osteocyte functionality. Dual YAP/TAZ deletion from osteocytes resulted in a
moderate skeletal fragility phenotype, characterized by defective osteocyte-mediated
remodeling. Chapter 3 identifies YAP and TAZ as regulators of bone quantity and quality
that

mediate

osteocyte

regulation

of

osteoblast/osteoclast

activity

and

perilacunar/canalicular remodeling. More specifically, we observed that osteocyte YAP
and TAZ are required for the expression of paracrine growth factors that regulate
osteoblast/osteoclast coupled remodeling and the effector enzymes that enable
perilacunar/canalicular remodeling. Overall, Chapter 3 demonstrated that osteocyte YAP
and TAZ regulate bone function via control of osteocyte-mediated remodeling.
5.1.3

Chapter 4 Conclusions
Given their important contributions to bone growth and remodeling, we next

characterized how skeletal cell YAP and TAZ contributed to endochondral bone fracture
repair. In Chapter 4, we again conditionally deleted YAP and/or TAZ using Osterix-Cre,
but here, we initiated deletion either constitutively (during embryonic development) or
inducibly (following skeletal maturity). Constitutive, Osterix-conditional YAP/TAZ
deletion impaired endochondral fracture repair with defective callus formation and
mineralization, especially in the mice lacking both alleles of TAZ. We attributed this defect
in callus formation to defective periosteal development as a result of YAP/TAZ deletion
during embryonic development. Thus, we allowed the development of a normal periosteal
progenitor population, then induced Osterix-Cre-mediated YAP/TAZ deletion prior to
fracture. Following inducible YAP/TAZ deletion, cartilaginous callus formation remained
intact, but we again observed defective callus mineralization and bone formation. Here, we
attributed the defect in the healing callus to reduced expansion and osteogenic
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differentiation of periosteal osteoblast precursor cells in response to fracture. Overall,
Chapter 4 demonstrated that osteoprogenitor YAP and TAZ promote bone fracture healing
via regulation of periosteal osteoblast precursor expansion and osteogenic differentiation.
5.2

Final Conclusions
This dissertation characterized the contributions of the paralogous transcription co-

effectors, YAP and TAZ, in skeletal lineage cells in the context of bone growth,
remodeling, and fracture repair. During skeletal development and early post-natal growth
and, YAP and TAZ in osteoprogenitor cells and their progeny combinatorially promoted
bone formation with their dual-deletion resulting in a severe osteogenesis imperfecta-like
phenotype. Later in the skeletal lineage, YAP/TAZ in osteocytes mediated not only
perilacunar/canalicular remodeling, but also osteocyte-mediated coordination of
osteoblast/osteoclast bone remodeling. Finally, skeletal lineage cell YAP and TAZ
promoted bone fracture repair by regulating both the development and expansion as well
as the osteogenic differentiation capacity of periosteal osteoblast precursors. Overall, this
work helps define the multifaceted roles of skeletal cell lineage YAP and TAZ throughout
bone function and provides a foundation for the development of new targeted therapeutic
strategies for the treatment of skeletal fragility disease and enhancement of fracture repair.
We started in Chapter 2 by elucidating the combinatorial in vivo contributions of
skeletal cell YAP and TAZ in promoting bone development and post-natal growth, given
the existing conflicting evidence for YAP/TAZ in promoting or inhibiting osteogenesis in
vitro. Next, in Chapter 3, we evaluated the role for YAP and TAZ later in the osteogenic
lineage, characterizing their regulation of osteocyte-mediated bone remodeling and
building upon the skeletal fragility phenotype discovered in Chapter 2. In Chapter 4, we
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investigated how skeletal cell YAP and TAZ contribute to bone fracture healing, observing
that both YAP and TAZ combinatorially promote periosteum development and together
YAP/TAZ regulate periosteal osteoblast precursor expansion, osteogenic differentiation,
and bone formation.
Taken together, we observed critical roles of skeletal cell YAP and TAZ where both
promote bone function in the context of growth, remodeling and fracture repair. As this
work is primarily observational in nature, future work determining the molecular
mechanisms by which YAP and TAZ exert their control on these various bone functions is
needed.
5.3
5.3.1

Future Directions
Bone mechanotransduction
Evaluating the putative roles for YAP and TAZ in bone mechanotransduction is an

obvious next area of investigation. YAP and TAZ are critical to cellular
mechanotransduction, responding to a variety of physical cues including extracellular
matrix rigidity, cell geometry, cell density and actin cytoskeletal tension129,150. Bone
growth, remodeling, and fracture repair require input from various mechanical signals to
coordinate an appropriate tissue-level adaptive response324,325. Given the initial
characterization of skeletal lineage cell YAP and TAZ in bone function, understanding
their cell-specific contributions to bone mechanotransduction is of potential interest.
During skeletal development and early post-natal growth, Osterix-conditional
YAP/TAZ knockout mice sustained spontaneous neonatal fractures. These long-bone
fractures eventually heal, but the underlying involvement of YAP/TAZ activity in response
to the mechanical environment during this healing time course is unknown. Experiments
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performed on neonatal long-bone fractures define a mechanical jack-like mechanism
driving spontaneous healing in neonatal mice, characterized by an important contribution
of muscle forces during angulated long-bone fracture realignment284. Similar experiments
using YAP/TAZ genetic manipulation models could elucidate the relative contributions of
YAP/TAZ in response to the mechanical environment during neonatal spontaneous
fracture reduction, identifying critical signaling pathways to modulate and improve adult
bone fracture healing.
Osteocytes are not only the most abundant skeletal cell but thought of as the
primary mechanosensory cell in bone23. Many signaling pathways are important to
osteocyte-mediated mechanotransduction and the subsequent adaptative response of bone,
including WNT/β-catenin5,326, which is known to intersect with YAP/TAZ signaling114–116.
In addition, mechanical stimuli affects osteocyte perilacunar/canalicular remodeling276,
suggesting a multidimensional role for osteocyte YAP/TAZ in bone adaptation to
mechanical loading. Standardized experimental conditions for in vivo tibial loading in mice
are becoming established327, providing an excellent model to study the role of YAP and
TAZ in bone mechanotransduction. Recent studies have demonstrated the ion channel
Piezo1 is upstream of YAP/TAZ activation with this signaling axis being required in vitro
and in vivo for osteoblast lineage cell mechanosensitivity328,329. Nonetheless, the putative
roles of skeletal cell YAP and TAZ in bone mechanotransduction are unknown.
Similar to growth and remodeling, the stages of bone fracture repair are highly
sensitive to the mechanical environment330–333. Moderate levels of interfragmentary motion
within the fracture result in healing primarily through endochondral ossification while rigid
fixation heals primarily through intramembranous bone formation333. During fracture
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healing, periosteal osteoblast precursor cell YAP and TAZ primarily promoted
intramembranous bone formation to accelerate fracture callus ossification. Thus,
manipulating both fracture fixation334 and YAP/TAZ activity could further elucidate the
mechanotransductive contributions of YAP/TAZ signaling during bone healing. Similar
experiments using the osteocyte-specific YAP/TAZ deletion model could clarify how the
osteocyte lacunar/canalicular network senses and responds to not only initial fracture, but
also later-stage bone remodeling.
5.3.2

Biological factors and spatial localization
The influence of the genetic background of mice is an important biological

consideration given the widespread use of skeletal lineage transgenic mouse models as
genetic background is known to affect bone structural and mechanical properties335,336. In
the context of skeletal fragility, genetic strain differences caused different expression of
phenotypic severity in a mouse model of osteogenesis imperfecta337. Throughout the
studies presented here, YAP/TAZ-floxed mice were acquired on a mixed C57BL/6J
background and then subsequently crossed with Osterix-Cre and 8kb-DMP1-Cre mice
generated on C57BL/6J backgrounds. However, the extent to which genetic background
variability is contributing to the observed skeletal phenotypes remains unknown.
Both age and sex are also critical biologic factors to consider when evaluating
skeletal phenotypes. Throughout the studies presented here, mice at multiple
developmental ages were evaluated. YAP/TAZ deletion from skeletal lineage cells
recapitulate aspects of age-related bone phenotypes, including age-related bone loss,
skeletal fragility, and impaired fracture healing. However, the exact contributions of
YAP/TAZ during the longitudinal time course of skeletal function (i.e. neonatal growth,
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skeletal maturity, aged-related decline) are only partially understood. Further, the studies
presented here were performed in both male and female mice, given that the initial skeletal
phenotyping did not demonstrate significant differences based on sex in either model.
Nonetheless, sex hormones and their receptors are critical to bone metabolism338,
suggesting a more detailed investigation of sex differences following YAP/TAZ
conditional deletion is warranted.
During bone function, spatial localization within the bone is critical for
coordinating local cellular function. For example, spatiotemporal cues are known to
regulate both osteogenic-angiogenic coupling during repair339, osteoblast-osteoclast
mediated bone remodeling340, and bone adaptation during axial tibial compression341.
Thus, YAP/TAZ-dependent regulation of skeletal cell function could vary between spatial
locations within the bone and surrounding muscles to coordinate the total tissue-level
response. Overall, future studies building on the work presented here should exercise
caution and carefully evaluate both biological factors, such as genetic background, age,
and sex, and also spatial localization within each bone compartment when evaluating the
in vivo contributions of YAP/TAZ in skeletal lineage cells.
5.3.3

Translational approaches
While the work presented here provides a better basic understanding of how YAP

and TAZ contribute to bone function, future efforts aimed at developing translational
strategies for treating skeletal fragility and enhancing fracture repair using this information
are needed. Given the vast network of YAP/TAZ-dependent signaling, systemic YAP/TAZ
modulation would cause irreversible off-target effects, suggesting local delivery systems
are needed to safely target the skeleton. While small molecule drugs that modulate
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YAP/TAZ-dependent activity exist, the exact specificity to which these drugs alter
YAP/TAZ activity remains unclear. For example, the most commonly used YAP/TAZ
inhibitor, verteporfin, was developed initially as a clinical photosensitizer in photodynamic
therapy for neovascular macular degeneration, but was shown as a potential inhibitor of
YAP/TAZ-TEAD downstream transcriptional activity218. However, recent work
demonstrated verteporfin elicited a similar therapeutic response independent of YAP
activity231, suggesting potential off-target effects. Additional inhibitors of YAP/TAZ
activity include the small molecule CA3342 and agonism of dopamine receptor D1343, yet
use of these YAP/TAZ inhibitors in the musculoskeletal field is limited. Regardless, small
molecule inhibition of YAP/TAZ activity in the skeleton would theoretically impair bone
function, given the skeletal phenotypes of genetic YAP/TAZ deletion.
However, pharmacological or genetic activation of YAP/TAZ presents a difficult
translational challenge, especially in the context of skeletal fragility and fracture repair.
First, small molecule drugs for specific YAP/TAZ activation remain elusive. Second, YAP
and TAZ are well known as potent proto-oncogenes, with their overexpression correlated
with tumorigenesis and poor cancer prognoses120,185. Thus, systemic pharmacological or
genetic YAP/TAZ activation is not a viable translational solution. Although targeting the
putative DNA binding co-factors interacting with YAP/TAZ is promising, important
consideration of the targeted cell type and context is needed. The cell type and contextdependent contributions of YAP/TAZ to osteogenic differentiation in vitro could provide
an interesting initial model system. If YAP/TAZ-dependent co-activation and YAP/TAZdependent co-repression of osteogenic genes could be observed in the same model system
with the addition of a single variable, co-immunoprecipitation combined with mass
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spectrometry344 could help identify the differences in putative YAP/TAZ DNA-binding cofactors giving rise to the context dependent regulation of osteogenesis. Instead of direct
YAP/TAZ activation, targeting context-specific YAP/TAZ co-factors could alternatively
promote bone formation to treat skeletal fragility and enhance fracture repair.

159

REFERENCES
1.

Robling, A. G., Castillo, A. B. & Turner, C. H. Biomechanical AND Molecular
Regulation of Bone Remodeling. Annu. Rev. Biomed. Eng. 8, 455–498 (2006).

2.

Datta, H. K., Ng, W. F., Walker, J. A., Tuck, S. P. & Varanasi, S. S. The cell
biology of bone metabolism. Journal of Clinical Pathology 61, 577–587 (2008).

3.

Florencio-Silva, R., Sasso, G. R. D. S., Sasso-Cerri, E., Simões, M. J. & Cerri, P.
S. Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone
Cells. BioMed Research International 2015, (2015).

4.

Rubin, J., Rubin, C. & Jacobs, C. R. Molecular pathways mediating mechanical
signaling in bone. Gene 367, 1–16 (2006).

5.

Robling, A. G. & Turner, C. H. Mechanical signaling for bone modeling and
remodeling. Critical Reviews in Eukaryotic Gene Expression 19, 319–338 (2009).

6.

Tranquilli Leali, P. et al. Bone fragility: current reviews and clinical features. Clin.
Cases Miner. Bone Metab. 6, 109–13 (2009).

7.

Bukata, S. V., Kates, S. L. & O’Keefe, R. J. Short-term and long-term orthopaedic
issues in patients with fragility fractures. in Clinical Orthopaedics and Related
Research 469, 2225–2236 (Springer New York LLC, 2011).

8.

Pietri, M. & Lucarini, S. The orthopaedic treatment of fragility fractures. Clinical
Cases in Mineral and Bone Metabolism 4, 108–116 (2007).

9.

Antoniazzi, F. Current and emerging treatments for the management of
osteogenesis imperfecta. Ther. Clin. Risk Manag. 6, 367 (2010).

10.

Gimigliano, F., Iolascon, G., Riccio, I., Frizzi, L. & Gimigliano, R. Post-surgical
rehabilitative approach to fragility fractures. in Aging Clinical and Experimental
Research 25, 23–25 (Springer, 2013).

11.

Strømsøe, K. Fracture fixation problems in osteoporosis. Injury 35, 107–113
(2004).

12.

Kyllönen, L., D’Este, M., Alini, M. & Eglin, D. Local drug delivery for enhancing
fracture healing in osteoporotic bone. Acta Biomater. 11, 412–434 (2015).

13.

Nikolaou, V. S., Efstathopoulos, N., Kontakis, G., Kanakaris, N. K. & Giannoudis,
P. V. The influence of osteoporosis in femoral fracture healing time. Injury 40,
663–668 (2009).

14.

Sillence, D. O., Senn, A. & Danks, D. M. Genetic heterogeneity in osteogenesis
imperfecta. J. Med. Genet. 16, 101–16 (1979).

15.

Ward, L. M. et al. Osteogenesis imperfecta type VII: an autosomal recessive form
of brittle bone disease. Bone 31, 12–8 (2002).

16.

Forlino, A. & Marini, J. C. Osteogenesis imperfecta. Lancet 387, 1657–1671
(2016).

17.

van Dijk, F. S. et al. Osteogenesis Imperfecta: A Review with Clinical Examples.
Mol. Syndromol. 2, 1–20 (2011).
160

18.

Raisz, L. G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J.
Clin. Invest. 115, 3318–25 (2005).

19.

Burge, R. et al. Incidence and Economic Burden of Osteoporosis-Related
Fractures in the United States, 2005-2025. J. Bone Miner. Res. 22, 465–475
(2007).

20.

Mundlos, S. & Olsen, B. R. Heritable diseases of the skeleton. Part I: Molecular
insights into skeletal development-transcription factors and signaling pathways.
FASEB J. 11, 125–132 (1997).

21.

Yang, X. & Karsenty, G. Transcription factors in bone: developmental and
pathological aspects. Trends Mol. Med. 8, 340–345 (2002).

22.

Berendsen, A. D. & Olsen, B. R. Bone development. Bone 80, 14–18 (2015).

23.

Burr, D. B. & Allen, M. R. Basic and Applied Bone Biology. Basic and Applied
Bone Biology (Elsevier Inc., 2013). doi:10.1016/C2011-0-05817-9

24.

Capulli, M., Paone, R. & Rucci, N. Osteoblast and osteocyte: Games without
frontiers. Archives of Biochemistry and Biophysics 561, 3–12 (2014).

25.

Kronenberg, H. M. Developmental regulation of the growth plate. Nature 423,
332–336 (2003).

26.

Bellido, T. Osteocyte-driven bone remodeling. Calcif. Tissue Int. 94, 25–34
(2014).

27.

Prideaux, M., Findlay, D. M. & Atkins, G. J. Osteocytes: The master cells in bone
remodelling. Curr. Opin. Pharmacol. 28, 24–30 (2016).

28.

Franz-Odendaal, T. A., Hall, B. K. & Witten, P. E. Buried alive: How osteoblasts
become osteocytes. Dev. Dyn. 235, 176–190 (2006).

29.

Palumbo, C., Palazzini, S., Zaffe, D. & Marotti, G. Osteocyte Differentiation in the
Tibia of Newborn Rabbit: An Ultrastructural Study of the Formation of
Cytoplasmic Processes. Cells Tissues Organs 137, 350–358 (1990).

30.

Hattner, R., Epker, B. N. & Frost, H. M. Suggested sequential mode of control of
changes in cell behaviour in adult bone remodelling. Nature 206, 489–90 (1965).

31.

Marotti, G., Ferretti, M., Muglia, M. A., Palumbo, C. & Palazzini, S. A
quantitative evaluation of osteoblast-osteocyte relationships on growing endosteal
surface of rabbit tibiae. Bone 13, 363–8 (1992).

32.

Qing, H. et al. Demonstration of osteocytic perilacunar/canalicular remodeling in
mice during lactation. J. Bone Miner. Res. 27, 1018–29 (2012).

33.

Tang, S. Y., Herber, R.-P., Ho, S. P. & Alliston, T. Matrix metalloproteinase-13 is
required for osteocytic perilacunar remodeling and maintains bone fracture
resistance. J. Bone Miner. Res. 27, 1936–50 (2012).

34.

Holmbeck, K. et al. The metalloproteinase MT1-MMP is required for normal
development and maintenance of osteocyte processes in bone. J. Cell Sci. 118,
147–156 (2005).

161

35.

Baylink, D. & Wergedal, J. Bone formation by osteocytes. Am. J. Physiol. Content
221, 669–678 (1971).

36.

Qing, H. & Bonewald, L. F. Osteocyte Remodeling of the Perilacunar and
Pericanalicular Matrix. Int. J. Oral Sci. 1, 59–65 (2009).

37.

Gerstenfeld, L. C., Cullinane, D. M., Barnes, G. L., Graves, D. T. & Einhorn, T. A.
Fracture healing as a post-natal developmental process: Molecular, spatial, and
temporal aspects of its regulation. J. Cell. Biochem. 88, 873–884 (2003).

38.

Ferguson, C., Alpern, E., Miclau, T. & Helms, J. A. Does adult fracture repair
recapitulate embryonic skeletal formation? Mech. Dev. 87, 57–66 (1999).

39.

Einhorn, T. A. & Gerstenfeld, L. C. Fracture healing: Mechanisms and
interventions. Nature Reviews Rheumatology 11, 45–54 (2015).

40.

Morgan, E. F., De Giacomo, A. & Gerstenfeld, L. C. Overview of skeletal repair
(fracture healing and its assessment). Methods Mol. Biol. 1130, 13–31 (2014).

41.

Shapiro, F. Bone development and its relation to fracture repair. The role of
mesenchymal osteoblasts and surface osteoblasts. European Cells and Materials
15, 53–76 (2008).

42.

Schlundt, C. et al. Macrophages in bone fracture healing: Their essential role in
endochondral ossification. Bone 106, 78–89 (2018).

43.

Bahney, C. S. et al. Cellular biology of fracture healing. Journal of Orthopaedic
Research 37, 35–50 (2019).

44.

Yu, Y. Y., Lieu, S., Lu, C. & Colnot, C. Bone morphogenetic protein 2 stimulates
endochondral ossification by regulating periosteal cell fate during bone repair.
Bone 47, 65–73 (2010).

45.

Evans, S. F. et al. Periosteum, bone’s ‘smart’ bounding membrane, exhibits
direction-dependent permeability. J. Bone Miner. Res. 28, 608–617 (2013).

46.

Moore, S. R. et al. Translating Periosteum’s Regenerative Power: Insights From
Quantitative Analysis of Tissue Genesis With a Periosteum Substitute Implant.
Stem Cells Transl. Med. 5, 1739–1749 (2016).

47.

Colnot, C., Zhang, X. & Tate, M. L. K. Current insights on the regenerative
potential of the periosteum: Molecular, cellular, and endogenous engineering
approaches. Journal of Orthopaedic Research 30, 1869–1878 (2012).

48.

Duchamp De Lageneste, O. et al. Periosteum contains skeletal stem cells with high
bone regenerative potential controlled by Periostin. Nat. Commun. 9, 1–15 (2018).

49.

Colnot, C. Skeletal cell fate decisions within periosteum and bone marrow during
bone regeneration. J. Bone Miner. Res. 24, 274–282 (2009).

50.

Einhorn, T. A. The cell and molecular biology of fracture healing. in Clinical
Orthopaedics and Related Research (Lippincott Williams and Wilkins, 1998).
doi:10.1097/00003086-199810001-00003

51.

Marie, P. J. Transcription factors controlling osteoblastogenesis. Archives of
Biochemistry and Biophysics 473, 98–105 (2008).
162

52.

de Crombrugghe, B., Lefebvre, V. & Nakashima, K. Regulatory mechanisms in
the pathways of cartilage and bone formation. Curr. Opin. Cell Biol. 13, 721–7
(2001).

53.

Karsenty, G. & Wagner, E. F. Reaching a genetic and molecular understanding of
skeletal development. Developmental Cell 2, 389–406 (2002).

54.

Komori, T. Regulation of osteoblast differentiation by transcription factors.
Journal of Cellular Biochemistry 99, 1233–1239 (2006).

55.

Marie, P. J. The molecular genetics of bone formation: implications for therapeutic
interventions in bone disorders. American journal of pharmacogenomics :
genomics-related research in drug development and clinical practice 1, 175–187
(2001).

56.

Latchman, D. S. Transcription factors: An overview. Int. J. Biochem. Cell Biol. 29,
1305–1312 (1997).

57.

Elefteriou, F. & Yang, X. Genetic mouse models for bone studies-Strengths and
limitations. Bone 49, 1242–1254 (2011).

58.

Dallas, S. L., Xie, Y., Shiflett, L. A. & Ueki, Y. Mouse Cre Models for the Study
of Bone Diseases. Current Osteoporosis Reports 16, 466–477 (2018).

59.

Bouabe, H. & Okkenhaug, K. Gene targeting in mice: A review. Methods in
Molecular Biology 1064, 315–336 (2013).

60.

Song, A. J. & Palmiter, R. D. Detecting and Avoiding Problems When Using the
Cre–lox System. Trends in Genetics 34, 333–340 (2018).

61.

Rauch, A. et al. Glucocorticoids suppress bone formation by attenuating osteoblast
differentiation via the monomeric glucocorticoid receptor. Cell Metab. 11, 517–
531 (2010).

62.

Liu, F. et al. Expression and activity of osteoblast-targeted Cre recombinase
transgenes in murine skeletal tissues. Int. J. Dev. Biol. 48, 645–653 (2004).

63.

Rodda, S. J. & McMahon, A. P. Distinct roles for Hedgehog and canonical Wnt
signaling in specification, differentiation and maintenance of osteoblast
progenitors. Development 133, 3231–3244 (2006).

64.

Kim, J. E., Nakashima, K. & De Crombrugghe, B. Transgenic mice expressing a
ligand-inducible cre recombinase in osteoblasts and odontoblasts: A new tool to
examine physiology and disease of postnatal bone and tooth. Am. J. Pathol. 165,
1875–1882 (2004).

65.

Dacquin, R., Starbuck, M., Schinke, T. & Karsenty, G. Mouse α1(I)-collagen
promoter is the best known promoter to drive efficient Cre recombinase expression
in osteoblast. Dev. Dyn. 224, 245–251 (2002).

66.

Zhang, M. et al. Osteoblast-specific knockout of the insulin-like growth factor
(IGF) receptor gene reveals an essential role of IGF signaling in bone matrix
mineralization. J. Biol. Chem. 277, 44005–44012 (2002).

67.

Lu, Y. et al. DMP1 -Targeted Cre expression in odontoblasts and osteocytes. J.
163

Dent. Res. 86, 320–325 (2007).
68.

Powell, W. F. et al. Targeted ablation of the PTH/PTHrP receptor in osteocytes
impairs bone structure and homeostatic calcemic responses. J. Endocrinol. 209,
21–32 (2011).

69.

Bivi, N. et al. Cell autonomous requirement of connexin 43 for osteocyte survival:
Consequences for endocortical resorption and periosteal bone formation. J. Bone
Miner. Res. 27, 374–389 (2012).

70.

Xiong, J. et al. Osteocytes, not Osteoblasts or Lining Cells, are the Main Source of
the RANKL Required for Osteoclast Formation in Remodeling Bone. PLoS One
10, e0138189 (2015).

71.

Tu, X. et al. Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin
signaling in bone. Proc. Natl. Acad. Sci. U. S. A. 112, E478-86 (2015).

72.

Wang, L., Mishina, Y. & Liu, F. Osterix-Cre Transgene Causes Craniofacial Bone
Development Defect. Calcif. Tissue Int. 96, 129–137 (2015).

73.

Chen, J. et al. Osx-Cre Targets Multiple Cell Types besides Osteoblast Lineage in
Postnatal Mice. PLoS One 9, e85161 (2014).

74.

Kalajzic, I. et al. In vitro and in vivo approaches to study osteocyte biology. Bone
54, 296–306 (2013).

75.

Ducy, P. et al. A Cbfa1-dependent genetic pathway controls bone formation
beyond embryonic development. Genes Dev. 13, 1025–1036 (1999).

76.

Komori, T. et al. Targeted Disruption of Cbfa1 Results in a Complete Lack of
Bone Formation owing to Maturational Arrest of Osteoblasts. Cell 89, 755–764
(1997).

77.

Otto, F. et al. Cbfa1, a Candidate Gene for Cleidocranial Dysplasia Syndrome, Is
Essential for Osteoblast Differentiation and Bone Development. Cell 89, 765–771
(1997).

78.

Mundlos, S. et al. Mutations Involving the Transcription Factor CBFA1 Cause
Cleidocranial Dysplasia. Cell 89, 773–779 (1997).

79.

McGee-Lawrence, M. E. et al. Runx2 is required for early stages of endochondral
bone formation but delays final stages of bone repair in Axin2-deficient mice.
Bone 66, 277–286 (2014).

80.

Takarada, T. et al. An analysis of skeletal development in osteoblast-specific and
chondrocyte-specific runt-related transcription factor-2 (Runx2) knockout mice. J.
Bone Miner. Res. 28, 2064–2069 (2013).

81.

Komori, T. Roles of Runx2 in skeletal development. in Advances in Experimental
Medicine and Biology 962, 83–93 (Springer New York LLC, 2017).

82.

Adhami, M. D. et al. Loss of Runx2 in committed osteoblasts impairs postnatal
skeletogenesis. J. Bone Miner. Res. 30, 71–82 (2015).

83.

Adhami, M. D., Rashid, H., Chen, H. & Javed, A. Runx2 activity in committed
osteoblasts is not essential for embryonic skeletogenesis. in Connective Tissue
164

Research 55, 102–106 (Informa Healthcare, 2014).
84.

Liu, W. et al. Overexpression of Cbfa1 in osteoblasts inhibits osteoblast
maturation and causes osteopenia with multiple fractures. J. Cell Biol. 155, 157–
166 (2001).

85.

Kanatani, N. et al. Cbfβ regulates Runx2 function isoform-dependently in
postnatal bone development. Dev. Biol. 296, 48–61 (2006).

86.

Geoffroy, V., Kneissel, M., Fournier, B., Boyde, A. & Matthias, P. High Bone
Resorption in Adult Aging Transgenic Mice Overexpressing Cbfa1/Runx2 in Cells
of the Osteoblastic Lineage. Mol. Cell. Biol. 22, 6222–6233 (2002).

87.

Enomoto, H. et al. Induction of osteoclast differentiation by Runx2 through
receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin
regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL
transgene. J. Biol. Chem. 278, 23971–23977 (2003).

88.

Glass, D. A. & Karsenty, G. In Vivo Analysis of Wnt Signaling in Bone.
Endocrinology 148, 2630–2634 (2007).

89.

Haegel, H. et al. Lack of β-catenin affects mouse development at gastrulation.
Development 121, 3529–3537 (1995).

90.

Day, T. F., Guo, X., Garrett-Beal, L. & Yang, Y. Wnt/β-catenin signaling in
mesenchymal progenitors controls osteoblast and chondrocyte differentiation
during vertebrate skeletogenesis. Dev. Cell 8, 739–750 (2005).

91.

Hill, T. P., Später, D., Taketo, M. M., Birchmeier, W. & Hartmann, C. Canonical
Wnt/β-catenin signaling prevents osteoblasts from differentiating into
chondrocytes. Dev. Cell 8, 727–738 (2005).

92.

Glass, D. A. et al. Canonical Wnt signaling in differentiated osteoblasts controls
osteoclast differentiation. Dev. Cell 8, 751–764 (2005).

93.

Holmen, S. L. et al. Essential role of β-catenin in postnatal bone acquisition. J.
Biol. Chem. 280, 21162–21168 (2005).

94.

Kramer, I. et al. Osteocyte Wnt/ -Catenin Signaling Is Required for Normal Bone
Homeostasis. Mol. Cell. Biol. 30, 3071–3085 (2010).

95.

Duan, P. & Bonewald, L. F. The role of the wnt/β-catenin signaling pathway in
formation and maintenance of bone and teeth. International Journal of
Biochemistry and Cell Biology 77, 23–29 (2016).

96.

Silkstone, D., Hong, H. & Alman, B. A. β-Catenin in the race to fracture repair: In
it to Wnt. Nature Clinical Practice Rheumatology 4, 413–419 (2008).

97.

Chen, Y. et al. Beta-catenin signaling plays a disparate role in different phases of
fracture repair: Implications for therapy to improve bone healing. PLoS Med. 4,
1216–1229 (2007).

98.

Bao, Q. et al. An appropriate Wnt/β-catenin expression level during the
remodeling phase is required for improved bone fracture healing in mice. Sci. Rep.
7, 1–11 (2017).
165

99.

Wu, M., Chen, G. & Li, Y. P. TGF-β and BMP signaling in osteoblast, skeletal
development, and bone formation, homeostasis and disease. Bone Res. 4, 1–21
(2016).

100. Chen, G., Deng, C. & Li, Y. P. TGF-β and BMP signaling in osteoblast
differentiation and bone formation. International Journal of Biological Sciences 8,
272–288 (2012).
101. Feng, X.-H. & Derynck, R. Specificity and versatility in TGF-β signaling through
Smads. Annu. Rev. Cell Dev. Biol. 21, 659–693 (2005).
102. Longobardi, L. et al. TGF-β Type II Receptor/MCP-5 Axis: At the Crossroad
between Joint and Growth Plate Development. Dev. Cell 23, 71–81 (2012).
103. Spagnoli, A. et al. TGF-β signaling is essential for joint morphogenesis. J. Cell
Biol. 177, 1105–1117 (2007).
104. Seo, H. S. & Serra, R. Deletion of Tgfbr2 in Prx1-cre expressing mesenchyme
results in defects in development of the long bones and joints. Dev. Biol. 310, 304–
316 (2007).
105. Qiu, T. et al. TGF-Β type II receptor phosphorylates PTH receptor to integrate
bone remodelling signalling. Nat. Cell Biol. 12, 224–234 (2010).
106. Dole, N. S. et al. Osteocyte-Intrinsic TGF-β Signaling Regulates Bone Quality
through Perilacunar/Canalicular Remodeling. Cell Rep. 21, 2585–2596 (2017).
107. Borton, A. J., Frederick, J. P., Datto, M. B., Wang, X. F. & Weinstein, R. S. The
loss of Smad3 results in a lower rate of bone formation and osteopenia through
dysregulation of osteoblast differentiation and apoptosis. J. Bone Miner. Res. 16,
1754–1764 (2001).
108. Salazar, V. S. et al. Embryonic ablation of osteoblast Smad4 interrupts matrix
synthesis in response to canonical wnt signaling and causes an osteogenesisimperfectalike phenotype. J. Cell Sci. 126, 4974–4984 (2013).
109. Salazar, V. S. et al. Postnatal ablation of osteoblast Smad4 enhances proliferative
responses to canonical Wnt signaling through interactions with β-catenin. J. Cell
Sci. 126, 5598–5609 (2013).
110. Tan, X. et al. Smad4 is required for maintaining normal murine postnatal bone
homeostasis. J. Cell Sci. 120, 2162–2170 (2007).
111. McCarthy, T. L. & Centrella, M. Novel links among Wnt and TGF-βsignaling and
Runx2. Mol. Endocrinol. 24, 587–597 (2010).
112. Zaidi, S. K. et al. Tyrosine phosphorylation controls Runx2-mediated subnuclear
targeting of YAP to repress transcription. EMBO J. 23, 790–9 (2004).
113. Hong, J.-H. et al. TAZ, a Transcriptional Modulator of Mesenchymal Stem Cell
Differentiation. Science (80-. ). 309, (2005).
114. Rosenbluh, J. et al. β-Catenin-driven cancers require a YAP1 transcriptional
complex for survival and tumorigenesis. Cell 151, 1457–1473 (2012).
115. Heallen, T. et al. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte
166

proliferation and heart size. Science 332, 458–61 (2011).
116. Azzolin, L. et al. YAP/TAZ Incorporation in the β-Catenin Destruction Complex
Orchestrates the Wnt Response. Cell 158, 157–170 (2014).
117. Varelas, X. et al. TAZ controls Smad nucleocytoplasmic shuttling and regulates
human embryonic stem-cell self-renewal. Nat. Cell Biol. 10, 837–848 (2008).
118. Varelas, X. et al. The Crumbs complex couples cell density sensing to Hippodependent control of the TGF-β-SMAD pathway. Dev. Cell 19, 831–44 (2010).
119. Yu, F.-X., Zhao, B. & Guan, K.-L. Hippo Pathway in Organ Size Control, Tissue
Homeostasis, and Cancer. Cell 163, 811–828 (2015).
120. Mo, J.-S., Park, H. W. & Guan, K.-L. The Hippo signaling pathway in stem cell
biology and cancer. EMBO Rep. 15, 642–56 (2014).
121. Vassilev, A., Kaneko, K. J., Shu, H., Zhao, Y. & DePamphilis, M. L. TEAD/TEF
transcription factors utilize the activation domain of YAP65, a Src/Yes-associated
protein localized in the cytoplasm. Genes Dev. 15, 1229–41 (2001).
122. Yagi, R., Chen, L.-F., Shigesada, K., Murakami, Y. & Ito, Y. A WW domaincontaining Yes-associated protein (YAP) is a novel transcriptional co-activator.
EMBO J. 18, 2551–2562 (1999).
123. Yu, F. X. et al. Regulation of the Hippo-YAP pathway by G-protein-coupled
receptor signaling. Cell 150, 780–791 (2012).
124. Halder, G., Dupont, S. & Piccolo, S. Transduction of mechanical and cytoskeletal
cues by YAP and TAZ. Nat. Rev. Mol. Cell Biol. 13, 591–600 (2012).
125. Schroeder, M. C. & Halder, G. Regulation of the Hippo pathway by cell
architecture and mechanical signals. Semin. Cell Dev. Biol. 23, 803–811 (2012).
126. Zhao, B. et al. TEAD mediates YAP-dependent gene induction and growth
control. Genes Dev. 22, 1962–1971 (2008).
127. Sudol, M. & Harvey, K. F. Modularity in the Hippo signaling pathway. Trends in
Biochemical Sciences 35, 627–633 (2010).
128. Dong, J. et al. Elucidation of a Universal Size-Control Mechanism in Drosophila
and Mammals. Cell 130, 1120–1133 (2007).
129. Low, B. C. et al. YAP/TAZ as mechanosensors and mechanotransducers in
regulating organ size and tumor growth. FEBS Lett. 588, 2663–2670 (2014).
130. Totaro, A., Panciera, T. & Piccolo, S. YAP/TAZ upstream signals and downstream
responses. Nature Cell Biology 20, 888–899 (2018).
131. Varelas, X. The Hippo pathway effectors TAZ and YAP in development,
homeostasis and disease. Development 141, 1614–1626 (2014).
132. Hong, W. & Guan, K.-L. The YAP and TAZ transcription co-activators: Key
downstream effectors of the mammalian Hippo pathway. Semin. Cell Dev. Biol.
23, 785–793 (2012).
133. Plouffe, S. W. et al. The Hippo pathway effector proteins YAP and TAZ have both
167

distinct and overlapping functions in the cell. J. Biol. Chem. 293, 11230–11240
(2018).
134. Li, Z. et al. Structural insights into the YAP and TEAD complex. Genes Dev. 24,
235–240 (2010).
135. Webb, C. et al. Structural features and ligand binding properties of tandem WW
domains from YAP and TAZ, nuclear effectors of the hippo pathway.
Biochemistry 50, 3300–3309 (2011).
136. Salah, Z., Alian, A. & Aqeilan, R. I. WW domain-containing proteins:
Retrospectives and the future. Frontiers in Bioscience 17, 331–348 (2012).
137. Oka, T. & Sudol, M. Nuclear localization and pro-apoptotic signaling of YAP2
require intact PDZ-binding motif. Genes to Cells 14, 607–615 (2009).
138. Jang, E. J. et al. TAZ suppresses NFAT5 activity through tyrosine
phosphorylation. Mol. Cell. Biol. 32, 4925–32 (2012).
139. Levy, D., Adamovich, Y., Reuven, N. & Shaul, Y. Yap1 Phosphorylation by c-Abl
Is a Critical Step in Selective Activation of Proapoptotic Genes in Response to
DNA Damage. Mol. Cell 29, 350–361 (2008).
140. Chen, L. et al. Structural basis of YAP recognition by TEAD4 in the Hippo
pathway. Genes Dev. 24, 290–300 (2010).
141. Basu, S., Totty, N. F., Irwin, M. S., Sudol, M. & Downward, J. Akt phosphorylates
the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation
of p73-mediated apoptosis. Mol. Cell 11, 11–23 (2003).
142. Kanai, F. et al. TAZ: a novel transcriptional co-activator regulated by interactions
with 14-3-3 and PDZ domain proteins. EMBO J. 19, 6778–91 (2000).
143. Sudol, M. Yes-Associated Protein (YAP65) is a proline-rich phosphoprotein that
binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 9, 2145–
2152 (1994).
144. Sen, B. et al. Intranuclear Actin Regulates Osteogenesis. Stem Cells 33, 3065–
3076 (2015).
145. Lin, X. et al. AP2a enhanced the osteogenic differentiation of mesenchymal stem
cells by inhibiting the formation of YAP/RUNX2 complex and BARX1
transcription. Cell Prolif. 52, e12522 (2019).
146. Basu-Roy, U. et al. Sox2 antagonizes the Hippo pathway to maintain stemness in
cancer cells. Nat. Commun. 6, 6411 (2015).
147. Seo, E. et al. SOX2 Regulates YAP1 to Maintain Stemness and Determine Cell
Fate in the Osteo-Adipo Lineage. Cell Rep. 3, 2075–2087 (2013).
148. Park, H. W. et al. Alternative Wnt Signaling Activates YAP/TAZ. Cell 162, 780–
794 (2015).
149. Yang, B. et al. YAP1 influences differentiation of osteoblastic MC3T3‐E1 cells
through the regulation of ID1. J. Cell. Physiol. 234, 14007–14018 (2019).

168

150. Dupont, S. et al. Role of YAP/TAZ in mechanotransduction. Nature 474, 179–83
(2011).
151. Liu, X. et al. AMOT130/YAP pathway in topography-induced BMSC osteoblastic
differentiation. Colloids Surfaces B Biointerfaces 182, 110332 (2019).
152. Xue, X., Hong, X., Li, Z., Deng, C. X. & Fu, J. Acoustic tweezing cytometry
enhances osteogenesis of human mesenchymal stem cells through cytoskeletal
contractility and YAP activation. Biomaterials 134, 22–30 (2017).
153. Pan, H. et al. YAP-mediated mechanotransduction regulates osteogenic and
adipogenic differentiation of BMSCs on hierarchical structure. Colloids Surfaces B
Biointerfaces 152, 344–353 (2017).
154. Tao, S.-C. et al. Decreased extracellular pH inhibits osteogenesis through protonsensing GPR4-mediated suppression of yes-associated protein. Sci. Rep. 6, 26835
(2016).
155. Murakami, K. et al. Olfactomedin-like protein OLFML1 inhibits Hippo signaling
and mineralization in osteoblasts. Biochem. Biophys. Res. Commun. 505, 419–425
(2018).
156. Hong, J. et al. TAZ, a Transcriptional Modulator of Mesenchymal Stem Cell
Differentiation. Science (80-. ). 309, 1074–1078 (2005).
157. Hong, J.-H. & Yaffe, M. B. TAZ: A &amp;beta;-Catenin-like Molecule that
Regulates Mesenchymal Stem Cell Differentiation. Cell Cycle 5, 176–179 (2006).
158. Feng, J., Sun, Q., Liu, L. & Xing, D. Photoactivation of TAZ via Akt/GSK3β
signaling pathway promotes osteogenic differentiation. Int. J. Biochem. Cell Biol.
66, 59–68 (2015).
159. Byun, M. R. et al. (-)-Epicatechin gallate (ECG) stimulates osteoblast
differentiation via Runt-related transcription factor 2 (RUNX2) and transcriptional
coactivator with PDZ-binding motif (TAZ)-mediated transcriptional activation. J.
Biol. Chem. 289, 9926–35 (2014).
160. Byun, M. R. et al. Canonical Wnt signalling activates TAZ through PP1A during
osteogenic differentiation. Cell Death Differ. 21, 854–863 (2014).
161. Byun, M. R. et al. FGF2 stimulates osteogenic differentiation through ERK
induced TAZ expression. Bone 58, 72–80 (2014).
162. Qian, W. et al. Nanotopographic Regulation of Human Mesenchymal Stem Cell
Osteogenesis. ACS Appl. Mater. Interfaces 9, 41794–41806 (2017).
163. Hwang, J.-H. et al. Nanotopological plate stimulates osteogenic differentiation
through TAZ activation. Sci. Rep. 7, 3632 (2017).
164. Hwang, J.-H. et al. Extracellular Matrix Stiffness Regulates Osteogenic
Differentiation through MAPK Activation. PLoS One 10, e0135519 (2015).
165. Chen, Z., Luo, Q., Lin, C., Kuang, D. & Song, G. Simulated microgravity inhibits
osteogenic differentiation of mesenchymal stem cells via depolymerizing F-actin
to impede TAZ nuclear translocation. Sci. Rep. 6, 30322 (2016).
169

166. Kim, K. M. et al. Shear Stress Induced by an Interstitial Level of Slow Flow
Increases the Osteogenic Differentiation of Mesenchymal Stem Cells through TAZ
Activation. PLoS One 9, e92427 (2014).
167. Zhu, Y. et al. Pharmacological activation of TAZ enhances osteogenic
differentiation and bone formation of adipose-derived stem cells. Stem Cell Res.
Ther. 9, 53 (2018).
168. Xiao, Z. et al. Polycystin-1 interacts with TAZ to stimulate osteoblastogenesis and
inhibit adipogenesis. J. Clin. Invest. 128, 157–174 (2018).
169. Tang, Y., Feinberg, T., Keller, E. T., Li, X.-Y. & Weiss, S. J. Snail/Slug binding
interactions with YAP/TAZ control skeletal stem cell self-renewal and
differentiation. Nat. Cell Biol. 18, 917–929 (2016).
170. Kegelman, C. D. et al. Skeletal cell YAP and TAZ combinatorially promote bone
development. FASEB J. 32, 2706–2721 (2018).
171. Xiong, J., Almeida, M. & O’Brien, C. A. The YAP/TAZ transcriptional coactivators have opposing effects at different stages of osteoblast differentiation.
Bone 112, 1–9 (2018).
172. Li, W., Deng, Y., Feng, B. & Mak, K. K.-L. Mst1/2 Kinases Modulate Glucose
Uptake for Osteoblast Differentiation and Bone Formation. J. Bone Miner. Res. 33,
1183–1195 (2018).
173. Kalajzic, I. et al. Use of Type I Collagen Green Fluorescent Protein Transgenes to
Identify Subpopulations of Cells at Different Stages of the Osteoblast Lineage. J.
Bone Miner. Res. 17, 15–25 (2002).
174. Liu, F. et al. Expression and activity of osteoblast-targeted Cre recombinase
transgenes in murine skeletal tissues. Int. J. Dev. Biol. 48, 645–653 (2004).
175. Yang, J.-Y. et al. Osteoblast-Targeted Overexpression of TAZ Increases Bone
Mass In Vivo. PLoS One 8, e56585 (2013).
176. Yin, Z. et al. Lentivirus-TAZ Administration Alleviates Osteoporotic Phenotypes
in the Femoral Neck of Ovariectomized Rats. Cell. Physiol. Biochem. 38, 283–294
(2016).
177. Pan, J.-X. et al. YAP promotes osteogenesis and suppresses adipogenic
differentiation by regulating β-catenin signaling. Bone Res. 6, 18 (2018).
178. Zhao, G. et al. CYR61/CCN1 Regulates Sclerostin Levels and Bone Maintenance.
J. Bone Miner. Res. 33, 1076–1089 (2018).
179. Canalis, E., Zanotti, S., Beamer, W. G., Economides, A. N. & Smerdel-Ramoya,
A. Connective Tissue Growth Factor Is Required for Skeletal Development and
Postnatal Skeletal Homeostasis in Male Mice. Endocrinology 151, 3490–3501
(2010).
180. Kegelman, C. D. et al. YAP and TAZ Mediate Osteocyte Perilacunar/Canalicular
Remodeling. J. Bone Miner. Res. jbmr.3876 (2019). doi:10.1002/jbmr.3876
181. Deng, Y. et al. Yap1 Regulates Multiple Steps of Chondrocyte Differentiation
170

during Skeletal Development and Bone Repair. Cell Rep. 14, 2224–2237 (2016).
182. Piccolo, S., Dupont, S. & Cordenonsi, M. The Biology of YAP/TAZ: Hippo
Signaling and Beyond. Physiol. Rev. 94, 1287–1312 (2014).
183. Moya, I. M. & Halder, G. Hippo–YAP/TAZ signalling in organ regeneration and
regenerative medicine. Nature Reviews Molecular Cell Biology 20, 211–226
(2019).
184. Wang, K.-C. et al. Flow-dependent YAP/TAZ activities regulate endothelial
phenotypes and atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 113, 11525–11530
(2016).
185. Zanconato, F., Cordenonsi, M. & Piccolo, S. YAP/TAZ at the Roots of Cancer.
Cancer Cell 29, 783–803 (2016).
186. Liu, F. et al. Mechanosignaling through YAP and TAZ drives fibroblast activation
and fibrosis. Am. J. Physiol. Cell. Mol. Physiol. 308, L344–L357 (2015).
187. Mannaerts, I. et al. The Hippo pathway effector YAP controls mouse hepatic
stellate cell activation. J. Hepatol. 63, 679–688 (2015).
188. Xin, M. et al. Hippo pathway effector Yap promotes cardiac regeneration. Proc.
Natl. Acad. Sci. U. S. A. 110, 13839–44 (2013).
189. Iyer, S. R. et al. Differential YAP nuclear signaling in healthy and dystrophic
skeletal muscle. Am. J. Physiol. Physiol. 317, C48–C57 (2019).
190. Bertrand, A. T. et al. Cellular microenvironments reveal defective mechanosensing
responses and elevated YAP signaling in LMNA-mutated muscle precursors. J.
Cell Sci. 127, 2873–2884 (2014).
191. Panciera, T., Azzolin, L., Cordenonsi, M. & Piccolo, S. Mechanobiology of YAP
and TAZ in physiology and disease. Nat. Rev. Mol. Cell Biol. 18, 758–770 (2017).
192. Lemyre, E., Azouz, E. M., Teebi, A. S., Glanc, P. & Chen, M. F. Bone dysplasia
series. Achondroplasia, hypochondroplasia and thanatophoric dysplasia: review
and update. Can. Assoc. Radiol. J. 50, 185–97 (1999).
193. Rauch, F. & Glorieux, F. H. Osteogenesis imperfecta. Lancet 363, 1377–1385
(2004).
194. Khillan, J. S., Olsen, A. S., Kontusaari, S., Sokolov, B. & Prockop, D. J.
Transgenic mice that express a mini-gene version of the human gene for type I
procollagen (COL1A1) develop a phenotype resembling a lethal form of
osteogenesis imperfecta. J. Biol. Chem. 266, 23373–9 (1991).
195. Pereira, R., Khillan, J. S., Helminen, H. J., Hume, E. L. & Prockop, D. J.
Transgenic mice expressing a partially deleted gene for type I procollagen
(COL1A1). A breeding line with a phenotype of spontaneous fractures and
decreased bone collagen and mineral. J. Clin. Invest. 91, 709–16 (1993).
196. Chipman, S. D. et al. Defective pro alpha 2(I) collagen synthesis in a recessive
mutation in mice: a model of human osteogenesis imperfecta. Proc. Natl. Acad.
Sci. U. S. A. 90, 1701–5 (1993).
171

197. Liu, Y. et al. A novel transgenic murine model with persistently brittle bones
simulating osteogenesis imperfecta type I. Bone 127, 646–655 (2019).
198. Feng, X. & McDonald, J. M. Disorders of bone remodeling. Annu. Rev. Pathol. 6,
121–45 (2011).
199. Vashishth, D., Verborgt, O., Divine, G., Schaffler, M. B. & Fyhrie, D. P. Decline
in osteocyte lacunar density in human cortical bone is associated with
accumulation of microcracks with age. Bone 26, 375–380 (2000).
200. Karsenty, G. cbfa. Annu. Rev. Genomics Hum. Genet. 9, 183–196 (2008).
201. Javed, A., Chen, H. & Ghori, F. Y. Genetic and transcriptional control of bone
formation. Oral Maxillofac. Surg. Clin. North Am. 22, 283–93, v (2010).
202. Kato, M. et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia,
and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt
coreceptor. J. Cell Biol. 157, (2002).
203. Afzal, F. et al. Smad function and intranuclear targeting share a Runx2 motif
required for osteogenic lineage induction and BMP2 responsive transcription. J.
Cell. Physiol. 204, 63–72 (2005).
204. Morin-Kensicki, E. M. et al. Defects in yolk sac vasculogenesis, chorioallantoic
fusion, and embryonic axis elongation in mice with targeted disruption of Yap65.
Mol. Cell. Biol. 26, 77–87 (2006).
205. Hossain, Z. et al. Glomerulocystic kidney disease in mice with a targeted
inactivation of Wwtr1. Proc. Natl. Acad. Sci. U. S. A. 104, 1631–6 (2007).
206. Miesfeld, J. B. et al. Yap and Taz regulate retinal pigment epithelial cell fate.
Development 142, (2015).
207. McLeod, M. J. Differential staining of cartilage and bone in whole mouse fetuses
by alcian blue and alizarin red S. Teratology 22, 299–301 (1980).
208. Bouxsein, M. L. et al. Guidelines for assessment of bone microstructure in rodents
using micro-computed tomography. J. Bone Miner. Res. 25, 1468–1486 (2010).
209. Caroti, C. M. et al. A Novel Technique for Accelerated Culture of Murine
Mesenchymal Stem Cells that Allows for Sustained Multipotency. Sci. Rep. 7,
13334 (2017).
210. Ducy, P. & Karsenty, G. Two distinct osteoblast-specific cis-acting elements
control expression of a mouse osteocalcin gene. Mol. Cell. Biol. 15, 1858–69
(1995).
211. Tanas, M. R. et al. Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion
oncoprotein. Oncogene 35, 929–38 (2016).
212. Schneider, P., Voide, R., Stampanoni, M., Donahue, L. R. & Müller, R. The
importance of the intracortical canal network for murine bone mechanics. Bone 53,
120–128 (2013).
213. Akaike, H. A new look at the statistical model identification. IEEE Trans.
Automat. Contr. 19, 716–723 (1974).
172

214. Jepsen, K. J., Silva, M. J., Vashishth, D., Guo, X. E. & van der Meulen, M. C. H.
Establishing biomechanical mechanisms in mouse models: practical guidelines for
systematically evaluating phenotypic changes in the diaphyses of long bones. J.
Bone Miner. Res. 30, 951–66 (2015).
215. Kourtis, L. C., Carter, D. R. & Beaupre, G. S. Improving the Estimate of the
Effective Elastic Modulus Derived from Three-Point Bending Tests of Long
Bones. Ann. Biomed. Eng. 42, 1773–1780 (2014).
216. Guss, J. D. et al. Alterations to the Gut Microbiome Impair Bone Strength and
Tissue Material Properties. J. Bone Miner. Res. (2017). doi:10.1002/jbmr.3114
217. Chen, X., Nadiarynkh, O., Plotnikov, S. & Campagnola, P. J. Second harmonic
generation microscopy for quantitative analysis of collagen fibrillar structure. Nat.
Protoc. 7, 654–669 (2012).
218. Liu-Chittenden, Y. et al. Genetic and pharmacological disruption of the TEADYAP complex suppresses the oncogenic activity of YAP. Genes Dev. 26, 1300–5
(2012).
219. Kim, M., Kim, T., Johnson, R. L. & Lim, D.-S. Transcriptional co-repressor
function of the hippo pathway transducers YAP and TAZ. Cell Rep. 11, 270–82
(2015).
220. Tang, Y. et al. MT1-MMP-Dependent Control of Skeletal Stem Cell Commitment
via a β1-Integrin/YAP/TAZ Signaling Axis. Dev. Cell 25, 402–416 (2013).
221. Kim, K. M. et al. Shear Stress Induced by an Interstitial Level of Slow Flow
Increases the Osteogenic Differentiation of Mesenchymal Stem Cells through TAZ
Activation. PLoS One 9, e92427 (2014).
222. Rauch, F., Travers, R., Parfitt, A. M. & Glorieux, F. H. Static and dynamic bone
histomorphometry in children with osteogenesis imperfecta. Bone 26, 581–9
(2000).
223. Vanleene, M. et al. Ultra-structural defects cause low bone matrix stiffness despite
high mineralization in osteogenesis imperfecta mice. Bone 50, 1317–1323 (2012).
224. Nadiarnykh, O. et al. Second harmonic generation imaging microscopy studies of
osteogenesis imperfecta. J. Biomed. Opt. 12, 051805 (2007).
225. Li, H. et al. Immature osteoblast lineage cells increase osteoclastogenesis in
osteogenesis imperfecta murine. Am. J. Pathol. 176, 2405–13 (2010).
226. Kaan, H. Y. K. et al. Crystal structure of TAZ-TEAD complex reveals a distinct
interaction mode from that of YAP-TEAD complex. Sci. Rep. 7, 2035 (2017).
227. Karystinou, A. et al. Yes-associated protein (YAP) is a negative regulator of
chondrogenesis in mesenchymal stem cells. Arthritis Res. Ther. 17, 147 (2015).
228. Kent, W. J. et al. The human genome browser at UCSC. Genome Res. 12, 996–
1006 (2002).
229. Richter, A. M., Cerruti-Sola, S., Sternberg, E. D., Dolphin, D. & Levy, J. G.
Biodistribution of tritiated benzoporphyrin derivative (3H-BPD-MA), a new potent
173

photosensitizer, in normal and tumor-bearing mice. J. Photochem. Photobiol. B. 5,
231–44 (1990).
230. Akens, M. K. et al. Photodynamic Therapy of Vertebral Metastases: Evaluating
Tumor-to-Neural Tissue Uptake of BPD-MA and ALA-PpIX in a Murine Model
of Metastatic Human Breast Carcinoma. Photochem. Photobiol. 83, 1034–1039
(2007).
231. Zhang, H. et al. Tumor-selective proteotoxicity of verteporfin inhibits colon cancer
progression independently of YAP1. Sci. Signal. 8, (2015).
232. Schuit, S. C. . et al. Fracture incidence and association with bone mineral density
in elderly men and women: the Rotterdam Study. Bone 34, 195–202 (2004).
233. Delmas, P., Li, Z. & Cooper, C. Relationship Between Changes in Bone Mineral
Density and Fracture Risk Reduction With Antiresorptive Drugs: Some Issues
With Meta-Analyses. J. Bone Miner. Res. 19, 330–337 (2003).
234. Sarkar, S. et al. Relationships Between Bone Mineral Density and Incident
Vertebral Fracture Risk with Raloxifene Therapy. J. Bone Miner. Res. 17, 1–10
(2002).
235. Hernandez, C. J. & Keaveny, T. M. A biomechanical perspective on bone quality.
Bone 39, 1173–81 (2006).
236. Recker, R., Lappe, J., Davies, K. M. & Heaney, R. Bone Remodeling Increases
Substantially in the Years After Menopause and Remains Increased in Older
Osteoporosis Patients. J. Bone Miner. Res. 19, 1628–1633 (2004).
237. Knothe Tate, M. L., Adamson, J. R., Tami, A. E. & Bauer, T. W. The osteocyte.
Int. J. Biochem. Cell Biol. 36, 1–8 (2004).
238. Buenzli, P. R. & Sims, N. A. Quantifying the osteocyte network in the human
skeleton. Bone 75, 144–150 (2015).
239. Kawaki, H. et al. Differential roles of CCN family proteins during osteoblast
differentiation: Involvement of Smad and MAPK signaling pathways. Bone 49,
975–989 (2011).
240. Zhao, G. et al. CYR61/CCN1 Regulates Sclerostin Levels and Bone Maintenance.
J. Bone Miner. Res. (2018). doi:10.1002/jbmr.3394
241. Su, J.-L. et al. CYR61 regulates BMP-2-dependent osteoblast differentiation
through the {alpha}v{beta}3 integrin/integrin-linked kinase/ERK pathway. J. Biol.
Chem. 285, 31325–36 (2010).
242. Chen, C.-Y. et al. CCN1 induces oncostatin M production in osteoblasts via
integrin-dependent signal pathways. PLoS One 9, e106632 (2014).
243. Si, W. et al. CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an
important role in Wnt3A-induced osteoblast differentiation of mesenchymal stem
cells. Mol. Cell. Biol. 26, 2955–64 (2006).
244. Smerdel-Ramoya, A., Zanotti, S., Deregowski, V. & Canalis, E. Connective tissue
growth factor enhances osteoblastogenesis in vitro. J. Biol. Chem. 283, 22690–9
174

(2008).
245. Crockett, J. C. et al. The Matricellular Protein CYR61 Inhibits Osteoclastogenesis
by a Mechanism Independent of α v β 3 and α v β 5. Endocrinology 148, 5761–5768
(2007).
246. Zhang, H. et al. TEAD transcription factors mediate the function of TAZ in cell
growth and epithelial-mesenchymal transition. J. Biol. Chem. 284, 13355–62
(2009).
247. Zhang, H., Pasolli, H. A. & Fuchs, E. Yes-associated protein (YAP) transcriptional
coactivator functions in balancing growth and differentiation in skin. Proc. Natl.
Acad. Sci. U. S. A. 108, 2270–5 (2011).
248. Qin, Z., Xia, W., Fisher, G. J., Voorhees, J. J. & Quan, T. YAP/TAZ regulates
TGF-β/Smad3 signaling by induction of Smad7 via AP-1 in human skin dermal
fibroblasts. Cell Commun. Signal. 16, 18 (2018).
249. Miranda, M. Z. et al. TGF-β1 regulates the expression and transcriptional activity
of TAZ protein via a Smad3-independent, myocardin-related transcription factormediated mechanism. J. Biol. Chem. 292, 14902–14920 (2017).
250. Otsu, N. A threshold selection method from gray-level histograms. IEEE Trans.
Syst. Man. Cybern. 9, 62–66 (1979).
251. Mader, K. S., Schneider, P., Müller, R. & Stampanoni, M. A quantitative
framework for the 3D characterization of the osteocyte lacunar system. Bone 57,
142–154 (2013).
252. Hemmatian, H. et al. Age-related changes in female mouse cortical bone
microporosity. Bone 113, 1–8 (2018).
253. Tiede-Lewis, L. M. et al. Degeneration of the osteocyte network in the C57BL/6
mouse model of aging. Aging (Albany. NY). 9, 2190–2208 (2017).
254. Heveran, C. M., Rauff, A., King, K. B., Carpenter, R. D. & Ferguson, V. L. A new
open-source tool for measuring 3D osteocyte lacunar geometries from confocal
laser scanning microscopy reveals age-related changes to lacunar size and shape in
cortical mouse bone. Bone 110, 115–127 (2018).
255. McCreadie, B. R., Hollister, S. J., Schaffler, M. B. & Goldstein, S. A. Osteocyte
lacuna size and shape in women with and without osteoporotic fracture. J.
Biomech. 37, 563–572 (2004).
256. Ploton, D. et al. Improvement in the staining and in the visualization of the
argyrophilic proteins of the nucleolar organizer region at the optical level.
Histochem. J. 18, 5–14 (1986).
257. Jáuregui, E. J. et al. Parallel mechanisms suppress cochlear bone remodeling to
protect hearing. Bone 89, 7–15 (2016).
258. Dyment, N. A. et al. High-Throughput, Multi-Image Cryohistology of Mineralized
Tissues. J. Vis. Exp. e54468–e54468 (2016). doi:10.3791/54468
259. Arganda-Carreras, I., Fernández-González, R., Muñoz-Barrutia, A. & Ortiz-De175

Solorzano, C. 3D reconstruction of histological sections: Application to mammary
gland tissue. Microsc. Res. Tech. 73, 1019–1029 (2010).
260. Delgado-Calle, J. et al. Control of Bone Anabolism in Response to Mechanical
Loading and PTH by Distinct Mechanisms Downstream of the PTH Receptor. J.
Bone Miner. Res. 32, 522–535 (2017).
261. Zambonin Zallone, A. Z., Teti, A., Nico, B. & Primavera, M. V. Osteoplastic
activity of mature osteocytes evaluated by H-proline incorporation. Basic Appl.
Histochem. 26, 65–7 (1982).
262. Zambonin Zallone, A., Teti, A., Primavera, M. V & Pace, G. Mature osteocytes
behaviour in a repletion period: the occurrence of osteoplastic activity. Basic Appl.
Histochem. 27, 191–204 (1983).
263. Kalajzic, I. et al. Dentin matrix protein 1 expression during osteoblastic
differentiation, generation of an osteocyte GFP-transgene. Bone 35, 74–82 (2004).
264. Woo, S. M., Rosser, J., Dusevich, V., Kalajzic, I. & Bonewald, L. F. Cell line
IDG-SW3 replicates osteoblast-to-late-osteocyte differentiation in vitro and
accelerates bone formation in vivo. J. Bone Miner. Res. 26, 2634–46 (2011).
265. Spatz, J. M. et al. The Wnt Inhibitor Sclerostin Is Up-regulated by Mechanical
Unloading in Osteocytes in Vitro. J. Biol. Chem. 290, 16744–58 (2015).
266. Bartholin, L., Wessner, L. L., Chirgwin, J. M. & Guise, T. A. The human Cyr61
gene is a transcriptional target of transforming growth factor beta in cancer cells.
Cancer Lett. 246, 230–236 (2007).
267. Grotendorst, G. R. Connective tissue growth factor: a mediator of TGF-beta action
on fibroblasts. Cytokine Growth Factor Rev. 8, 171–9 (1997).
268. Kegelman, C. D. et al. Skeletal cell YAP and TAZ redundantly promote bone
development by regulation of collagen I expression and organization. bioRxiv
143982 (2017). doi:10.1101/143982
269. Aoyama, E., Kubota, S., Khattab, H. M., Nishida, T. & Takigawa, M. CCN2
enhances RANKL-induced osteoclast differentiation via direct binding to RANK
and OPG. Bone 73, 242–248 (2015).
270. Nishida, T., Emura, K., Kubota, S., Lyons, K. M. & Takigawa, M. CCN family
2/connective tissue growth factor (CCN2/CTGF) promotes osteoclastogenesis via
induction of and interaction with dendritic cell-specific transmembrane protein
(DC-STAMP). J. Bone Miner. Res. 26, 351–363 (2011).
271. Canalis, E., Zanotti, S., Beamer, W. G., Economides, A. N. & Smerdel-Ramoya,
A. Connective Tissue Growth Factor Is Required for Skeletal Development and
Postnatal Skeletal Homeostasis in Male Mice. Endocrinology 151, 3490–3501
(2010).
272. Li, C. Y. et al. Mice Lacking Cathepsin K Maintain Bone Remodeling but
Develop Bone Fragility Despite High Bone Mass. J. Bone Miner. Res. 21, 865–
875 (2006).

176

273. O’Brien, C. A. et al. Control of Bone Mass and Remodeling by PTH Receptor
Signaling in Osteocytes. PLoS One 3, e2942 (2008).
274. Rhee, Y. et al. PTH receptor signaling in osteocytes governs periosteal bone
formation and intracortical remodeling. J. Bone Miner. Res. 26, 1035–1046 (2011).
275. Bonewald, L. F. Mechanosensation and Transduction in Osteocytes. Bonekey
Osteovision 3, 7–15 (2006).
276. Gardinier, J. D., Al-Omaishi, S., Morris, M. D. & Kohn, D. H. PTH signaling
mediates perilacunar remodeling during exercise. Matrix Biol. 52–54, 162–175
(2016).
277. Musculoskeletal injuries report: incidence, risk factors and prevention. American
Academy of Orthopaedic Surgeons (2000).
278. Ferguson, C., Alpern, E., Miclau, T. & Helms, J. A. Does adult fracture repair
recapitulate embryonic skeletal formation? Mech. Dev. 87, 57–66 (1999).
279. Böhm, A. M. et al. Activation of Skeletal Stem and Progenitor Cells for Bone
Regeneration Is Driven by PDGFRβ Signaling. Dev. Cell 51, 236-254.e12 (2019).
280. Kühn, R., Schwenk, F., Aguet, M. & Rajewsky, K. Inducible gene targeting in
mice. Science (80-. ). 269, 1427–1429 (1995).
281. Feil, R. et al. Ligand-activated site-specific recombination in mice. Proc. Natl.
Acad. Sci. U. S. A. 93, 10887–10890 (1996).
282. Furth, P. A. et al. Temporal control of gene expression in transgenic mice by a
tetracycline-responsive promoter. Proc. Natl. Acad. Sci. U. S. A. 91, 9302–9306
(1994).
283. Nakashima, K. et al. The novel zinc finger-containing transcription factor osterix
is required for osteoblast differentiation and bone formation. Cell 108, 17–29
(2002).
284. Rot, C., Stern, T., Blecher, R., Friesem, B. & Zelzer, E. A Mechanical Jack-like
Mechanism Drives Spontaneous Fracture Healing in Neonatal Mice. Dev. Cell 31,
159–170 (2014).
285. Holstein, J. H. et al. Advances in the Establishment of Defined Mouse Models for
the Study of Fracture Healing and Bone Regeneration. J. Orthop. Trauma 23, S31–
S38 (2009).
286. Duvall, C. L., Taylor, W. R., Weiss, D., Wojtowicz, A. M. & Guldberg, R. E.
Impaired Angiogenesis, Early Callus Formation, and Late Stage Remodeling in
Fracture Healing of Osteopontin-Deficient Mice. J. Bone Miner. Res. 22, 286–297
(2006).
287. Street, J. et al. Vascular endothelial growth factor stimulates bone repair by
promoting angiogenesis and bone turnover. Proc. Natl. Acad. Sci. U. S. A. 99,
9656–9661 (2002).
288. Boerckel, J. D. et al. Effects of in vivo mechanical loading on large bone defect
regeneration. J. Orthop. Res. 30, 1067–1075 (2012).
177

289. Brodt, M. D., Ellis, C. B. & Silva, M. J. Growing C57Bl/6 Mice Increase Whole
Bone Mechanical Properties by Increasing Geometric and Material Properties. J.
Bone Miner. Res. 14, 2159–2166 (1999).
290. Wang, L. et al. Periosteal Mesenchymal Progenitor Dysfunction and
Extraskeletally-Derived Fibrosis Contribute to Atrophic Fracture Nonunion. J.
Bone Miner. Res. 34, 520–532 (2019).
291. Wang, X. et al. PDGF Modulates BMP2-Induced Osteogenesis in Periosteal
Progenitor Cells. JBMR Plus 3, e10127 (2019).
292. Bragdon, B. C. & Bahney, C. S. Origin of Reparative Stem Cells in Fracture
Healing. Curr. Osteoporos. Rep. 16, 490–503 (2018).
293. Bais, M. et al. Transcriptional Analysis of Fracture Healing and the Induction of
Embryonic Stem Cell–Related Genes. PLoS One 4, e5393 (2009).
294. Tang, Y., Feinberg, T., Keller, E. T., Li, X. Y. & Weiss, S. J. Snail/Slug binding
interactions with YAP/TAZ control skeletal stem cell self-renewal and
differentiation. Nat. Cell Biol. 18, 917–929 (2016).
295. Marsell, R. & Einhorn, T. A. The biology of fracture healing. Injury 42, 551–5
(2011).
296. Garcia, E. L. & Mills, A. A. Getting around lethality with inducible Cre-mediated
excision. Semin. Cell Dev. Biol. 13, 151–8 (2002).
297. Albanese, C., Hulit, J., Sakamaki, T. & Pestell, R. G. Recent advances in inducible
expression in transgenic mice. Semin. Cell Dev. Biol. 13, 129–141 (2002).
298. Maes, C., Kobayashi, T. & Kronenberg, H. M. A Novel Transgenic Mouse Model
to Study the Osteoblast Lineage in Vivo. in Annals of the New York Academy of
Sciences 1116, 149–164 (Blackwell Publishing Inc., 2007).
299. Robinson, S. P., Langan-Fahey, S. M., Johnson, D. A. & Jordan, V. C.
Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and
mice compared to the breast cancer patient. Drug Metab. Dispos. 19, 36–43
(1991).
300. Danielian, P. S., Muccino, D., Rowitch, D. H., Michael, S. K. & McMahon, A. P.
Modification of gene activity in mouse embryos in utero by a tamoxifen-inducible
form of Cre recombinase. Curr. Biol. 8, 1323–1326 (1998).
301. Nishimura, R. et al. Osterix regulates calcification and degradation of
chondrogenic matrices through matrix metalloproteinase 13 (MMP13) expression
in association with transcription factor Runx2 during endochondral ossification. J.
Biol. Chem. 287, 33179–33190 (2012).
302. Xing, W., Godwin, C., Pourteymoor, S. & Mohan, S. Conditional disruption of the
osterix gene in chondrocytes during early postnatal growth impairs secondary
ossification in the mouse tibial epiphysis. Bone Res. 7, 1–8 (2019).
303. Shi, Y. et al. Gli1 identifies osteogenic progenitors for bone formation and fracture
repair. Nat. Commun. 8, 1–12 (2017).

178

304. Matthews, B. G. et al. Analysis of αSMA-Labeled Progenitor Cell Commitment
Identifies Notch Signaling as an Important Pathway in Fracture Healing. J. Bone
Miner. Res. 29, 1283–1294 (2014).
305. Debnath, S. et al. Discovery of a periosteal stem cell mediating intramembranous
bone formation. Nature 562, 133–139 (2018).
306. Kaback, L. A. et al. Osterix/Sp7 regulates mesenchymal stem cell mediated
endochondral ossification. J. Cell. Physiol. 214, 173–182 (2008).
307. Méndez-Ferrer, S. et al. Mesenchymal and haematopoietic stem cells form a
unique bone marrow niche. Nature 466, 829–834 (2010).
308. Greenbaum, A. et al. CXCL12 in early mesenchymal progenitors is required for
haematopoietic stem-cell maintenance. Nature 495, 227–230 (2013).
309. Worthley, D. L. et al. Gremlin 1 identifies a skeletal stem cell with bone, cartilage,
and reticular stromal potential. Cell 160, 269–284 (2015).
310. Morikawa, S. et al. Prospective identification, isolation, and systemic
transplantation of multipotent mesenchymal stem cells in murine bone marrow. J.
Exp. Med. 206, 2483–2496 (2009).
311. Chan, C. K. F. et al. Identification and specification of the mouse skeletal stem
cell. Cell 160, 285–298 (2015).
312. Maes, C. et al. Osteoblast precursors, but not mature osteoblasts, move into
developing and fractured bones along with invading blood vessels. Dev. Cell 19,
329–344 (2010).
313. Marecic, O. et al. Identification and characterization of an injury-induced skeletal
progenitor. Proc. Natl. Acad. Sci. U. S. A. 112, 9920–9925 (2015).
314. Mizoguchi, T. et al. Osterix marks distinct waves of primitive and definitive
stromal progenitors during bone marrow development. Dev. Cell 29, 340–349
(2014).
315. Yue, R., Zhou, B. O., Shimada, I. S., Zhao, Z. & Morrison, S. J. Leptin Receptor
Promotes Adipogenesis and Reduces Osteogenesis by Regulating Mesenchymal
Stromal Cells in Adult Bone Marrow. Cell Stem Cell 18, 782–796 (2016).
316. Yang, B. et al. YAP1 influences differentiation of osteoblastic MC3T3‐E1 cells
through the regulation of ID1. J. Cell. Physiol. 234, 14007–14018 (2019).
317. Pan, H. et al. YAP-mediated mechanotransduction regulates osteogenic and
adipogenic differentiation of BMSCs on hierarchical structure. Colloids Surfaces B
Biointerfaces 152, 344–353 (2017).
318. Tao, S.-C. et al. Decreased extracellular pH inhibits osteogenesis through protonsensing GPR4-mediated suppression of yes-associated protein. Sci. Rep. 6, 26835
(2016).
319. Murakami, K. et al. Olfactomedin-like protein OLFML1 inhibits Hippo signaling
and mineralization in osteoblasts. Biochem. Biophys. Res. Commun. 505, 419–425
(2018).
179

320. Klein, M. et al. Comparison of healing process in open osteotomy model and open
fracture model: Delayed healing of osteotomies after intramedullary screw
fixation. J. Orthop. Res. 33, 971–978 (2015).
321. Haffner-Luntzer, M., Kovtun, A., Rapp, A. E. & Ignatius, A. Mouse Models in
Bone Fracture Healing Research. Curr. Mol. Biol. Reports 2, 101–111 (2016).
322. Bonnarens, F. & Einhorn, T. A. Production of a standard closed fracture in
laboratory animal bone. J. Orthop. Res. 2, 97–101 (1984).
323. Tam, C. S. & Anderson, W. Tetracycline labeling of bone in vivo. Calcif. Tissue
Int. 30, 121–5 (1980).
324. Duncan, R. L. & Turner, C. H. Mechanotransduction and the functional response
of bone to mechanical strain. Calcif. Tissue Int. 57, 344–358 (1995).
325. Pavalko, F. M. et al. A Model for mechanotransduction in bone cells: The loadbearing mechanosomes. J. Cell. Biochem. 88, 104–112 (2003).
326. Yavropoulou, M. P. & Yovos, J. G. The molecular basis of bone
mechanotransduction. J. Musculoskelet. Neuronal Interact. 16, 221–236 (2016).
327. Main, R. P. et al. Murine Axial Compression Tibial Loading Model to Study Bone
Mechanobiology: Implementing the Model and Reporting Results. Journal of
Orthopaedic Research 38, 233–252 (2020).
328. Li, X. et al. Stimulation of piezo1 by mechanical signals promotes bone
anabolism. Elife 8, (2019).
329. Sun, W. et al. The mechanosensitive Piezo1 channel is required for bone
formation. Elife 8, (2019).
330. Klein, P. et al. The initial phase of fracture healing is specifically sensitive to
mechanical conditions. J. Orthop. Res. 21, 662–669 (2003).
331. Claes, L. E. et al. Effects of mechanical factors on the fracture healing process. in
Clinical Orthopaedics and Related Research (Lippincott Williams and Wilkins,
1998). doi:10.1097/00003086-199810001-00015
332. Epari, D. R., Taylor, W. R., Heller, M. O. & Duda, G. N. Mechanical conditions in
the initial phase of bone healing. Clin. Biomech. 21, 646–655 (2006).
333. Goodship, A. E., Watkins, P. E., Rigby, H. S. & Kenwright, J. The role of fixator
frame stiffness in the control of fracture healing. An experimental study. J.
Biomech. 26, 1027–1035 (1993).
334. McDermott, A. M. et al. Recapitulating bone development through engineered
mesenchymal condensations and mechanical cues for tissue regeneration. Sci.
Transl. Med. 11, (2019).
335. Akhter, M. P., Fan, Z. & Rho, J. Y. Bone intrinsic material properties in three
inbred mouse strains. Calcif. Tissue Int. 75, 416–420 (2004).
336. Mathis, N. J. et al. Differential changes in bone strength of two inbred mouse
strains following administration of a sclerostin-neutralizing antibody during
growth. PLoS One 14, e0214520 (2019).
180

337. Carleton, S. M. et al. Role of genetic background in determining phenotypic
severity throughout postnatal development and at peak bone mass in Col1a2
deficient mice (oim). Bone 42, 681–694 (2008).
338. Vico, L. & Vanacker, J. M. Sex hormones and their receptors in bone homeostasis:
Insights from genetically modified mouse models. Osteoporosis International 21,
365–372 (2010).
339. Huang, C. et al. Spatiotemporal Analyses of Osteogenesis and Angiogenesis via
Intravital Imaging in Cranial Bone Defect Repair. J. Bone Miner. Res. 30, 1217–
1230 (2015).
340. Buenzli, P. R., Pivonka, P. & Smith, D. W. Spatio-temporal structure of cell
distribution in cortical Bone Multicellular Units: A mathematical model. Bone 48,
918–926 (2011).
341. Patel, T. K., Brodt, M. D. & Silva, M. J. Experimental and finite element analysis
of strains induced by axial tibial compression in young-adult and old female
C57Bl/6 mice. J. Biomech. 47, 451–457 (2014).
342. Song, S. et al. A novel YAP1 inhibitor targets CSC-enriched radiation-resistant
cells and exerts strong antitumor activity in esophageal adenocarcinoma. Mol.
Cancer Ther. 17, 443–454 (2018).
343. Haak, A. J. et al. Selective YAP/TAZ inhibition in fibroblasts via dopamine
receptor D1 agonism reverses fibrosis. Sci. Transl. Med. 11, (2019).
344. Lee, J. Y. et al. Identification of cell context-dependent YAP-associated proteins
reveals β1 and β4 integrin mediate YAP translocation independently of cell
spreading. Sci. Rep. 9, 1–11 (2019).

181

APPENDICES
Experimental Protocols
MicroCT: AlignZ workflow
1) In 2D evaluation/contour mode, contour around the sample as close as possible.
a. Note 1: More empty/unused space around bone in each 2D slice makes
reorientation the slower
b. Note 2: Make sure to account for slice to slice movement of the sample
as needed i.e. go every 5 slices near the ends of the samples, then by 50
slices in the middle
i. These are suggestions, change as needed, but keep in mind Note
1.
2) In 3D evaluation/display mode, orient the 3D model in the preferred orientation
a. Note 1: Fracture and contralateral femur samples are most efficiently
scanned horizontally, but re-oriented vertically in this step
i. This will be different depending on person scanning, lab, etc.
3) In 3D evaluation/display mode, use the cut plane function to virtually cut through
the 3D model
a. Note 1: The cut plane default is at 100 (all the way to the right) but set it
around 0 to start and then manipulate the 3D model orientation (i.e. step
2), and the software will keep the same cut plane, allowing for vertical
orientation alignment
b. Note 2: Image does not need to be perfect match to example image
below. Just have a surface to hover over for each coordinate in that
direction.
c. Image 1:

4) Once the 3D model is aligned and the cut plane looks similar to above image,
hover over the three areas of interest (p1, p2, p3) and use shift-click, or
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command click or right click on the 3D model to get the coordinates at each
point.
a. Note 1: Write down the coordinates in order as they are needed for next
steps
b. Coordinate information:
i. P1: the coordinates of the new origin
ii. P2: the coordinates of a point on the new Z-axis
iii. P3: the coordinates of a point in the new XZ-plane
iv. Example: P1: (492,363,0); P2: (178,304,0); P3: (293,575,0)
c. Image 1:

5) Once you have contoured and recorded all the coordinates for each sample,
switch over to the terminal and get into the MEASUREMENT number directory
on the server
a. Using command “cd” with no quotation marks, enters into each directory
on the software
b. Using command “cd ..” moves up to the parent directory
c. Use “dir” to see what files are in the current directory
d. Screenshot:

6) Once in the correct MEASUREMENT directory, enter image processing language
(IPL) used by SCANCO, by typing “ipl”
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7) Once in IPL, use the following commands to re-align any sample
a. General IPL workflow is as follows:
i. Get into correct directory
ii. Start IPL
iii. Use “read” to read in the corresponding .AIM file corresponding to
the 3D model of the same measurement you use to get the
coordinates
iv. Use “align_z” to input the coordinates found with 3D model
v. Use “header” to adjust the new origin to [0 0 0]
1. This step keeps the new origin from going negative after
reorientation
vi. Write the .AIM file to an .ISQ file using “toisq” command
1. I think there is a way to do this in batch, but I have not
used it yet.
b. Note 1: This AlignZ method takes up a lot of memory on the microCT
network. Please be aware of people using the scanners and workstations,
as you will drastically slow down their reconstructions and evaluations.
i. Rule from microCT core is to always submit these jobs after
5pm, unless no one is using either scanner or any workstation,
which never happens
c. Note 2: Once inside the correct MEASUREMENT directory, you should
NOT read the actual file name in the “[in] >” prompt. Just press enter and
then you won’t use your own computers memory, but rather the microCT
workstations
d. Note 3: The “[in] >” from one command becomes the “[out] >” of the next
command, except for when transitioning from “read” to “align_z”
i. “[in] >” is still the “[in] >” file from “read”, so just press enter and
then enter again when prompted for “[out] >” during “align_z”
ii. Using the “header” and “toisq” commands, the “[in] >” is now “out”
e. Screenshots of the IPL commands/workflow
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f.
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Fracture healing surgery
Materials:
• Needles (25 gauge/blue needles, at least 1 inch long, 1.25 inch preferred)
• Surgical tools (Robuz tools preferred)
o Scalpel holder (RS-9843)
o Hemostats (RS-7111)
o Dissection scissors (RS-5882, RS-5840)
o Micro-dissection scissors (RS-5620)
o Small curved forceps (RS-5136)
o Large straight forceps (RS-8242)
o Needle holder with scissors (RS-7892)
• Metal wire cutters
• Mouse hair clippers/trimmers
• Sterile eye lubricant (Paralube)
• Small surgical drapes, 10 x 20 cm (3M: 1035)
• Absorbable sutures, 5-0, 13mm, reverse cutting, polyglactin braided (Ethicon:
J463G)
• Surgical gloves, multiple sizes from 6.5 to 8.0, powder-free (McKesson: 201080N)
• Betadine (Emerson healthcare LLC: 6761815117)
• Nair or equivalent generic brand hair remover
• Triple antibiotic ointment
• Sterile saline (Order through ULAR)
• Soft food or Diet gel (Order through ULAR)
• 70% ethanol
• Sterile water
• Sterile gauze pads
• Surgical pads
• Scalpels (#15)
• Dissection gowns
• Heat lamp
• Surgical masks
Drugs and dosing:
Dilute drugs in sterile vial with rubber top
• Isoflurane OR Ketamine, Xylazine (Rompun), and Acepromazine
(PromAce) but NOT BOTH
o Isoflurane preferred/easier to work with, but depends on
surgical set up
§ 1-5%, continuous for 1 hour, inhalation
o Ketamine – 70-100 mg/kg, once for 20-30 minutes, (i.p.)
o Xylazine – 5-12 mg/kg, once for 20-30 minutes, (i.p.)
o Acepromazine – 1-3 mg/kg, once for 20-30 minutes, (i.p.)
• Buprenorphine
o Buprenorphine-SR – 1 mg/kg, once, subcutaneous
o Buprenorphine-regular – 0.05 - 0.1 mg/kg, every 4-6 hours for
3 days post-surgery, subcutaneous
§ Dilute in 0.9% sterile saline
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•
•

Bupivacaine
o 0.25%, once, intra-incisional, dilute in sterile saline
Meloxicam
o 5 mg/kg, every 12-24 hours, 3 days post-op

Fracture surgery (performed in 326A or 328A Stemmler):
Pre-operation:
1) Weigh mouse
2) Anesthetize animals by either isoflurane inhalation or intraperitoneal
injection of rodent anesthetic cocktail
a. Isoflurane –induce on 3%, maintain on 1-2%
3) Place sterile eye lubricant in the eyes of the mice
4) Trim all hair with mouse hair clippers
5) Spread Nair or equivalent generic hair removal lotion to the surgical
site, do not leave on skin for more than ~1 minute
6) Cleanse surgical area with sterile water, repeat hair removal
application if needed
7) Cleanse area with betadine in counterclockwise motion away from
surgical incision site to maintain aseptic surgical area
8) Transfer mouse to surgical area with heating pad and/or thermal
waterbed under surgical/dissection pads
Surgical operation:
1) Apply surgical drape to mouse, exposing only the right limb
2) Make a unilateral incision on the lateral side of the right knee (3-5mm
incision)
3) Straighten leg and displace patella to uncover the femoral condyles
4) Insert intramedullary rod (25-gauge needle) by twisting and applying
slight pressure through the intrachondylar notch of the distal femur
a. Keep inserting until needle tip is within proximal trabecular
bone (you will feel increased resistance, if you keep pushing
past this point, you will push needle out the other side)
5) Use wire cutters to clip needle at the insertion point of the distal
femoral head
6) Close first incision site with absorbable sutures
7) Perform mid-diaphyseal fracture either with open or closed model
a. Open fracture model
i. Make a 1 cm cutaneous incision on the anterolateral
aspect of the limb near the mid-diaphysis of the femur
ii. Blunt dissected away the muscle with hemostats to
expose the mid-diaphysis of the femur
iii. Insert #15 scapel blade positioned transversely to the
femur axis
iv. Apply a three-point bend force to cause a transverse
fracture of the femur
v. Verify fracture success visually (transverse, oblique,
comminuted)
vi. Close surrounding muscles with single absorbable
suture
vii. Close skin with absorbable sutures
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8) Suture wounds close with 5-0 sutures
a. Close blunt dissecting muscle first
b. Close skin
9) Apply bupivacaine for local anesthesia at incision site during suturing
10) Apply triple antibiotic ointment

Post-operation:
1) Administer dose of Buprenorphine as mouse begins to recover from
Isoflurane to ensure pre-emptive analgesia immediately following surgery
a. Can be given before, but combination of Buprenorphine and
Isoflurane can cause mice to stop breathing/die during surgery
2) Allow mice to recover under heat lamp, on a heated pad, or heated
chamber to ensure maintenance of body temperature
3) After awakening, return mouse to their cage to allow free ambulation
4) Provide Nutrigel in cages with recovering mice as the surgery might
prevent them from reaching food immediately following surgery
5) Administer meloxicam subcutaneously every 12-24 hours for three days
post-surgery
6) Administer Buprenorphine every 4-8 hours for three days post-surgery
and as needed beyond three days post-surgery in animals showing signs
of lameness or distress
a. Weigh mouse every other day for first week
7) Observe mice in recovery for signs of posture, activity level, breathing,
hydration, body/coat condition throughout duration of experiment
a. Especially monitor intramedullary pin, as needle can become
displaced if not properly placed during surgery
b. Keep humane endpoint criteria in mind and euthanize mice
meeting these requirements:
i. Animals have body condition scoring (BCS) of 1
ii. Animals have a body condition scoring (BCS) of 2 in
addition to other signs such as hunched posture, inactivity,
ruffled hair coat, or dehydration
iii. Overt signs of surgical site infection (redness, swelling,
purulent discharge)
iv. Weight loss of 20%
v. Inability to ambulate
vi. Non-weight bearing lameness on fracture limb despite
analgesic treatment (e.g. limb dragging)
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